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Microvascular injury in acute ST-segment elevation myocardial infarction (STEMI) is an 
important predictor of adverse prognosis. However, persistent microvascular injury 
typically passes undetected after primary percutaneous coronary intervention (PCI), and is 
a problem of unmet therapeutic need. The aim of this work was to gain greater insight into 
the invasive assessment of acute microvascular injury following primary PCI, for risk-
stratification, and to provide mechanistic insights into the effects of intracoronary alteplase 
on the microcirculation. 
Methods: 
The first part of the thesis sought to establish the influence of coronary flow on the effects 
of adjunctive intracoronary alteplase, and to investigate the effects of intracoronary 
alteplase on invasive physiology measures of microvascular function. Through a multi-
centre, prospective, randomised controlled trial (T-TIME, NCT02257294), alteplase 10mg, 
and alteplase 20mg were compared to placebo, in patients undergoing primary PCI. 
Eligible participants presented within 6 hours from STEMI onset, and the study drug was 
administered before stent implantation. In 421 patients, TIMI (thrombolysis in myocardial 
infarction) flow grade was determined in the infarct-related artery immediately before 
study drug administration. In a subset of 144 patients, invasive physiology parameters were 
measured in the infarct-related artery at the end of the primary PCI procedure (the 
prespecified T-TIME physiology sub-study). These invasive physiology parameters 
included index of microcirculatory resistance (IMR), coronary flow reserve (CFR) and 
resistive reserve ratio (RRR). Microvascular obstruction (MVO) and myocardial 
haemorrhage were assessed on cardiovascular magnetic resonance (CMR) imaging at 2 to 
7 days post-STEMI, and CMR imaging was repeated at 3 months. 
 
The second part of the thesis sought to prospectively compare IMR, CFR, RRR, 
myocardial perfusion grade (MPG) and TIMI frame count (TFC), for predicting MVO and 
myocardial haemorrhage, and clinical outcomes at 1 year, in the T-TIME physiology sub-
study. The following adjudicated clinical outcomes were assessed: major adverse cardiac 
events, heart failure hospitalisations, and all-cause death/ heart failure hospitalisations. 
Furthermore, a retrospective analysis was performed in 271 acute STEMI patients from a 
single-centre observational study (MR-MI, NCT02072850), for the derivation of a newly 
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conceived invasive physiology parameter termed temperature recovery time (TRT). The 
associations between TRT and MVO (on 2 to 7 day CMR imaging) and clinical outcomes, 
were assessed in the MR-MI cohort, and were prospectively validated in the T-TIME 
physiology sub-study population. 
Results:  
The main findings are summarised as follows: 
§ Low-dose intracoronary alteplase given early during primary PCI, was associated 
with increased occurrence of MVO and myocardial haemorrhage in participants 
who had TIMI flow ≤2 immediately preceding drug administration. 
§ In participants with TIMI 3 flow immediately preceding drug administration, there 
was no difference in MVO or myocardial haemorrhage with intracoronary alteplase 
compared to placebo. 
§ There was overall no difference in microvascular function, measured by IMR, CFR 
and RRR, between intracoronary alteplase and placebo groups.  
§ In patients with ischaemic time <2 hours, CFR and RRR were higher with alteplase 
20mg vs. placebo, whereas in patients with ischaemic times ≥4 hours, MVO extent 
was higher with alteplase 20mg vs. placebo. 
§ In acute STEMI patients, lower RRR, IMR >40, and MPG ≤1 were associated with 
more MVO, myocardial haemorrhage presence and adverse clinical outcomes, 
whereas CFR ≤2 was not. 
§ In acute STEMI patients, TFC >27 was associated with adverse clinical outcomes, 
but was not associated with MVO or myocardial haemorrhage.  
§ Higher TRT independently predicted more MVO and adverse clinical outcomes, in 
two independent acute STEMI cohorts. 
Conclusions:  
The findings from this PhD are novel and clinically relevant. Invasive measures of 
microvascular injury during primary PCI allows potential for early administration of 
targeted adjunctive therapies to the highest risk patients. The data support IMR in 
conjunction with RRR instead of CFR, to select patients for adjunctive therapies. 
Moreover, TRT was found to detect failed microvascular perfusion and may have potential 
to refine risk stratification in acute STEMI. The findings raise a question as to the safety of 
intracoronary administration of alteplase in the context of STEMI when there is <TIMI 3 
flow. Finally, the data suggest that future studies evaluating the effects of intracoronary 
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Chapter 1: Introduction and literature review 
1.1 Scale of the problem and the wider context of myocardial infarction 
research 
ST-segment elevation myocardial infarction (STEMI) is a leading cause of premature 
morbidity and mortality worldwide1 and it is relatively more common in men2. The 
incidence of STEMI in Europe ranges from 43 to 144 per 100,000 per year3, and the 
incidence has been falling4. The mortality from contemporary STEMI management has 
significantly improved following the implementation of rapid reperfusion, with primary 
percutaneous coronary intervention (PCI), potent antithrombotic therapy, lifestyle 
modifications and secondary prevention5-7. Specifically, in contemporary practice the 30-
day mortality rate following primary PCI is approximately 4%6 and is even less in patients 
presenting without cardiogenic shock or cardiac arrest (approximately 2%)8. The 1-year 
mortality rate, following primary PCI, is approximately 4 to 7%9-11. The rate of heart 
failure hospitalisation at 1-year following primary PCI is approximately 5%12 13. 
 
As a result of the improvement in outcomes following contemporary STEMI management, 
current and future clinical trials now may need many thousands of patients to achieve 
adequate power to ascertain reductions in clinical outcome endpoints, including mortality, 
reinfarction and heart failure14. Therefore, clinical trials often use surrogate endpoints that 
are associated with clinical outcomes, to show differences between treatment groups. 
Cardiovascular magnetic resonance (CMR) imaging is useful in this regard, because 
continuous parameters, such as infarct size, can be measured that are associated with 
clinical outcomes15. Increasingly, assessment of the coronary microcirculation acutely in 
the catheterisation laboratory is being used in clinical trials, in a stratified therapy 
approach, to target adjunctive treatments to STEMI patients most likely to benefit16. 
Thereby, potentially reducing the number of patients needed to achieve adequate power to 
ascertain improvements in trial endpoints.  
1.2 The coronary microcirculation and the “no-reflow” phenomenon 
The coronary circulation consists of epicardial arteries, followed by small arteries called 
pre-arterioles (200 to 300µm in diameter), which taper into arterioles (10 to 200µm in 
diameter), and then capillaries (<10µm in diameter). Epicardial arteries make a negligible 
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contribution to flow resistance in the absence of significant stenosis17. On the other hand, 
pre-arterioles and arterioles contribute to flow resistance by changing their diameter, in 
order to maintain constant coronary perfusion over a range of perfusion pressures (Figure 
1.1). Arterioles make the largest contribution to total coronary resistance18. The diameter 
of larger arterioles (100 to 200µm) is regulated by blood flow related stimuli (endothelial 
cell mediated vasodilatation)19. The diameter of intermediate arterioles (40 to100µm) is 
largely regulated by intravascular pressure changes, detected by vascular smooth muscle 
stretch receptors20, however endothelial dependent flow induced mechanisms also have a 
role21. The diameter of the smaller arterioles (10 to 40µm) is regulated by tissue 
metabolites22. The diameter of capillaries is fixed, as their purpose is exchange of nutrients 
and oxygen23. Capillaries do not have a layer of vascular smooth muscle cells, which is 
found in arterioles. Therefore, capillaries consist only of an endothelial layer over a basal 
lamina, and are potentially susceptible to compression by intramyocardial or 
intraventricular pressures18. The microcirculation, i.e. vascular elements <300µm in 
diameter24 that contribute to myocardial  perfusion18, is too small to be visualised with the 
spatial resolution available at angiography.  
  
Figure 1.1 Schematic diagram illustrating the anatomy of the coronary microcirculation 




Even though primary PCI is a life-saving treatment25, and normal flow in the epicardial 
coronary artery is typically achieved, approximately half of STEMI patients sustain 
persistent impairment of microcirculatory blood flow26 27. When coronary flow is impaired, 
despite relief of the epicardial obstruction, this is described as “no reflow”. Kloner et al28 
first reported coronary “no reflow” in the 1970s, in a canine model. Kloner et al28 observed 
poor or absent perfusion in areas of the myocardium, despite complete epicardial coronary 
artery patency, and linked it to microvascular injury. At the time of epicardial coronary 
artery reopening following acute occlusion, myocardial reperfusion is achieved only in 
areas with anatomically preserved microvasculature, whereas reflow does not occur in 
myocardium with extensive microvascular damage. This is observed clinically as 
microvascular obstruction (MVO) on CMR imaging, and confers an adverse prognosis27 29. 
However, MVO usually passes undetected in daily practice, presenting an unmet 
therapeutic need. 
1.3 Pathophysiology of microvascular injury 
1.3.1 Distal embolization 
Embolization of atherothrombotic debris from the infarct-related artery during primary PCI 
is one of the key contributors to MVO30-33. Distal embolization can cause mechanical 
obstruction, as well as activate local inflammatory pathways, in situ thrombosis30 and 
release of vasoconstrictors, such as endothelin-134, from hypoxic cells. These processes in 
turn result in microvascular vasospasm, interstitial oedema and further cellular injury. The 
effects of distal embolization on myocardial damage are greater in patients who have large 
thrombus burden in the infarct-related artery35. 
1.3.2 Ischaemic injury 
In a canine model, involving 90 minutes of coronary artery occlusion followed by 
reperfusion, Kloner et al28 demonstrated histologically severe capillary damage, with 
endothelial protrusions that obstructed the capillary lumen, endothelial gaps (from 
destabilisation of cellular junctions36) and extravascular erythrocytes28. The erythrocyte 





On a molecular level, during ischaemia, glycogen is initially broken down by 
mitochondrial anaerobic glycolysis to produce adenosine triphosphate along with lactic 
acid38. This results in a decrease in pH, which then acts by negative feedback to inhibit 
further adenosine triphosphate production. A lack of adenosine triphosphate causes ionic 
pumps to fail, leading to increased cytosolic sodium concentrations39, causing water to 
move into cells in an attempt to maintain the osmotic equilibrium, resulting swelling of 
cells40. Furthermore, calcium is released from the mitochondria into the cytoplasm and 
extracellular spaces, thereby activating calcium-dependent proteases41. 
1.3.3 Reperfusion injury  
Reperfusion can paradoxically worsen myocardial injury. This was demonstrated in a 
rabbit model of 30 minutes of coronary occlusion, which showed that the extent of poorly 
or non-perfused myocardial regions increased following reperfusion42. Furthermore, in a 
rat model, 30 minutes of ischaemia without in vivo reperfusion showed only mild 
morphological changes to the coronary microvascular endothelium, whereas 30 minutes of 
ischaemia combined with 60 minutes of in vivo reperfusion resulted in visible 
microvascular damage43.  
 
A characteristic feature of reperfusion injury is intense oedema of myocytes, endothelial 
cells and the interstitium, which occludes the microvasculature due to external 
compression34. There is a reactive hyperaemia, due to the abrupt increase in capillary 
hydrostatic pressure, and subsequently a second wave of oedema is triggered by an influx 
of inflammatory cells, which increase microvascular permeability44 45. Carrick et al46 
reported that oedema follows a bimodal time course only in patients with accompanying 
myocardial haemorrhage, whereas in patients without myocardial haemorrhage, oedema 
seemed to evolve on a unimodal time course.  
 
On a molecular level, once ischaemic tissue is reperfused, an influx of molecular oxygen 
catalyses enzyme reactions that produce reactive oxygen species (ROS). For example, 
xanthine oxidase degrades hypoxanthine to uric acid, thereby releasing superoxide47 48. 
Superoxide is converted to hydrogen peroxide and the hydroxyl radical. Hydroxyl radical 
production consequently leads to peroxidation of the lipid in cell membranes, which 
disrupts cell permeability, resulting in cell death. Lipid peroxidation of cellular membranes 
releases arachidonic acid, which is the substrate for production of prostaglandins, 
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thromboxanes and leukotrienes. Prostaglandins are vasodilators, but they are short-lived 
and rapidly depleted, resulting in uninhibited vasoconstriction and exacerbation of 
ischaemia. In particular, thromboxane A2 promotes vasoconstriction and platelet 
aggregation. Moreover, leukotrienes activate inflammatory pathways, activate neutrophils, 
and result in accumulation of inflammatory cells49. Neutrophils secrete matrix 
metalloproteinases50 51, which degrade basement membranes contributing to tissue 
destruction.  
 
Platelets have emerged as a major contributing factor to ischaemia reperfusion injury52 53. 
First, activated platelets infiltrate the reperfused myocardium and contribute to injury by 
forming microthrombi, which cause microvascular plugging. This is mediated by platelets 
adhering to capillary endothelium, or to attached leukocytes. Platelet glycoproteins, such as 
IIbIIIa have a key role in platelet adhesion and aggregation. Possible mediators of platelet 
activation include the exposed extracellular matrices52, and release of platelet-activating 
cytokines, such as stromal cell-derived factor 1 alpha54. Second, the formation of platelet-
neutrophil aggregates55 56 promotes additional pro-inflammatory leukocyte infiltration and 
vasoconstriction57 58. In particular, thromboxane A2 is a potent vasoconstrictor released by 
activated platelets. Third, activated platelets shed microparticles, which have the potential 
to increase inflammation52. Last, platelets activate cardiac-sympathetic afferent nerves 
during ischaemia59, with associated tachyarrhythmia59, leading to further myocardial 
damage by increasing the cardiac oxygen demand. 
 
Overall, the mechanisms underlying myocardial reperfusion injury are complex, and the 
key pathways include the acute inflammatory response60, endothelial dysfunction with 
impaired endothelium-dependent vasodilatation61, intracellular calcium overload34 62, 
opening of the mitochondrial permeability transition pore34 63, increased generation of 
ROS47 64, platelet aggregation and microthrombi formation65.  
1.3.4 Individual susceptibility to acute microvascular injury 
In STEMI patients, hyperglycaemia rather than diabetes per se is associated with MVO on 
CMR imaging66-69. It has been postulated that endothelial dysfunction may increase the 
risk of reperfusion injury to the microcirculation. Indeed, in a hyperglycaemia canine 
model, endothelial-dependent coronary microvascular dilatation was impaired70. On the 
other hand, pre-existing hypertension in acute STEMI patients has not been associated with 
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CMR-defined MVO71 72. Current smoking has not been associated with MVO on CMR 
imaging in acute STEMI patients, but has been associated with myocardial haemorrhage 
when corrected for infarct size in some studies73 74. 
 
In STEMI patients, longer symptom onset to reperfusion time, i.e. ischaemic time >6 
hours, is an independent predictor of angiographic no reflow75-77 and CMR-defined 
MVO78. Advanced age is also an independent predictor of angiographic no-reflow77 79, and 
this association may be related to increased vascular oxidative stress with advanced age. 
Other independent predictors of angiographic no-reflow are initial TIMI (thrombolysis in 
myocardial infarction) flow grade ≤1 and a high thrombus burden77. Furthermore, anterior 
location of MI is associated with larger infarct size and more MVO on CMR imaging, than 
non-anterior MI80. 
1.4 Diagnosis of coronary microvascular dysfunction and prognostic 
significance 
1.4.1 Non-invasive assessment by CMR 
A reference non-invasive technique for detection of microvascular pathology is CMR. 
However, CMR has limitations when considered as an imaging test of the efficacy of 
reperfusion therapy in acute STEMI patients. First, CMR is not feasible acutely, it is 
typically performed 2 to 7 days after primary PCI, so it is not suitable for early risk 
stratification and is not widely available81. Second, CMR is only possible in medically 
stable patients, so the sickest patients with the most severe forms of MI may be excluded. 
Furthermore, gadolinium contrast agents used in CMR imaging are contraindicated in 
patients with severe renal dysfunction, and some patients may not be able to undergo CMR 
imaging due to claustrophobia, cardiac devices, or indwelling metallic objects. 
Microvascular obstruction 
Late gadolinium enhancement (LGE) CMR imaging is used to evaluate MVO. After 
intravenous administration of gadolinium, the extracellular contrast agent perfuses through 
myocardial capillaries and diffuses within the extracellular compartment. The rupture of 
cardiac cells in the early post-infarcted tissue, increases the interstitial volume, which 
reduces the washout rate of the gadolinium contrast from the extracellular space. This 
results in an increased concentration of contrast, compared to healthy myocardium. The 
persistence of gadolinium in the infarct zone for a longer time than in healthy tissue, leads 
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to a regional hyperintense (bright) area on T1-weighted imaging. A hypointense core 
(black area, due to absence of contrast in the obstructed capillaries) represents MVO within 
the hyperintense infarct zone in the area of LGE.  
 
The temporal change of MVO is very dynamic. By 3.5 hours following reperfusion, the 
zone of impaired perfusion extends from the sub-endocardium to the mid-myocardium82. 
During the first 24 hours following reperfusion the zone of impaired perfusion increases42. 
Imaging by CMR earlier than 2 days post-STEMI can over-estimate MVO. MVO is 
reasonably stable between days 2 to 7 post-STEMI. However, from 10 to 30 days post-
STEMI, MVO diminishes markedly, and in a variable proportion of patients MVO persists 
(linked to myocardial haemorrhage)26. By 7 to 8 months post-reperfusion, MVO on CMR 
imaging has usually resolved83.  
 
Previous studies have shown that MVO predicts heart failure27, adverse left ventricular 
(LV) remodelling, ventricular arrhythmia84, major adverse cardiac events (MACE) and 
death27 85 86. There is a weak correlation between MVO and infarct size (r=0.21, p<0.001)85 
and MVO predicts adverse clinical outcomes independent of infarct size86. The 
pathophysiological mechanisms through which MVO adversely impacts prognosis may be 
due to MVO limiting delivery and transit of promoters involved in post-infarction 
remodelling, as well as macrophages needed for phagocytosis of cellular debris, to 
contribute to optimal infarct healing87 88. 
Myocardial haemorrhage 
The most sensitive and established method for imaging myocardial haemorrhage is T2* 
based imaging89 90. However, a limitation of T2* imaging is that it requires relatively long 
breath holds to minimise respiratory movements, which is not possible in some patients. 
Therefore, there is difficulty in obtaining reliable diagnostic quality T2* images, in a 
proportion of patients91. On T2* maps, accumulation of paramagnetic haemoglobin 
degradation products, leads to a shortening of T2* relaxation times, resulting in reduced 
signal intensity (hypointense zone) on imaging, which represents tissue haemorrhage92 93. 
Previous validation in swine established that the hypointense zone on T2* maps 





Myocardial haemorrhage is a pathological subset of MVO, and is an irreversible 
consequence of severe microvascular injury94. Myocardial haemorrhage occurs when 
endothelial cell injury compromises capillary integrity, leading to blood extravasation into 
the extracellular space. The external compression of capillaries by extravasated blood in 
the interstitial space potentiates progression of microvascular damage. In the longer term, 
haemoglobin degradation leads to deposition of cytotoxic levels of iron in the myocardium, 
which triggers inflammation and fibrosis95 96. Myocardial haemorrhage is associated with 
larger infarct size93, heart failure, adverse LV remodelling97 98, late arrhythmia risk99, and is 
an even stronger predictor of MACE and death than CMR-defined MVO26 100 101. 
1.4.2 Non-invasive assessment by electrocardiography 
Less ST-segment resolution 90 minutes post-reperfusion compared to baseline (i.e. 90 
minutes after the initial restoration of flow in the infarct-related artery, compared to the 
electrocardiogram [ECG] on admission) is associated with MVO on CMR imaging (area 
under the curve [AUC]: 0.68, p<0.05)102. Incomplete ST-segment resolution (<70%) 60 
minutes post-reperfusion relative to baseline, appears to be a better predictor of MVO on 
CMR imaging than angiographically-derived TIMI flow grade, or TIMI myocardial 
perfusion grade (MPG)103. However, studies reporting the relationship between ST-
segment resolution and clinical outcomes have shown conflicting results104 105. A limitation 
of incomplete ST-segment resolution for predicting microvascular injury is that it requires 
calculation at least 60 minutes after the baseline ECG, and therefore is not immediately 
available during the primary PCI procedure. Furthermore, the optimal timing of ECG 
analysis remains uncertain106.  
1.4.3 Invasive assessment by angiography 
The therapeutic window for treating microvascular injury after the onset of STEMI, occurs 
immediately after reperfusion has been established43. CMR-defined MVO is unsuitable for 
early risk stratification in STEMI patients, because it is only feasible in medically 
stabilised patients and is not available at the time of emergency PCI. By the time CMR is 
performed the therapeutic window for minimising microvascular injury has lapsed. On the 
other hand, angiographic and invasive coronary physiology surrogates of failed myocardial 
perfusion can be measured immediately after epicardial patency has been restored, to 





TIMI flow grade and TIMI frame count 
The TIMI flow grade is a categorical grading system for epicardial antegrade flow, ranging 
from 0 (no flow) to 3 (complete antegrade flow). When assessed at the end of primary PCI, 
TIMI flow <3 is associated with larger infarct size, worse LV ejection fraction, and 
increased incidence of death, heart failure and MACE107-111. Furthermore, TIMI flow <3 
early during the primary PCI procedure (i.e. pre-stenting) is associated with higher rates of 
death, MACE and lower LV ejection fraction, than TIMI flow <3 at the end of primary 
PCI, i.e. post-stenting112. Nonetheless, TIMI flow grade is a relatively insensitive surrogate 
of microvascular perfusion, so TIMI 3 flow does not guarantee adequate microvascular 
perfusion26 103 113. Furthermore, TIMI flow <3 at the end of primary PCI does not 
necessarily guarantee impaired microvascular perfusion114.  
 
Because of a relatively high inter-rater variability in grading TIMI flow, the corrected 
TIMI frame count (TFC) was introduced, which provides a quantitative assessment of 
coronary flow. TFC has relatively good inter-rater and intra-observer reproducibility115-117. 
However, nitrate use, dye injection at the beginning of diastole and slower heart rate have 
been shown to affect TFC118 119. A TFC ≥28 in the infarct-related artery is considered 
abnormal120-123. The prognostic significance of TFC is uncertain. Some studies showed that 
increased TFC is independently associated with increased mortality121 124, whereas other 
studies showed no association between TFC and mortality125 126.  
 
Conversely, a very fast TFC at the end of PCI (TFC <14), which represents hyperaemic 
flow, has been associated with higher incidence of a composite of death/ MI (p<0.001) 
compared to normal flow (TFC 14 to 28), in patients with MPG ≤1 at the end of PCI127. 
This may be explained by hyperaemic arterial flow after reperfusion therapy for STEMI 
being caused by microembolization of platelet aggregates and atherothrombotic debris, 
with subsequent release of endogenous adenosine, a vasodilator, from surrounding 
territories127-129.  
 
Importantly, though TFC and TIMI flow grade at the end of primary PCI have been 
associated with MVO on CMR imaging, the associations are relatively weak (TFC: 
AUC=0.53, p<0.05; TIMI flow grade: AUC=0.54, p<0.05)102.  
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TIMI Myocardial perfusion grade 
Filling and clearing of contrast from a coronary angiogram is characterised by TIMI MPG, 
which is graded from 0 (no myocardial perfusion) to 3 (normal myocardial perfusion). 
MPG ≤1 at the end of primary PCI is associated with less myocardial salvage130 and a 
higher incidence of MVO on CMR imaging131, than MPG ≥2. Moreover, MPG ≤1 predicts 
mortality after STEMI, independent of TIMI flow grade132.  
 
However, MPG ≥2 is not synonymous with normal myocardial perfusion, and some of 
these patients have MVO on CMR imaging103 131. Another drawback of MPG is that visual 
assessment requires an experienced operator, and is limited by inter-rater variability116. 
Automated, off-line, computer-assisted quantification of myocardial blush is available, 
which has improved intra- and inter-observer variability133 and has been shown to predict 
clinical outcomes134. 
1.4.4 Invasive assessment by coronary physiology 
Angiographic parameters can lack sensitivity in clinical practice, with considerable 
observer disagreement135, and are best assessed in a core laboratory. Invasive physiology 
measures of microvascular dysfunction in the infarct-related artery have potential for early 
risk stratification of patients, and to guide the selection of patients for adjunctive therapies 
during primary PCI16. Figure 1.2 depicts invasive physiology parameters for measuring 
microvascular function in acute STEMI, organised into flow- or resistance-based, and 
thermodilution- or Doppler-derived parameters. In acute STEMI, the use of fractional flow 
reserve (distal coronary pressure [Pd] divided by aortic pressure [Pa] during hyperaemia) 
in the infarct-related artery is not recommended136, because the dynamic changes in the 





     
      Figure 1.2 Summary of invasive coronary physiology parameters to measure microvascular function in acute STEMI. Reproduced with permission 
from: Maznyczka A et al. The potential use of index of microcirculatory resistance (IMR) to guide stratification of patients for adjunctive therapy in acute 
myocardial infarction. JACC Cardiovasc Interv. 2019. 12(10): 951-966. Doi: 10.1016/j.jcin.2019.01.24616. 
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Index of microcirculatory resistance 
Microvascular resistance is the force that the coronary microcirculation exerts against 
coronary flow. When maximal hyperaemia is induced, for example pharmacologically with 
adenosine, auto-regulation by the microcirculation is exhausted, resistance vessels are 
maximally dilated, and blood flow varies linearly with perfusion pressure138, thereby the 
minimal microvascular resistance can be calculated. Ohm’s law is applied for calculating 
minimal microvascular resistance.  
 
Ohm’s law states that current equals the voltage difference divided by resistance. When 
Ohm’s law is applied to flow in blood vessels, the voltage difference is the pressure 
difference, the current is the blood flow, and the resistance is resistance to flow. Thereby, 
the resistance to blood flow is inversely related to absolute flow: 
 
Resistance = Pressure gradient 
                         Absolute flow 
 
Several assumptions are made when Ohm’s law is applied to describe the relationship 
between blood flow and vascular resistance, therefore it is an imperfect approximation of 
resistance. The equation assumes that blood flow is constant and linear. However, in reality 
blood flow is laminar, the size and shape of vessels varies, and in large arteries the 
propagation of the pressure pulse depends on the elastic property of the arterial wall. 
Additionally, the non-homogenous nature of blood makes it difficult to ascertain a single 
value for viscosity, and in the microcirculation the fact that blood is a suspension of cells 
influences its flow properties139. Furthermore, when considering the coronary anatomy it is 
important to acknowledge that collaterals provide anastamotic connections between 
arteries without an intervening capillary bed. Collateral flow can affect pressure 
measurements, but is not accounted for when Ohm’s law is applied. 
 
For calculating the pressure gradient across the microcirculation, the venous pressure is 
assumed to be negligible, during maximal hyperaemia. Therefore, minimal microvascular 
resistance can be simplified as the ratio of Pd to flow, at maximal hyperaemia.  
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Thermodilution methodology can be used to obtain the mean transit time (Tmn) of 
manually injected normal saline, which is used as a surrogate of coronary flow. For this 
purpose, a coronary guidewire is used, which combines a distal pressure sensor and 
temperature sensor (Abbott Vascular, California). Using thermodilution to quantify 
coronary blood flow and volume is based on the following relationship:  
 
Flow =                        volume 
                Tmn (at maximal hyperaemia) 
 
Because the vascular volume can be assumed to remain constant at maximal hyperaemia, 
the two above equations can be combined, so that microvascular resistance is proportional 
to the product of Pd and Tmn: 
 
Microvascular resistance = Pd (at maximal hyperaemia)  ÷                       1 
                                                                                                Tmn (at maximal hyperaemia) 
 
Microvascular resistance = Pd x Tmn (at maximal hyperaemia) 
 
The index of microcirculatory resistance (IMR) is defined by the above equation, i.e. Pd x 
Tmn at maximal hyperaemia140. IMR was initially validated in animals140 141. In a swine 
model, IMR was compared with true microvascular resistance, defined as Pd divided by 
absolute coronary flow measured using ultrasonic flow probes140. Microvascular 
dysfunction was created artificially using microspheres injected into the coronary arteries. 
There was a modest correlation between IMR and total microvascular resistance (r=0.54, 
p<0.001)140. The findings were validated in an in vitro model, which demonstrated 






When severe stenosis is present, the contribution of collateral flow may lead to 
overestimation of IMR143 144. In these circumstances IMR requires correction using either 
coronary wedge pressure (Pw), i.e. corrected IMR = Pa x Tmn x ([Pd – Pw] / [Pa – 
Pw])143, or Yong’s formula145 (corrected IMR = Pa x Tmn x [(1.35 x Pd / Pa) - 0.32]), with 
Pa, Tmn and Pd measured during hyperaemia. In the setting of stable ischaemic heart 
disease, i.e. not in the setting of acute STEMI, IMR has been shown to be influenced to a 
small extent by the amount of myocardium subtended by the epicardial artery under 
study146. 
 
In humans, IMR has been validated against positron emission tomography147, CMR148-156, 
single photon emission computed tomography (SPECT)157 and echocardiographic158 159 
imaging.  Stable patients without microvascular disease generally have IMR values <25160-
162. In STEMI, IMR correlates with the adequacy of microvascular perfusion, evidenced by 
the association of elevated IMR with MVO148-150 152 153 155 156 and myocardial haemorrhage 
on CMR imaging150 156. Moreover, Cuculi et al163 showed that IMR is modifiable when 
assessed repeatedly within 24 hours of reperfusion.  
 
Carrick et al156 performed the largest study in STEMI patients (n=288) comparing IMR 
measured at the end of emergency PCI with MVO on CMR imaging (MR-MI study 
[detection and significance of heart injury in STEMI]). Carrick et al156 found that IMR >27 
was most closely associated with MVO and myocardial haemorrhage on CMR imaging. 
However, this IMR threshold differs from a meta-analysis of 6 studies by Bulluck et al152, 
which suggested an IMR cut-off >41 at the end of primary PCI for predicting MVO on 
CMR imaging. 
 
In acute STEMI, an elevated IMR at the end of PCI also correlates with worse recovery of 
infarct size147 149 150 153 155 158, adverse LV remodeling and worse LV function149 153 154 158 159. 
Fearon et al158 reported that an IMR ≤32 (median) at the end of primary PCI was 
associated with recovery of LV function (assessed echocardiographically). An IMR ≤32 
correlated with improvement in wall motion score index at 3 months relative to baseline, 
whereas patients with IMR >32 had no change in wall motion score index158. The findings 
were validated by Faustino et al159 and Lim et al147 who reported improvements in 
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echocardiographic wall motion score index with IMR <26 and ≤33 respectively at the end 
of primary PCI. 
 
Interestingly, De Maria et al155 found that patients with CMR-defined MVO and IMR ≤40 
had regression of infarct size, whereas those with IMR >40 did not. In patients without 
MVO on CMR imaging, those with IMR ≤40 had regression of infarct size, whereas those 
with IMR >40 did not155. One interpretation of these findings155 is that patients with the 
highest IMRs might have sustained irreversible microvascular damage, that may 
potentially be less modifiable by adjunctive therapies. 
 
Perhaps most clinically relevant, an IMR >40 after primary PCI predicts all-cause death, 
heart failure readmissions, and MACE149 164 165. In STEMI patients (n=253), Fearon et al164 
reported that IMR >40 (mean) at the end of primary PCI was independently associated 
with all-cause death (hazard ratio [HR]: 4.3 [95% confidence interval (CI): 1.3, 15.0] 
p=0.02), or all-cause death/ rehospitalisation for heart failure at 1 year (HR: 2.2 [95% CI: 
1.1, 4.5] p=0.03). An IMR >31 (median) was independently associated with all-cause 
death/ rehospitalisation for heart failure at 1 year (HR: 3.1 [95% CI: 1.4, 6.6] p=0.004), but 
not with all-cause death alone164. Carrick et al149 reported that IMR >40 at the end of 
emergency PCI was independently associated with all-cause death/ heart failure 
hospitalisations at 2 years, in 283 acute STEMI patients (odds ratio [OR]: 4.36 [95% CI: 
2.10, 9.06] p<0.001). Fahrni et al165 reported that IMR >40 at the end of primary PCI 
predicted major cardiac complications 30-days post-STEMI (16.7% vs. 0%, p<0.001) 
(n=261). 
 
Advantages of IMR are as follows: (i) it can be performed at the time of primary PCI; (ii) 
from a technical perspective it is relatively straightforward to obtain the measurements; 
(iii) it is reproducible166; (iv) it has been robustly validated in animals and humans140 141 147-
162, and; (v) studies have shown that it can reliably predict clinical outcomes149 164 165. 
However, IMR has some potential limitations. First, large side branches might potentially 
result in overestimation of flow, and thereby underestimation of IMR, due to loss of saline 
down the side branches. Second, vessel compression during systole might potentially affect 
the result if saline is injected mainly during systole especially in bradycardic patients167, 
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therefore Tmn is measured in triplicate and the mean value is recorded. Third, manual 
saline injections can potentially be a source of variability168 169.  
Hyperaemic microvascular resistance 
Hyperaemic microvascular resistance (HMR) is measured with a combined Doppler-
pressure wire (Phillips Volcano Corporation, California), in the infarct-related artery. It is 
the ratio of mean Pd to mean Doppler flow peak velocity. The mean Doppler peak flow 
velocity is used as a surrogate of coronary flow. In the setting of a flow limiting stenosis, 
HMR requires correction for the contribution of collateral flow to myocardial flow, 
however, when measured post-primary PCI in patients with no residual epicardial stenosis, 
corrections for the impact of collaterals are not required170. HMR correlates with MVO on 
CMR imaging (optimal cut-off >2.5mmHg/cm per second)171 172, regional wall motion 
abnormalities173, infarct size174 175, and adverse LV remodeling176. In a comparative study 
(n=33 STEMI patients), Williams et al172 found no significant difference between HMR 
and IMR for predicting the presence of extensive MVO (defined as >3ml MVO present) on 
CMR imaging (AUC: 0.83 vs. 0.72, p=0.22). In STEMI patients (n=145), an elevated 
HMR (>2.82 mmHg/cm per second) independently predicted long-term MACE (mean 
follow up 7 years) (HR: 1.74 [95% CI: 1.35, 2.26] p<0.001)177. In another study (n=130 
STEMI patients), an elevated HMR (≥3.0 mmHg/cm per second) predicted all-cause death 
and hospitalisation for heart failure in the longer term (median follow up 3.2 years), HR: 
7.0 (95% CI: 1.5, 33.7)178.  
 
The limitations of HMR relate to the technical challenges associated with obtaining 
adequate quality Doppler flow velocity tracings, resulting in higher failure rates than when 
measuring IMR using thermodilution methodology169 178. Another limitation is the lack of a 
consistent optimal threshold for predicting clinical outcomes. 
Thermodilution-based absolute flow and resistance 
The measurement of thermodilution-based absolute flow and resistance requires a pressure 
wire with a temperature sensor and a dedicated coronary catheter, with multiple side 
holes179, for continuous saline infusion. The advantage of using continuous thermodilution 
to assess absolute coronary flow, is that it permits an invasive evaluation of microvascular 
resistance based on actual coronary flow measurement, and not a surrogate180. The method 
relies on some important observations. First, constant infusion of room temperature saline 
at 20ml/min through the dedicated catheter with multiple side holes produces steady-state 
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maximal hyperaemia equivalent to that obtained with adenosine181. Second, coronary flow 
can be calculated from the rate and temperature of infused saline and the temperature of 
mixed blood with the infused saline. The technique has been validated in vitro179 182, in a 
canine model183 and in humans183-185, and there is significant agreement between 
thermodilution-based absolute flow and positron emission tomography derived myocardial 
blood flow (the gold standard for quantification of myocardial perfusion186) (r=0.91, 
p<0.001)180.  
 
The thermodilution-based absolute flow and resistance technique has potential to reduce 
variability from manual saline injections, and thereby has potential to provide a more 
accurate and reproducible assessment of coronary microvascular status187. Studies have 
shown that this approach is feasible in acute STEMI184 185. However, current limitations 
are: (i) there is no established “normal range” of values; (ii) it can be technically 
challenging, taking longer to perform than IMR measurements; (iii) data on association 
with clinical outcomes is lacking, and: (iv) there are no direct comparison studies with 
IMR. Moreover, because the technique requires complete mixing of blood and saline183 185, 
the pressure wire tip should be ≥3cm distal to the infusion catheter tip, which precludes 
flow measurements in short vessels and may affect measurements in coronary segments 
proximal to large side branches180. Lastly, because continuous saline infusion elicits 
hyperaemia, the technique does not permit resting flow to be determined, therefore the 













Coronary flow reserve 
CFR was first described by Gould et al in 1974188, and it represents the property of 
coronary artery blood flow to increase in response to ischaemia189, i.e. vasodilatory 
reserve. CFR is defined as the ratio of hyperaemic flow to resting coronary flow: 
 
CFR =  Hyperaemic flow 
                Resting flow 
 
Because flow is the ratio of volume to Tmn, the CFR equation can be expressed as follows: 
 
CFR =     Volume    at hyperaemia   ÷      Volume    at rest 
                   Tmn                                           Tmn 
 
Assuming the epicardial volume remains unchanged, thermodilution-derived CFR can be 
calculated as follows: 
 
CFR =                 1                     ÷               1 
             Tmn at hyperaemia              Tmn at rest 
 
CFR =        Tmn at rest 
              Tmn at hyperaemia 
 
Doppler-derived CFR, termed coronary flow velocity reserve, is defined as the ratio of 
average peak velocity during hyperaemia and at rest. A head-to-head comparison, in 40 
patients with stable coronary artery disease, found that thermodilution-derived CFR had 
inferior agreement with positron emission tomography when compared to Doppler-derived 
CFR (r: 0.55 vs. 0.82, p<0.001)169. Moreover, higher intra-observer variability of 
thermodilution-, compared to Doppler-derived CFR measurements was demonstrated169. 
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However, the quality of data was poorer with Doppler-derived CFR, than with 
thermodilution methodology169. The thermodilution technique for assessing CFR assumes 
a constant coronary vessel diameter167, however in reality vessel diameter changes with 
endothelial-mediated vasodilatation190.  
 
In acute STEMI, CFR predicts MVO on CMR imaging, and larger infarct size, and the 
optimal threshold for abnormal CFR is ≤2.0149 191. However, previous studies have shown 
that CFR is inferior to IMR or HMR for predicting MVO, and does not add to the 
predictive utility to IMR or HMR149 178.  
 
An important limitation of CFR is that it is sensitive to both epicardial and microvascular 
disease192 193. The presence of residual epicardial coronary narrowing, as well as the 
presence of microvascular dysfunction, both lower CFR. Thus, CFR reflects epicardial and 
microcirculatory vasodilator capacity, as well as residual epicardial stenosis. Another 
limitation of CFR is that it is affected by determinants of resting coronary blood flow, i.e. 
heart rate and blood pressure, which diminishes the reproducibility of CFR166. Specifically, 
CFR decreases during pacing induced tachycardia or dobutamine infusion166. In contrast, 
IMR and HMR are independent of haemodynamic variation166. A further limitation of CFR 
is it’s inferior reproducibility compared to IMR, with a mean coefficient of variation of 6.9 
± 6.5% for IMR compared to 18.6 ± 9.6% for CFR166.  
Resistive reserve ratio 
The resistive reserve ratio (RRR) is a newer, less well-studied parameter, which is derived 
as the ratio between basal resting tone in the microcirculation (i.e. basal resistance index) 
and microcirculatory resistance at maximal hyperaemia (i.e. IMR)194: 
 
RRR = Basal resting tone in coronary microvasculature 
           Microvascular resistance at maximal hyperaemia 
 
RRR =                      Pd at baseline x Tmn at baseline 
            Pd at maximal hyperaemia x Tmn at maximal hyperaemia 
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RRR represents the ability of the coronary microcirculation to vary its resistance in 
response to a hyperaemic stimulus, such as adenosine194. Higher RRR values indicate 
greater vasodilatation of the microcirculation in response to hyperaemia. On the other 
hand, lower RRR values indicate poor vasodilator capacity of the coronary 
microcirculation. RRR is theoretically distinct from CFR, since RRR is an integrated index 
of both pressure and flow, whereas CFR is a surrogate marker of flow velocity195.  
 
Layland et al194 found that RRR was lower in patients with STEMI (n=40) compared to 
patients with non-STEMI (n=50) or stable angina (n=50). In another study of 73 STEMI 
patients196, RRR measured in non-culprit vessels was lower acutely vs. 1 month later, 
which indicates a blunted hyperaemic vasodilatory response acutely. Scarsini et al197 
investigated 24 STEMI patients, and found that RRR ≤1.98 (median for the cohort) at the 
end of primary PCI was associated with the extent of MVO on CMR imaging (2 days post-
PCI) and infarct size assessed at 6 months. Scarsini et al197 reported that RRR performed 
better compared to IMR and CFR in predicting 6-month infarct size (AUCs: 0.85, 0.70 and 
0.67 respectively). However, these findings need to be verified in a larger cohort. 
Lee et al195 reported that lower RRR measured in non-culprit intermediate stenoses, in 
patients with stable ischaemic heart disease from 3 pooled registries (n=1245 patients), has 
utility incremental to CFR and FFR for predicting adverse clinical outcomes. Specifically, 
among patients with CFR >2 and deferred revascularisation, RRR <3.5 (median value for 
the cohort) was associated with increased risk of adverse clinical outcomes (a combination 
of all-cause mortality, MI, or any revascularisation events during 5-year follow up)195. 
Similarly, among patients with FFR >0.8 and deferred revascularisation, RRR<3.5 was 
associated with increased risk of adverse clinical outcomes195. The association between 
RRR measured in the infarct-related artery at the end of primary PCI and clinical outcomes 
is yet to be determined. 
Thermodilution waveforms 
Because downstream microvascular resistance influences coronary blood flow, the shape 
of the thermodilution waveform in the infarct-related artery may reflect microvascular 
dysfunction. In a study of 88 acute STEMI patients, Fukunaga et al198 showed that a 
bimodal thermodilution waveform is associated with MVO on CMR imaging (within 2 
weeks), adverse LV remodeling199 (assessed by echocardiography at 6 months) and cardiac 
death at 6 months198. In an analysis of 278 acute STEMI patients from the MR-MI study, 
the association between bimodal thermodilution waveform and CMR-defined MVO or 
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myocardial haemorrhage became insignificant when the multivariable model included IMR 
>40200. However, bimodal waveform predicted all-cause death and heart failure 
hospitalisation at 4 years, independent of IMR >40200.  
 
The thermodilution bimodal waveform has limitations for translation into clinical practice. 
First, it is not quantitative, and so has limitations for detecting responses to adjunctive 
treatments in clinical trials. Second, the bimodal thermodilution waveform appears to 
underestimate microvascular dysfunction in STEMI, because the reported incidence of 
bimodal waveform ranges from 13%200 to 17%198, whereas MVO on CMR imaging occurs 
in about 50% of patients treated with primary PCI26 103.  Third, off-line post-processing is 
required to analyse thermodilution waveforms.  
Coronary zero flow pressure  
Coronary zero flow pressure (Pzf) is another parameter that can be used to assess 
microvascular resistance and is measured with a combined Doppler-pressure wire (Phillips 
Volcano Corporation, California) in the infarct-related artery175. Pzf is measured from 
hyperaemic diastolic coronary pressure-flow velocity loops (i.e. plots of average Pd and 
instantaneous peak velocity against time). Automated algorithms sample the pressure-
velocity loop at the mid-diastolic segment of the averaged cardiac cycle. A linear 
relationship between pressure and flow values exists during the mid-late phases of diastole. 
The slope of the regression line obtained over this period expresses microcirculatory 
conductance. Pzf is calculated by extrapolation from the regression line described above, 
and Pzf is the pressure where this line intercepts the x-axis. Specifically, Pzf is the Pd 
when theoretically, coronary flow would cease and mainly informs on the external pressure 
on the coronary microcirculation201. Theoretically, Pzf should reflect the intraluminal 
pressure required to maintain patent compressible elements against extravascular 
compression202. 
 
Pzf measured at the end of primary PCI predicts early infarct size174, microvascular 
perfusion defects171, adverse LV remodelling203, myocardial salvage and LV function175. 
The advantage of Pzf over the other described invasive physiology parameters is that it 
permits the assessment of coronary flow over a pressure range without the interference of 
cardiac contraction, and Pzf does not require hyperaemia. However, Pzf appears less 
transferable to clinical practice, for the following reasons: (i) difficulties acquiring high 
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quality, artefact-free, Doppler tracings; (ii) a requirement for offline post-processing; and 
(iii) lack of a validated normal range, or longer-term outcome data16.  
Summary of invasive physiology testing for microvascular injury 
In summary, invasive coronary physiology measurements are useful for early identification 
of microvascular dysfunction in acute STEMI. Compared to other invasive indices, IMR 
has more validation data suggesting a stronger potential for implementation into clinical 
practice. However, IMR is an imperfect predictor of MVO and prognosis, and it does not 
measure microvascular vasodilator capacity, whereas RRR does. If a novel invasive 
parameter were easy to obtain, reproducible and accurately predicted MVO and clinical 
outcomes, with incremental utility over IMR, this might represent an advance for clinical 
practice. 
1.4.5 LV haemodynamics 
The LV end diastolic pressure (LVEDP) is a simple haemodynamic measurement that is 
readily measured during cardiac catheterisation. Because of the proximity of the vascular 
and myocardial compartments, intramyocardial vessels may be susceptible to changes in 
LV cavity pressure30. An increased pressure in the LV cavity may result in transmitted 
external compressive forces on the microcirculation, thereby increasing endocardial 
capillary pressure, which may in turn lead to decreased perfusion pressure, with subsequent 
impairment of microvascular perfusion in the territory of the infarct-related artery30 204. 
This concept is supported by correlations between LVEDP with Pzf201.  
 
In a pooled analysis of TIMI trials, Kirtane et al204 observed that LVEDP associates with 
angiographic measures of microvascular function in the territory of the infarct-related 
artery, i.e. LVEDP was higher in patients with MPG ≤1 vs. ≥2. Higher LVEDP was also 
associated with larger infarct size (assessed by nuclear scintigraphy)205. The relationships 
between LVEDP and IMR, CFR, RRR, or MVO, have not been previously described in 
STEMI. In contrast to IMR, which is a specific measure of microvascular resistance, 
multiple overlapping factors may affect LVEDP in acute STEMI, therefore LVEDP is not 
a specific measure of microvascular function. LVEDP measured during primary PCI 
reflects acute LV pump function, including the extent of ischaemic injury, filling, 
contractility and compliance (which can be reduced due to oedema in the myocardium). 
Other factors that may potentially affect LVEDP in acute STEMI, include intravascular 
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volume status206 207, and vasodilatory drugs, e.g. nitrate, which may transiently reduce 
LVEDP. 
 
LVEDP has prognostic value in patients treated by primary PCI205 208-210. Specifically, 
elevated LVEDP (>18mmHg [median] in one study208, >22mmHg [median] in another 
study209) correlates with increased MACE, including heart failure and death, by 30 days208, 
90 days209 and 2 years208. LVEDP at the end of primary PCI also predicts mortality in the 
long-term, i.e. at 8 years follow up (HR: 1.18 [95% CI: 1.02, 1.36] p=0.022, for 5mmHg 
incremental increase in LVEDP values)205. However, there is no validated, accepted, 
LVEDP threshold for predicting adverse clinical outcomes.  
1.5 Therapeutic approaches for addressing microvascular injury 
To date, there are no effective evidence-based therapeutic strategies for preventing 
microvascular injury in acute STEMI patients with “no reflow”. Intracoronary isosorbide 
dinitrate is used on an ad hoc basis to treat patients with “no reflow” during PCI, and in 
small studies intracoronary isosorbide dinitrate was associated with improvements in 
TFC211. However, larger trials are needed to verify practice guideline recommendations on 
intracoronary nitrates for “no reflow”.  
 
Recent clinical trials of treatments designed to reduce microvascular injury, have failed to 
provide benefit, including: intravenous beta blockers212; intravenous morphine213; deferred 
stenting214-218; thrombus aspiration219 220; intracoronary adenosine91; sodium 
nitroprusside91; ticagrelor221; glycoprotein IIbIIIa inhibitors222; statins223-225; calcium 
channel blockers226; cyclosporine227 228, and; ischaemic conditioning229. Evidence from key 
clinical trials is summarised in the following section.  
1.5.1 Thrombus aspiration 
Because the effects of distal embolization on myocardial damage are greatest in patients 
who have large thrombus burden in the infarct-related artery35, clinical trials of thrombus 
aspiration during primary PCI were performed219 220 230. Following the TASTE trial219 
(thrombus aspiration during STEMI) (n=7244) and TOTAL trial220 (trial of routine 
aspiration thrombectomy with PCI vs. PCI alone in patients with STEMI) (n=10,732), 
routine aspiration thrombectomy in all-comers is not recommended. However, a meta-
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analysis of the 3 main trials of thrombus aspiration in STEMI, found that the sub-group 
with high thrombus burden had non-statistically significant trends towards reduced 
cardiovascular death, and increased stroke231. A selective strategy of bail-out aspiration 
thrombectomy in patients with high thrombus burden might be recommended, however, 
there is insufficient data to establish effectiveness25.  
1.5.2 Glycoprotein IIbIIIa inhibitors 
Glycoprotein IIbIIIa inhibitors, for example abciximab, prevent platelet aggregation. In the 
CMR sub-study (n=795) of the AIDA STEMI trial (Abciximab intravenous vs 
intracoronary in STEMI) intracoronary administration of glycoprotein IIbIIIa inhibitors 
during PCI for STEMI did not improve MVO or infarct size, when compared with 
intravenous administration222. Intracoronary glycoprotein IIbIIIa inhibitors are 
recommended as a bailout strategy during primary PCI when there is “no reflow” and large 
thrombus burden1, however, evidence for this recommendation is lacking. 
1.5.3 Deferred stenting 
Deferred stenting is a strategy whereby TIMI 3 flow is restored to the infarct-related artery 
with balloon angioplasty (without stenting), during the primary PCI procedure. The patient 
subsequently receives an infusion of heparin or glycoprotein IIbIIIa inhibitor on the ward 
to reduce thrombus burden, before returning to the catheterisation laboratory for stenting. 
In the DEFER-STEMI trial (deferred stenting vs. immediate stenting to prevent no- or 
slow-reflow in acute STEMI), 101 STEMI patients with ≥1 risk factor for no-reflow were 
randomised to deferred stenting (4 to 16 hours later) vs. standard primary PCI214. Deferred 
stenting was associated with fewer angiographic intraprocedural thrombotic events, lower 
incidence of final TIMI flow grade ≤2 and improved 6-month myocardial salvage index, 
however there was no difference in CMR-defined MVO at 2 to 7 days, or infarct size at 6 
months with deferred stenting vs. standard primary PCI214.  
 
The DANAMI-DEFER 3 trial (deferred vs. conventional stent implantation in patients with 
STEMI) compared deferred stenting at 48 hours (n=603) with standard primary PCI 
(n=612) in STEMI patients <12 hours from symptom onset215. The primary endpoint (all-
cause mortality, heart failure hospitalisation, recurrent MI, or unplanned revascularisation 
of the infarct-related artery) did not differ between patients randomised to deferred stenting 
vs. standard primary PCI (HR: 0.99 [95% CI: 0.76, 1.29] p=0.92)215. The CMR sub-study 
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(n=510) of the DANAMI-DEFER 3 trial demonstrated no difference in MVO or infarct 
size with deferred stenting vs. standard primary PCI216.  
 
The INNOVATION trial (impact of immediate stent implantation versus deferred stent 
implantation on infarct size and microvascular perfusion in patients with STEMI) (n=114) 
randomised patients within 12 hours of STEMI onset to deferred stenting (72 hours later) 
or standard primary PCI217. Overall, there was no difference in the primary endpoint 
(infarct size at 3 to 7 days post-STEMI), or CMR-defined MVO, between the 2 groups217. 
However, in the subset of patients with anterior STEMI (n=69), deferred stenting was 
associated with reduced infarct size (16.7% vs. 22.7%, p=0.017), and less MVO (43.8% 
vs.70.3%, p=0.047)217. An adequately powered randomised clinical trial may potentially be 
indicated, to assess whether deferred stenting may improve outcomes in patients with high 
thrombus burden218.  
1.5.4 Adenosine and sodium nitroprusside 
Adenosine is a coronary vasodilator, which additionally inhibits adhesion/ migration of 
neutrophils, which may contribute to ischaemia-reperfusion injury232. Sodium nitroprusside 
is a direct nitric oxide donor that mediates potent arteriolar vasodilatation233. The open-
label REOPEN-AMI trial (intracoronary nitroprusside vs. adenosine in acute MI)234 found 
that the primary endpoint of incidence of complete (>70%) ST-segment resolution on the 
ECG at 90 minutes post-reperfusion was higher with intracoronary adenosine (2mg) 
(n=80) compared to saline control (n=80) (71% vs. 51%, p=0.009). However, a limitation 
of the REOPEN-AMI trial is that non-invasive imaging was not performed to assess MVO 
or infarct characteristics234.   
 
In the open-label REFLOW-STEMI trial (reperfusion facilitated by local adjunctive 
therapy in STEMI), vasodilator therapy with high-dose intracoronary adenosine (2 to 3mg) 
(n=82) and intracoronary sodium nitroprusside (n=79) during primary PCI did not reduce 
CMR-derived infarct size or MVO, when compared to standard PCI (n=86)91. In fact, high-
dose intracoronary adenosine was associated with larger infarct size (12,0% vs. 8.3%, 
p=0.031), worse LV ejection fraction (42.5% vs. 45.7%, p=0.027) and an increase in 
MACE at 6 months (HR: 5.39 [95% CI: 1.18, 24.60] p=0.04)91. The findings suggest a 
safety concern with high dose intracoronary adenosine in STEMI patients with “no 
reflow”91. Adenosine may reduce coronary flow in STEMI when the infarct-related artery 
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has large collaterals and a profound fixed microvascular injury, which is unresponsive to 
adenosine, resulting in inter-coronary steal phenomenon, i.e. where blood is diverted away 
from the myocardium supplied by the infarct-related artery, to adjacent vascular beds, 
which dilated with adenosine235. 
1.5.5 Antiplatelet therapy 
Ticagrelor has been reported to increase plasma adenosine levels, due to off-target 
properties236. The REDUCE-MVI trial (reducing microvascular dysfunction in acute MI by 
ticagrelor) evaluated 110 patients undergoing primary PCI, and found no differences in 
invasive measures of microvascular injury measured at 1-month, between patients 
randomised to ticagrelor vs. placebo221. 
1.5.6 Beta blockers  
Recent STEMI guidelines suggest that intravenous beta blocker should be considered at 
presentation in patients undergoing primary PCI, without contraindications, i.e. acute heart 
failure or systolic blood pressure ≤120mmHg1. Intravenous administration of the β1 
selective blocker metoprolol, before reperfusion, may impair neutrophil migration, by 
preventing changes to neutrophil structure, which are needed to initiate intracellular 
interactions and tissue infiltration, in the early phases of neutrophil recruitment237. 
 
The EARLY-BAMI trial (early-beta blocker administration before reperfusion primary 
PCI in patients with STEMI) was a randomised, double-blind trial, which compared 
intravenous metoprolol (2 x 5mg bolus, administered immediately before PCI) to placebo, 
in all-comer STEMI patients undergoing primary PCI, <12 hours from symptom onset 
(n=683)212. The primary endpoint (infarct size at 30 days, assessed by CMR imaging) did 
not differ between the metoprolol vs. placebo group (15.3% vs. 14.9%, p=0.616)212. MVO 
was not reported in the EARLY-BAMI trial212. In contrast, the METOCARD-CNIC trial 
(effect of metoprolol in cardioprotection during an acute MI) compared intravenous 
metoprolol (3 x 5mg bolus, administered in the ambulance before PCI) to standard care in 
patients with anterior STEMI undergoing primary PCI <6 hours from symptom onset 
(n=270)238. METOCARD-CNIC was a single-blind trial, i.e. the outcome assessors were 
blinded239. The primary endpoint (infarct size 5 to 7 days post-STEMI, assessed by CMR 
imaging) was smaller with intravenous metoprolol vs. control (25.6g vs. 32.0g, adjusted 
difference: -6.53 [95% CI: -11.39, -1.78] p=0.012). Moreover, there was a 40% reduction 
in CMR-defined MVO with intravenous metoprolol vs. control237. LV ejection fraction at 6 
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months post-STEMI was higher with intravenous metoprolol vs. control (48.7% vs. 45.0%, 
adjusted treatment effect: 3.49% [95% CI: 0.44, 6.55] p=0.025)240. At 2 years follow up, 
there was no difference in the prespecified composite outcome of death, heart failure 
admission, reinfarction and malignant arrhythmias between the intravenous metoprolol 
group and controls (10.8% vs. 18.3%, adjusted HR: 0.55 [95% CI: 0.26, 1.04] p=0.065)240. 
The contrasting findings of the EARLY-BAMI and METOCARD-CNIC trials may relate 
to the different dosing of metoprolol (10mg vs. 15mg) and the different trial populations 
(all-comers vs. anterior STEMI, and ischaemic time <12 hours vs. <6 hours). An 
adequately powered, double-blind, randomised clinical trial of intravenous metoprolol 
(15mg) in STEMI patients <6 hours from symptom onset vs. placebo may be warranted.  
1.5.7 Statins 
High-dose statin therapy has been postulated to prevent “no reflow”, due to pleiotropic 
effects, including activation of mitochondrial potassium channels following statin pre-
treatment241, anti-inflammatory effects242 and improvement of endothelial function. 
However, the effects of pre-treatment with statins on microvascular injury in STEMI 
patients is conflicting243-245, and randomised clinical trials, which used CMR to assess 
infarct characteristics, have shown that statins prior to primary PCI did not reduce MVO223 
224, or infarct size223 225. 
1.5.8 Ischaemic conditioning  
Ischaemic conditioning has been postulated to reduce reperfusion injury, and is defined as: 
(i) repeated brief episodes of mechanical ischaemic reperfusion (either at the site of the 
target organ or at a remote site), or (ii) pharmacological prevention of the opening of the 
mitochondrial permeability transition pore at the onset of reperfusion202. In randomised 
clinical trials, cyclopsorine, which inhibits the mitochondrial permeability transition pore, 
did not improve clinical outcomes, when administered intravenously during primary PCI227 
228. The CONDI-2/ERICPPCI trial (effect of remote ischaemic conditioning on clinical 
outcomes in STEMI patients undergoing primary PCI) was a large multicentre, single-
blind, randomised controlled trial (n=5401 primary PCI patients), which compared remote 
ischaemic conditioning to standard care229. The primary endpoint of the CONDI-
2/ERICPPCI trial (12-month cardiac death or hospitalisation for heart failure) did not differ 
between the remote ischaemic conditioning group vs. standard care229. Infarct size 
(evaluated by troponin T levels) also did not differ between the remote ischaemic 
conditioning group vs. standard care229. 
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1.5.9 Intracoronary hypothermia  
In animal models of MI, hypothermia has been shown to reduce infarct size246. The 
underlying mechanism of this protective effect may be that intracoronary hypothermia 
reduces metabolic demand, which in turn reduces oxidative stress on the ischaemic 
myocardium, thereby attenuating myocardial reperfusion injury247. However, systemic 
hypothermia in humans has failed to demonstrate a reduction in infarct size, perhaps due to 
inability of the myocardium to reach the target temperature before reperfusion248. 
Furthermore, systemic cooling can cause adverse effects, such as volume overload and 
severe shivering249. Selective intracoronary hypothermia to the infarcted myocardium 
overcomes the limitations of systemic cooling, and has been shown to be feasible and 
safe250. In a pilot study of 60 patients undergoing primary PCI, intracoronary hypothermia 
before stent implantation was associated with smaller infarct size (2 to 7 day) assessed by 
CMR imaging, compared to standard care251. The ongoing EURO-ICE trial (European 
intracoronary cooling evaluation in patients with STEMI) is a randomised controlled trial, 
which is investigating localised intracoronary hypothermia administered to the infarct-
related artery (pre-stent implantation), in anterior STEMI patients with symptom onset ≤6 
hours (NCT03447834)252 253. The target sample size for EURO-ICE is 200 patients, the 
primary endpoint is 3-month infarct size (assessed by CMR imaging), and the estimated 
study completion date is in 2022253. 
1.6 Coronary physiology to select patients for treatments and to assess 
treatment efficacy 
Because microvascular dysfunction does not occur in all STEMI patients, clinical trial 
design could potentially be improved by the initial selection of patients at increased risk, in 
whom adjunctive treatment might be of benefit. Some studies have used IMR as a tool for 
acute risk stratification, to select patients at high risk of “no reflow” for novel therapies 
during primary PCI254 255, and to assess response to treatment221 254-268. Figure 1.3 depicts 
the potential use of IMR for prognostication and hypothetical future directions to guide 











Figure 1.3 Illustration of the potential value of IMR as a prognostic biomarker, and 
hypothetical scenarios using IMR to guide stratification of acute STEMI patients for 
adjunctive therapies in randomised trials. Abbreviation: PICSO = pressure-controlled 
intermittent coronary sinus occlusion. Adapted from: Maznyczka A et al. The potential use 
of index of microcirculatory resistance (IMR) to guide stratification of patients for 
adjunctive therapy in acute myocardial infarction. JACC Cardiovasc Interv. 2019. 12(10): 
951-966. Doi: 10.1016/j.jcin.2019.01.24616.  
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1.6.1 Studies using IMR as a theragnostic biomarker 
Stratified medicine is the identification of patient sub-groups (or endotypes) within a 
heterogeneous population, these being distinguishable by disease severity and potential for 
response to therapy16 269. A theragnostic biomarker is a metric that predicts therapeutic 
response16. In a small observational study with no control group (n=18), Morimoto et al254 
used IMR ≥30 immediately post-primary PCI, as a theragnostic biomarker to select 
patients for adjunctive intracoronary sodium nitroprusside (Table 1.1).  
 
In the OxAMI-PICSO non-randomised pilot study (Oxford acute MI – pressure-controlled 
intermittent coronary sinus occlusion), De Maria et al255 used IMR >40 pre-stenting to risk 
stratify anterior STEMI patients for treatment with PICSO (pressure-controlled intermittent 
coronary sinus occlusion) during primary PCI (Table 1.1). The postulated therapeutic 
action of PICSO is that cyclic balloon inflations in the coronary sinus for ≥30 minutes may 
redistribute blood from the remote non-ischaemic myocardium to under perfused areas, i.e. 
to the border zone of the ischaemic myocardium. The redistribution of blood when the 
balloon is inflated may be due to retrograde perfusion from the distal infarct-related artery, 
as well as augmented collateral inflow, from adjacent non-infarct-related arteries supplying 
the border zone of the myocardium. In addition, arterial pressure decreases during deflation 
of the coronary sinus balloon, which may create a suction effect, which enhances washout 
of embolic material. In OxAMI-PICSO, there was no difference in IMR at the end of 
primary PCI between PICSO and historical controls255. However, at 24 to 48 hours 
following primary PCI, IMR was lower in the PICSO group (24.8 vs. 45.0, p<0.001)255. 
There were no between-group differences in acute infarct size, or MVO, but 6-month 
infarct size (assessed by CMR imaging) was lower with PICSO (26.0% vs. 33.0%, 
p=0.006)255. The PiCSO-AMI-I trial (pressure-controlled intermittent coronary sinus 
occlusion in acute MI) is an ongoing, randomised (1:1) clinical trial, using pre-stenting 
IMR >40 to select acute anterior STEMI patients for intervention with PICSO 
(NCT03625869)270. The target enrolment for the PiCSO-AMI-I trial is 144 patients, and 
the estimated completion date is 2023270. 
 
A precision medicine approach using pre-stenting IMR is being used to evaluate deferred 
stenting in a large ongoing clinical trial, with a target sample size of 880 acute STEMI 
patients) (NCT03581513)271. The comparator groups are IMR ≤40 randomised to either 
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deferred stenting or standard primary PCI, and IMR >40 randomised to either deferred 
stenting or standard primary PCI. The primary outcome is the prevalence of heart failure, 
repeat MI, or target vessel revascularisation at 1 year. Two more ongoing, randomised 
clinical trials, are using post-stent IMR (>30, or >32) as a theragnostic biomarker to guide 
stratified therapy with adjunctive intracoronary fibrinolytics during primary PCI, and are 
described in section 1.7.9 ([NCT02894138]272 and [ACTRN12618000778280]273). 
1.6.2 Studies using IMR to assess treatment efficacy 
Non-randomised254-257 274 and randomised221 258 261-268 studies that measured IMR in STEMI 
patients, to assess the immediate efficacy of adjunctive treatments, which were designed to 
reduce microvascular injury, are presented in Tables 1.1 and 1.2. The quality of studies is 
variable, with some non-randomised254-257 252, some without a control group254 257 261, some 
without blinding254 255 257 261 264-268, some without non-invasive imaging254 256 258 and some 
with small sample sizes254 256 257 259 264 266.  
 
The timing for the IMR measurement to assess therapeutic response in different studies is 
not consistent. The majority of studies measured IMR post-stenting, at the end of the same 
PCI procedure254 256 257 262-265 268. However, some studies made another IMR measurement 
2 days later255, and some only measured IMR during an additional catheterisation 
laboratory procedure, performed 2 days post-PCI259 260, or 4 to 5 days post-PCI266. The 
timing for IMR measurement is relevant, because there are dynamic changes in 
microvascular dysfunction following acute STEMI, related to ischaemic time16. IMR and 
CFR undergo partial recovery in the first 24 to 48 hours following reperfusion, with further 
recovery to 6 months157 163 275 276. It may be that in patients with a short duration of 
ischaemia a decrease in IMR over time post-PCI reflects a microvascular recovery 
response16. However, repeated invasive procedures to measure IMR 24 to 48 hours after 
primary PCI would create additional costs, logistical issues and potential safety risks, 
therefore information from invasive coronary physiology is most practically useful at the 


























Ito et al256  
2010 
 
40 Intracoronary nicorandil 
post-PCI vs. placebo 
control 
IMR immediately after PCI, pre-
study drug and post-study drug 
• IMR was lower post- vs. pre-nicorandil 
(median values: 18.7 vs. 27.7, p<0.001).  
• No difference in IMR post vs. pre-control 
(23.8 vs. 24.3, p=0.819).  
• In the sub-group with baseline IMR ≥21, 
IMR was lower with nicorandil vs. control. 
 
Not reported 




32 Intracoronary nicorandil 
post-PCI (no control) 
IMR immediately post-PCI and 
10 minutes post-nicorandil 
 
IMR was lower post- vs. pre-nicorandil (mean 
values: 9.9 vs. 14.1, p<0.001) 
Improvement in wall motion score index on 
echocardiography at 3 months post-PCI vs. 24 hours 
post-PCI (1.07 vs. 1.14, p=0.004) 
 
Morimoto et al254 
2012 
 
18 patients with 
IMR ³30 post-PCI 
Intracoronary sodium 
nitroprusside (no control) 
 
IMR immediately post-PCI pre-
study drug and post-study drug 





Pressure-controlled intermittent coronary sinus occlusion: 
 




75 patients with 
IMR >40 
(25 patients treated 
with PICSO and 50 
historical controls) 
PICSO vs. standard 
primary PCI 
 
• IMR immediately post-PCI in 
all patients. 
• IMR 24 to 48 hours post-PCI 
in 20 PICSO patients and in 
31 controls with IMR >40 
• IMR was lower 24 - 48 hours post-PCI in 
the PICSO group vs. control group (median 
values: 24.8 vs. 45.0, p<0.001) 
• No difference between groups for IMR 
measured immediately post-PCI (p=0.40) 
 
• Infarct size on CMR 6-months post-PCI was lower 
with PICSO vs. controls (26% vs. 33%, p=0.006). 
• No difference between PICSO vs. controls for 
infarct size (39% vs. 41%, p=0.42) or MVO 





Firman et al274 
2020 
45 patients with 
high thrombus 
burden 
Thrombus aspiration vs. 
standard primary PCI 
IMR immediately post-PCI 
 
No difference in IMR in patients who received 
thrombus aspiration vs. standard primary PCI 
(51.9 vs. 47.1, p=0.723) 
No difference in global longitudinal strain on 
echocardiography at 6 months with thrombus aspiration 
vs. standard primary PCI (-13.0 vs. -12.8, p=0.912). 
 
 



















Difference in IMR +/ - CFR 
 




















• As a first administration nicorandil reduced 
IMR more than nitroglycerin (median 
values: 10.8 vs. 2.1, p=0.0002). 
• As a second administration, nicorandil 
further reduced IMR, whereas nitroglycerin 






Sezer et al259 
2007 
 





IMR and CFR 
at 2 days and 
infarct size at 
6 months 
IMR and CFR 
2 days post-
PCI 
• IMR was lower with streptokinase (mean 
values: 16.3 vs. 32.5, p<0.001). 
• CFR was higher with streptokinase (mean 
values: 2.0 vs. 1.4, p=0.002) 
 
No difference in infarct size by SEPCT at 6 months 
with streptokinase vs. controls (27.8% vs. 37.3%, 
p=0.17) 
Sezer et al260 
2009  









Infarct size at 
6 months 
IMR and CFR 
2 days post-
PCI 
• IMR was lower with streptokinase vs. 
controls (mean values: 20.2 vs. 34.2, 
p<0.001). 
• CFR was higher with streptokinase vs. 
controls (mean values: 2.5 vs. 1.7, p<0.001) 
 
  
Infarct size by SPECT 6 months post-primary-PCI 
was smaller with streptokinase vs. controls (22.7% 
vs. 32.9%, p=0.003) 

















IMR was lower with prourokinase vs. thrombus 
aspiration (mean values: 28.2 vs. 33.6, 
p=0.005). 
• LV ejection fraction by echocardiography (12 
months post STEMI) was higher with 
prourokinase vs. thrombus aspiration (58.1% vs. 
55.2%, p=0.043). 
• Infarct size by SPECT at 12 months was higher 
with prourokinase vs. thrombus aspiration 
(18.6% vs. 22.7%, p=0.046) 
  
 





















Difference in IMR +/ - CFR 
 













IMR was lower with thrombus aspiration vs. 
controls (mean values: 23.5 vs. 34.2, p=0.018) 
Reduction in wall motion score index on 
echocardiography during first admission for STEMI 
and 6 months later was greater with thrombus 
aspiration vs. controls (-0.12 vs. -0.004, p=0.001). 
 
Hoole et al263 
2015 
IMPACT trial  
 








No difference in IMR between aspiration 
thrombectomy vs. balloon angioplasty (mean 
values: 43.3 vs. 44.6, p=0.90).  
 
No difference in MVO occurrence, or infarct size, 
on CMR 1-day post-PCI with aspiration 
thrombectomy vs. balloon angioplasty. 
 















• IMR was lower in the combination group vs. 
abciximab only group (mean values: 23.5 vs. 
66.9, p=0.001). 
• No difference in IMR between the 
combination group vs. aspiration 
thrombectomy only group (mean values: 
23.5 vs. 37.2, p=0.07) 
• MVO occurrence on CMR 5 days post-STEMI 
was lower in the combination group vs. 
abciximab only group (18.8% vs. 88.9%, 
p=0.002).   
• No difference in MVO occurrence in the 
combination vs. aspiration thrombectomy only 
group (18.8% vs. 66.7%, p=0.054) 
 
Direct thrombin inhibition: 
 













Infarct size by 





IMR was lower with bivalirudin vs. 
unfractionated heparin (mean values: 43.5 vs. 
68.7, p=0.014) 
• No difference in mean infarct size on CMR with 
bivalirudin vs. heparin (25.0% vs. 27.1%, 
p=0.75). 
• No difference in MVO extent with bivalirudin 
vs. heparin (5.3g vs. 7.7g, p=0.17) 
  
 






















Difference in IMR +/ - CFR 
                                                                     





van Leeuwen et al221 
2019 
REDUCE-MVI 









• No difference in IMR at 1 month with 
ticagrelor vs. prasugrel (median values: 21 
vs. 18, p=0.08). 
• No difference in CFR at 1 month with 
ticagrelor vs. prasugrel (mean values: 3.7 vs. 
3.9, p=0.66). 
• No difference in MVO at 2 to 7 days with 
ticagrelor vs. prasugrel (mean values: 11 vs. 17, 
p=0.35). 
• Less myocardial haemorrhage at 2 to 7 days 
with ticagrelor vs. prasugrel (8 vs. 18, p=0.04). 
• No difference in infarct size at 1 month with 
ticagrelor vs. prasugrel (7.6% vs. 8.7%, 
p=0.14). 
 









IMR and CFR IMR and 
invasive CFR 
4 to 5 days 
post-PCI 
• IMR did not differ with intracoronary vs. 
intravenous tirofiban (mean values: 27 vs. 
35, p=0.08). 
• CFR did not differ with intracoronary vs. 
intravenous tirofiban (mean values: 2.2 vs. 
1.9, p=0.25) 
 
No difference in infarct size on SPECT at 6 months 
with intracoronary vs. intravenous tirofiban (18% 
vs. 12%, p=0.26). 















No difference in IMR between cangrelor and 
ticagrelor groups 
No difference in infarct size on CMR 3 months 
post-PCI between cangrelor and ticagrelor groups. 










IMR was lower with ticagrelor vs. clopidogrel 
(mean values: 22.2 vs. 34.4, p=0.005).  
No difference in estimated infarct size by wall 
motion score index on echocardiography with 
ticagrelor vs. clopidogrel at 24 hours (1.55 vs. 1.61, 
p=0.41), or 3 months (1.42 vs. 1.47, p=0.57). 
 
 
Table 1.2 (page 3 of 3) Randomised studies, using IMR to measure the efficacy of interventions designed to reduce microvascular injury in STEMI patients 
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1.7 Intracoronary fibrinolysis as a potential adjunctive treatment for 
acute microvascular dysfunction 
There has been recent interest in the potential efficacy of intracoronary low-dose 
fibrinolytic therapy, to minimise microvascular damage, during primary PCI. The 
following section is an overview of intracoronary fibrinolytic therapy, which critically 
appraises the evidence from randomised clinical studies and describes the ongoing trials.  
1.7.1 Mechanism of action of fibrinolytic drugs 
Thrombolytic drugs activate endogenous fibrinolysis130, by catalysing the formation of 
plasmin from plasminogen (Figure 1.4). Plasmin then breaks down the cross-linked fibrin 
matrix in thrombus277, releasing soluble fibrin degradation products. Plasmin also has 
paradoxical procoagulant effects, due to the activation of factor V to Va. The factor X – Va 
complex converts prothrombin to thrombin, releasing prothrombin fragments F1+2. 
Thrombin then converts fibrinogen to fibrin, forming thrombus. Thrombin also activates 
platelets, which are a source of coagulation proteins and release plasminogen activator 
inhibitor-1 (PAI-1) (a plasmin antagonist that can inhibit fibrinolysis).  
 
The oldest thrombolytic drug is streptokinase, which is a protein produced by group B 
haemolytic streptococci bacteria278 279 and purified for clinical use. Streptokinase (plasma 
half-life: 12 to 18 minutes)280 is a first-generation, non-fibrin specific, allergenic, 
thrombolytic drug. Another first-generation, non-fibrin specific thrombolytic agent is 
urokinase. Urokinase is an enzyme cultured from human kidney cells and has a plasma 
half-life of 15 to 20 minutes280.  
 
Newer thrombolytic agents were developed to enable fibrin specificity. Prourokinase 
(plasma half-life: 9 minutes)281 is a fibrin-specific, second-generation fibrinolytic agent. 
Prourokinase is a proenzyme precursor of urokinase. When two single chain prourokinase 
units are activated by fibrin-associated plasmin, they bind at the thrombus surface to form 
an active two chain urokinase molecule282. Alteplase (plasma half-life: 4 to 8 minutes)281 is 
another second-generation fibrin-specific fibrinolytic drug. Alteplase is a serine protease 
found on endothelial cells and is manufactured from recombinant biotechnology, being 
referred to as recombinant tissue plasminogen activator (r-TPA).  
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Third-generation thrombolytic agents have been developed with focus on (i) longer half-
lives (to enable intravenous bolus injections, instead of the continuous infusions required 
with the earlier-generation thrombolytics)283, (ii) higher fibrin-specificity284 285 (to increase 
potency and potentially decrease undesirable bleeding events), and (iii) greater resistance 
to plasminogen activator inhibitor-1 (to increase potential potency especially for platelet 
rich clots)286 287. Tenecteplase (plasma half-life: 20 minutes)281 is a third-generation fibrin-
specific r-TPA. Specifically, tenecteplase is a glycoprotein, developed by introducing 
modifications to the complementary deoxyribonucleic acid for natural TPA283. 
 
 
Figure 1.4 Competing processes involved in local fibrinolytic therapy. Adapted and 
reproduced with permission from: Berry C, Maznyczka A, McCartney P. Failed 
myocardial reperfusion during primary PCI: an unmet therapeutic need. EuroIntervention. 
2019. 14:1628-1630. Doi: 10.4244/EIJV14I16A279.288 
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1.7.2 Insights from systemic fibrinolysis combined with PCI 
The STREAM trial (strategic reperfusion early after MI) (n=939) explored a pharmaco-
invasive strategy consisting of early fibrinolysis (within 3 hours of symptom onset) for 
patients unable to undergo primary PCI within 1 hour, followed by either rescue PCI (for 
failed thrombolysis), or non-urgent angiography within 24 hours289. When compared to 
primary PCI without fibrinolysis, the pharmaco-invasive strategy had more open vessels at 
the start of angiography289. There were no differences between the 2 groups for death, 
shock, heart failure, or reinfarction at 30-days, however the fibrinolysis arm was associated 
with an increased risk of intracranial haemorrhage (1.0% vs. 0.2%, p=0.04)289.  
 
These data should be put into context with the findings from studies of facilitated primary 
PCI, i.e. where thrombolysis (full- or half-dose) is followed by immediate pre-planned 
PCI, to mitigate the delay associated with PCI. Fibrinolytic therapy before immediate 
planned PCI improved initial vessel patency290 291. However, the ASSENT-4 trial290 
(assessment of the safety and efficacy of a new treatment strategy with PCI 4) found that 
primary PCI with prior full-dose tenecteplase (n=823) was associated with higher 
mortality, reinfarction, congestive heart failure and more ischaemic strokes than standard 
primary PCI without fibrinolysis (n=831). The FINESSE trial291 (facilitated intervention 
with enhanced reperfusion speed to stop events) (n=2452) reported that facilitated primary 
PCI with combinations of reteplase plus abxicimab, or abxicimab alone did not improve 
clinical outcomes compared to standard primary PCI. 
 
The results from the studies of facilitated primary PCI290 291, may be partly explained by 
the fact that clopidogrel was not given at that time. Furthermore, the results of the 
ASSENT-4 trial290 could potentially be explained by relatively inadequate anticoagulation 
and potentially paradoxical activation of thrombin, with formation of fibrin and thrombus 







1.7.3 Intracoronary fibrinolysis 
Intracoronary administration of fibrinolytic drugs allows lower systemic and higher local 
concentrations of the drug at the site of the thrombus. Registries have demonstrated that 
intracoronary fibrinolysis can be an effective treatment for acute coronary thrombosis293-
295. Randomised clinical studies of adjunctive low-dose intracoronary fibrinolytic therapy 
during primary PCI are summarised in Table 1.3. These studies259-261 292 296-303 did not show 
any significant bleeding events with intracoronary low-dose fibrinolytics. 
 
A recent meta-analysis of 6 randomised controlled trials, found no difference in the 
primary endpoint, i.e.TIMI flow ≥2 in the infarct-related artery, with intracoronary 
fibrinolysis vs. standard care/ placebo304. Nonetheless, there was a higher incidence of 
complete ST-segment resolution with intracoronary fibrinolysis vs. placebo, and a trend 
favouring fewer in-hospital MACE with intracoronary fibrinolysis, which led the authors 
to conclude that  intracoronary fibrinolysis is safe and potentially effective during primary 
PCI304. However, the primary endpoint of TIMI flow ≥2 is not synonymous with 
normalised myocardial perfusion, and the meta-analysis304 did not include a subsequent 
sub-group analysis from T-TIME (trial of low-dose adjunctive alteplase during primary 
PCI), which raises a safety concern with intracoronary alteplase303. 
1.7.4 Intracoronary streptokinase 
One of the earliest reports of intracoronary streptokinase administration in the management 
of STEMI patients (n=5) was by Rentrop in the 1970s305. The feasibility of intracoronary 
streptokinase was further demonstrated in an observational study of STEMI patients from 
the 1980s, which reported successful reperfusion in 38 of 46 single vessel occlusions 
associated with a first MI306. Moreover, it has been demonstrated histopathologically in a 
canine model of LAD occlusion, that intracoronary streptokinase administered over 30 
minutes, after 2 hours of LAD occlusion, improved microvascular reperfusion, when 
compared to control307. 
 
The first randomised clinical trial of intracoronary streptokinase in STEMI patients was 
reported by Sezer et al in 2007259. Forty-one patients undergoing primary PCI <12 hours 
from symptom onset, were randomised to adjunctive intracoronary streptokinase (250 kU) 
infused over 3 minutes immediately post-stent implantation (n=21), or no additional 
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therapy (n=20). They reported improvements in mean CFR and IMR when catheterisation 
was repeated 2 days later, in the streptokinase group vs. standard care group (CFR: 2.0 vs. 
1.4, p=0.002; IMR: 16.3 vs. 32.5, p<0.001)259. The findings suggest that streptokinase 
might reduce microvascular damage and improve myocardial reperfusion. When enrolment 
was increased to 95 patients, in a second report from the same group, mean TFC was lower 
and MPG ≥2 occurred more frequently in the streptokinase group (n=51) than with 
standard care (n=44) (TFC: 20.7 vs. 29.2, p<0.001; MPG ≥2: 86% vs. 36%, p<0.001)260. 
However, there was no difference in % ST-segment resolution between streptokinase and 
standard care groups260. At 6 months, Sezer et al260 also recorded improvements in mean 
infarct size, LV volumes and LV ejection fraction (assessed by SPECT) in the 
streptokinase group vs. standard care group (infarct size: 22.7% vs. 32.9%, p=0.003; LV 
ejection fraction: 57.2% vs. 51.8%, p=0.018). There was no difference in MACE at 6 
months, however the study was underpowered for clinical outcomes. 
 
The findings reported by Sezer et al259 260 should be interpreted with some caution. The 
intervention was open-label, with no placebo, and the acquisition and analysis of endpoints 
was mainly performed by unblinded investigators. Furthermore, the size of the cohort was 
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Yes Pre-stent  Used in 27% 
of patients 
• Overall, no difference with alteplase vs. placebo for 
MVO assessed by CMR imaging (at 2 to 7 days), or 
1-year clinical outcomes. 
 
Gibson et al296 
2020 




4mg x 2 
Volume - 
matched saline 
(2ml x 2) 
No 4mg pre-stent, 
followed by 4mg 
post-stent 
Not reported • More patients in the tenecteplase group had reduction 
in TIMI thrombus grade after the first bolus of study 
drug than controls. 
• Fewer patients in the Tenecteplase group had TFC 
<14 than in the placebo group. 
• No difference in MPG, or % diameter stenosis of the 
infarct-related lesion with tenecteplase vs. control. 
 







No Pre-stent Not reported • Lower peak troponin I, higher rate of ST-segment 
resolution >70% and better myocardial perfusion 
assessed by echocardiography (at 7 days) with 
prourokinase vs. controls. 
• No difference in 6-month MACE. 
 







No Pre-stent Used in all 
patients 
• Lower TFC, lower peak troponin, greater rates of ST-
segment resolution >70% and improved 6-month LV 
ejection fraction with prourokinase vs. control. 
• Lower 6-month MACE rates with prourokinase vs. 
control. 
 
Xiao et al261 
2019 
71 Prourokinase 
10 – 20mg 
Thrombus 
aspiration 
No Pre-stent Only as 
comparator  
IMR, MPG, TFC, 12-month infarct size, LV ejection 
fraction and MACE rates improved with prourokinase 
vs. thrombus aspiration. 
 
        
 
Table 1.3 (page 1 of 2) Summary of randomised clinical studies of adjunctive intracoronary fibrinolysis, during primary PCI. All studies reported that 
intracoronary low-dose fibrinolysis was not associated with significant bleeds. 
 
 



































No Pre-stent Used in all 
patients  
• Greater volume of thrombus aspirated with urokinase 
vs. control. 
• Higher rates of final TIMI 3 flow, MPG ≥2, and ST-
segment resolution >70% with urokinase vs. control. 




Sezer et al259 260 




250 kU (20ml) 
Standard care No Post-stent Not reported • Better CFR, IMR, TFC, MPG ≥2 rates, and better 6-
month infarct size, LV volumes and ejection fraction 
(by SPECT) with streptokinase vs. standard care. 
• No difference in 6-month MACE 
 
 












No Pre-stent Used in 34% 
of patients 
• Higher TFC and lower rates of MPG ≥2 with 
tenecteplase vs. abciximab. 
• No difference in 4-month infarct size (by CMR). 
Zhu et al301 
2013 
ICTUS – AMI trial 
490 Urokinase 







No Pre-stent Not reported • No difference in rates of ST-segment resolution 
≥70%. 
• Absolute % ST-segment resolution worse with 
urokinase vs. tirofiban 
 
Table 1.3 (part 2 of 2) Summary of randomised clinical studies of adjunctive intracoronary fibrinolysis, during primary. All studies reported that 
intracoronary low-dose fibrinolysis was not associated with significant bleeds. 
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1.7.5 Intracoronary urokinase and up-front fibrinolysis before manual thrombectomy 
The DISSOLUTION randomised clinical trial (delivery of thrombolytics before 
thrombectomy in patients with STEMI undergoing primary PCI) explored the effects of 
intracoronary urokinase prior to aspiration thrombectomy (n=102)299. Acute STEMI 
patients <12 hours from symptom onset, with TIMI 0 flow in the infarct-related artery on 
initial angiography were included. Up-front intracoronary urokinase (administered over 5 
minutes) was associated with increased volume of thrombus aspirated with manual 
thrombectomy, compared to saline control. Up-front urokinase was also associated with a 
higher incidence of TIMI 3 flow at the end of PCI, increased rate of MPG ≥2 at the end of 
PCI, and increased rate of ST-segment resolution >70%299. At 6 months, MACE was less 
frequent in the urokinase group, driven by a reduction in rehospitalisation for heart failure 
(6% vs. 21%, log-rank p=0.044). The DISSOLUTION trial299 had some limitations. First, 
it was an open-label study, so there was potential bias from cardiologists knowing whether 
the participants were receiving urokinase or saline. Second, non-invasive imaging to assess 
infarct size, or myocardial perfusion was not performed. To date, there are no other 
randomised trials of up-front intracoronary fibrinolysis, prior to manual thrombectomy, in 
STEMI patients with large thrombus burden. 
 
The ICTUS-AMI trial (intracoronary tirofiban vs. urokinase as an adjunct to primary PCI 
in patients with acute STEMI)301 compared adjunctive intracoronary urokinase to 
intracoronary glycoprotein IIbIIIa inhibitor (n=490). The adjunctive intervention was 
administered within 1 minute, immediately after restoration of infarct-related artery 
patency, pre-stent implantation. Even though there was no difference in the primary 
endpoint, (ST-segment resolution ≥70%), absolute % ST-segment resolution was worse in 
the urokinase group compared to the glycoprotein IIbIIIa inhibitor group301. 
1.7.6 Intracoronary prourokinase 
The open-label randomised clinical studies of intracoronary prourokinase compared to 
volume-matched saline control297 298, or compared to thrombus aspiration261, during 
primary PCI, should be interpreted with some caution, because the administration of the 





Xiao et al261 compared intracoronary prourokinase (10 to 20mg), which was administered 
distal to the lesion pre-stent implantation (n=38), to thrombus aspiration pre-stent 
implantation (n=33). STEMI patients <12 hours from symptom onset were included. IMR 
measured at the end of the PCI procedure was lower with prourokinase vs. thrombus 
aspiration (mean values: 28.2 vs. 33.6, p=0.005)261. At 12 months, LV ejection fraction 
assessed echocardiographically was higher with prourokinase vs. thrombus aspiration 
(58.1% vs. 55.2%, p=0.043) and infarct size assessed by SPECT was lower with 
prourokinase (18.6% vs. 22.7%, p=0.046)261. Moreover, 12-month MACE rates were lower 
with prourokinase vs. thrombus aspiration (45% vs. 70%, p=0.034)261. 
 
Geng et al297 included STEMI patients <12 hours of symptom onset. Intracoronary 
prourokinase (10mg) was administered distal to the lesion over 3 minutes, pre-stent 
implantation (n=118), or for the control group 10ml of saline was administered in the same 
way (n=112). Peak levels of troponin I (surrogate marker of infarct size) were lower in the 
prourokinase group (mean: 21.5ng/L vs. 23.1ng/L, p=0.017)297. More patients in the 
prourokinase group had ST-segment resolution >70% than in the control group (89% vs. 
79%, p=0.047)297. Myocardial perfusion, evaluated by contrast echocardiography 7-days 
after primary PCI, revealed higher myocardial blood flow with prourokinase compared 
with controls297. At 6 months, MACE rates did not differ between prourokinase vs. control 
groups (9% vs. 13%, p=0.434)297.  
 
External validation for the findings297 was provided by Wang et al298. Acute STEMI 
patients <12 hours from symptom onset, were randomised to intracoronary prourokinase 
(20mg) administered proximal to the lesion over 3 minutes (n=92), or control, i.e.10ml 
saline administered in the same way (n=90)298. There were improvements in numerous 
surrogates of myocardial perfusion in the prourokinase group vs. control group, including: 
(i) mean TFC at the end of PCI (29.6 vs, 22.9, p=0.020), (ii) peak troponin I (mean: 
52.2ng/L vs. 60.9ng/L, p=0.029), (iii) ST-segment resolution >70% (57% vs. 39%, 
p=0.017), and (iv) 6-month LV ejection fraction assessed by echocardiography (55.2 vs. 
52.2, p=0.041)298. Interestingly, 6-month MACE rates were lower in the urokinase group 





1.7.7 Intracoronary tenecteplase 
Numerous case reports, or case series, have reported feasibility and efficacy with 
intracoronary tenecteplase or alteplase, during primary PCI, usually as a bail-out agent in 
STEMI patients with large thrombus burden and no-reflow308-312, but also as an adjunct to 
PCI in cases of thrombotic complications and no-reflow313 314.  
 
Morales-Ponce et al300 explored associations between adjunctive intracoronary 
tenecteplase (one fifth of systemic dose, infused over 3 minutes, pre-stent implantation) vs. 
intracoronary glycoprotein IIbIIIa inhibitor therapy, during primary PCI (n=76). 
Angiography was repeated 48 hours later to assess TFC and MPG. There was no difference 
in the primary endpoint (infarct size assessed by CMR imaging at 4 months) between 
tenecteplase vs. glycoprotein IIbIIIa inhibitor groups (17.0g vs. 21.1g, p=0.22)300. 
However, final TFC was higher in the tenecteplase group (18.2 vs. 14.2, p=0.02) and the 
proportion of participants with final MPG ≥2 was lower with tenecteplase (68% vs. 90%, 
p=0.03)300. The study was limited by the open-label design, lack of a volume-matched 
placebo control group, and CMR imaging was not performed within the first week from 
admission to allow quantification of MVO300. However, the findings are consistent with 
the ICTUS–AMI trial301 (section 1.7.5). A potential explanation for the findings300 301 may 
be the competing fibrinolytic and procoagulant effects of thrombolytic drugs288 (Figure 
1.4). 
 
The first randomised study of adjunctive intracoronary tenecteplase compared to volume-
matched placebo during primary PCI was ICE T-TIMI 49 (intracoronary tenecteplase 
during balloon angioplasty to treat heart attacks)296. ICE T-TIMI 49 was an open-label, 
randomised controlled pilot trial, of intracoronary tenecteplase (4mg, over 2 minutes) 
administered before and after stent implantation (n=20) during primary PCI, compared to 
volume matched control (n=20). All patients received intravenous glycoprotein IIbIIIa 
inhibitors. Patients were eligible for inclusion if they were within 6 hours of symptom 
onset, and had TIMI flow ≤1 on the initial angiogram. The median ischaemic time for the 
population was relatively short (approximately 2 hours). The primary endpoint (percent 
diameter stenosis of the infarct-related lesion after the administration of study drug) did not 
differ between treatment groups, neither did MPG, or 30-day mortality296. In ICE T-TIMI 
49, there was a greater incidence of hyperaemic flow measured using TFC <14 (a marker 
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of distal embolization)127 with placebo vs. intracoronary tenecteplase, and participants 
were more likely to have reduction in TIMI thrombus grade after the first bolus of 
intracoronary tenecteplase compared to placebo296. The ICE T-TIMI 49 study was not 
powered for clinical outcomes and cardiologists were not blinded during study drug 
administration296. Furthermore, the optimal dose of intracoronary tenecteplase is unknown, 
and non-invasive imaging to measure myocardial perfusion was not performed. 
1.7.8 Intracoronary alteplase and the T-TIME trial 
To date, the largest randomised controlled trial of intracoronary thrombolysis is T-
TIME292. In T-TIME, STEMI patients ≤6 hours from symptom onset, with an occluded 
artery, or thrombus-laden patent artery, on initial angiography, were randomised to receive 
intracoronary alteplase or placebo, pre-stenting. The rationale for administering the drug 
before stent implantation, was based on an analysis from the INFUSE-AMI trial315. The 
INFUSE-AMI trial compared intracoronary glycoprotein IIbIIIa inhibitor pre-stent 
implantation vs. no glycoprotein IIbIIIa inhibitor therapy, and manual thrombectomy vs. 
no thrombectomy, during primary PCI for anterior STEMI, in a 2 x 2 factorial design316. 
Patients with pre-stent TIMI 3 flow (n=175) had lower 30-day infarct size (assessed by 
CMR imaging), compared to patients with TIMI 2 flow pre-stent (n=47), or TIMI flow ≤1 
pre-stent (n=68) (15.5% vs. 22.6% vs. 19.5%, p<0.001)315. The findings suggest that 
optimisation of microvascular perfusion pre-stent implantation may reduce infarct size in 
patients undergoing primary PCI315.  
 
T-TIME intended to randomise 558 patients to alteplase 20mg, alteplase 10mg, or volume 
matched placebo. However, following a prespecified futility analysis, the Sponsor 
discontinued enrolment on December 21st 2017 based on a recommendation from the Data 
and Safety Monitoring Committee.  
 
The futility analysis was performed when 40% of patients had been randomised and 
followed-up to 3 months. Considering MVO extent on CMR imaging, each active 
treatment arm was compared to the placebo arm and if the conditional power for showing a 
benefit over placebo was less than 30%, the recommendation was to stop recruitment. The 
sample size calculation for the T-TIME trial was based on data from the British Heart 
Foundation funded MR-MI study (detection and significance of heart injury in STEMI) 149 
156. For 80% power at a 5% level of significance to detect between-group mean differences 
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in MVO extent of 1.49%, assuming mean (± standard deviation [SD]) of 3.2 (±5.1%) for 
MVO extent in the placebo group, a minimum sample size of 186 per group was needed 
(558 patients randomised in total).  
 
Of the 440 patients randomised, the primary endpoint (mean amount of MVO on CMR 
imaging performed 2 to 7 days post-STEMI) did not differ between 20mg alteplase (3.5%) 
vs. placebo (2.3%) groups (mean difference: 1.16% [95% CI: -0.08, 2.41%] p=0.32)292. 
There was also no difference in mean amount of MVO between alteplase 10mg (2.6%) vs. 
placebo (mean difference: 0.29% [95% CI: -0.76, 1.35%] p=0.74)292. There was no 
difference in clinical outcomes at 1-year between treatment groups (MACE rates with 
alteplase 20mg [10%] vs. placebo [11%], OR: 0.96 [95% CI: 0.45, 2.04]; MACE rates with 
alteplase 10mg [15%] vs. placebo, OR: 1.52 [95% CI: 0.76, 3.05])302. However, even 
though T-TIME was designed to study 1-year outcomes it was not powered to do so.  
 
In the T-TIME trial292, intracoronary alteplase was administered after low-pressure balloon 
inflation, or thrombus aspiration, but before stent implantation. Hypothetically, persisting 
impaired antegrade flow in the infarct-related artery might influence the effect of 
intracoronary alteplase. One might speculate that impaired antegrade flow may lead to 
inadequate drug delivery to the microcirculation. 
1.7.9 Ongoing trials of intracoronary fibrinolysis 
Three other randomised controlled trials of low-dose intracoronary lytic therapy are 
ongoing (Table 1.4). In the STRIVE trial317 (adjunctive low-dose tPA in primary PCI for 
STEMI) (NCT03335839), intracoronary alteplase is being administered via a microcatheter 
routinely to enhance local drug deliver. Intracoronary alteplase is also being investigated in 
the OPTIMAL trial272 (optimal coronary flow after PCI for MI) (NCT02894138). 
Intracoronary tenecteplase is being investigated in the RESTORE-MI trial273 (restoring 
microcirculatory perfusion in STEMI) (ACTRN12618000778280). In all three trials the 
comparator intervention is volume matched saline or water, and patients with ischaemic 
time up to 12 hours are included. In RESTORE-MI273 and OPTIMAL272, the study 
intervention is administered at the end of PCI after stent implantation, and patients are 
eligible for inclusion if they have a post-stent IMR in the infarct-related artery >32 or >30 
respectively.  However, it is unclear if this risk-based selection strategy, which is targeting 
patients with invasive evidence of microcirculatory damage, could be selecting some 
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patients with irreversible microvascular damage, in whom intracoronary fibrinolytics might 
exacerbate haemorrhagic transformation of the infarct core.  
1.7.10 Summary of evidence for intracoronary fibrinolysis during primary PCI 
The quality of evidence supporting intracoronary low-dose fibrinolysis during primary PCI 
is variable. The findings reported by different studies are inconsistent. Differences might 
be related to variability in timing of fibrinolytic drug administration, i.e. pre- or post-stent 
implantation, and different fibrinolytic agents and doses used. However, all trials so far 
were negative on their primary endpoints. 
 
The following uncertainties remain: (i) whether low-dose intracoronary tenecteplase 
(which is less procoagulant than alteplase318) administered at the end of PCI to patients 
with large thrombus burden and short ischaemic time (<4 hours) might be beneficial; (ii) in 
which patient sub-groups might intracoronary fibrinolysis potentially be harmful, for 
example those with more aggressive antithrombotic therapy, or those who already have 
extensive (possibly irreversible) microvascular damage. The findings from further analyses 




     
 


















Patients within 12 hours 
of symptom onset 
Tenecteplase 
1/3 of weight based 
systemic dose 
Yes 
IMR >32  
Cardiovascular mortality and 







Patients within 6 to 12 
hours of symptom onset 
Alteplase  
10mg or 20mg 
No Composite of post-procedural MPG ≤1 and 







Patients within 12 hours 
of symptom onset 
 
Alteplase 20mg Yes 
IMR >30  
 




Table 1.4 Ongoing randomised clinical trials of adjunctive intracoronary fibrinolysis during primary PCI.
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1.8 Hypotheses and project aims  
The principle aim of this work is to gain greater insight into the invasive assessment of 
acute microvascular injury following primary PCI, and to provide mechanistic insights to 
better understand the effects of intracoronary alteplase on the microcirculation. The first 
part of the thesis aims to determine whether adjunctive intracoronary alteplase during 
primary PCI has any effect on acute microvascular function, assessed by thermodilution-
derived invasive physiology parameters, and to evaluate whether the effect of 
intracoronary alteplase is related to TIMI flow grade immediately preceding study-drug 
administration. The second part of the thesis aims to investigate the utility of novel 
physiology parameters, namely RRR and the newly conceived temperature recovery time 
(TRT), for predicting MVO on CMR imaging. In addition, the utility of IMR, CFR, RRR, 
MPG and TFC will be compared for predicting MVO, myocardial haemorrhage and 
prognosis following acute STEMI. The utility of TRT for predicting prognosis will also be 
investigated. The body of work incorporated in this thesis principally involves prospective 
analyses from the T-TIME randomised clinical trial292, as well as a retrospective analysis 
from the MR-MI observational study149. 
 
The specific aims of this thesis are as follows: 
1) To evaluate the effects of intracoronary alteplase, according to sub-groups of TIMI 
coronary flow grade immediately preceding study drug administration, during 
primary PCI (Chapter 3). 
 
2) To evaluate the effects of intracoronary alteplase during primary PCI on IMR, CFR 
and RRR (Chapter 4). 
 
3) To compare IMR, CFR, RRR, MPG and TFC, measured at the end of primary PCI, 
for predicting MVO, myocardial haemorrhage and clinical outcomes (Chapter 5). 
 
4) To investigate whether a newly conceived parameter (TRT) is associated with 





The specific hypotheses investigated in this thesis are stated below: 
1) In acute STEMI patients with TIMI 3 flow immediately preceding study drug 
administration, intracoronary alteplase is associated with less MVO and less 
myocardial haemorrhage on CMR imaging, compared to placebo (Chapter 3). 
 
2) In acute STEMI patients with TIMI flow ≤2 immediately before study drug 
administration, there is no difference in MVO or myocardial haemorrhage on CMR 
imaging with intracoronary alteplase vs. placebo (Chapter 3). 
 
3) Intracoronary alteplase administered pre-stenting, is associated with lower IMR, 
higher CFR and higher RRR at the end of primary PCI, compared to placebo 
(Chapter 4). 
 
4) In the sub-group of patients with shorter ischaemic time (≤2 hours), intracoronary 
alteplase administered pre-stenting is associated with lower IMR, higher CFR and 
higher RRR at the end of primary PCI, compared to placebo (Chapter 4). 
 
5) In the sub-group of patients with TIMI 3 flow immediately preceding study drug 
administration, intracoronary alteplase is associated with lower IMR, higher CFR 
and higher RRR at the end of primary PCI, compared to placebo (Chapter 4). 
 
6) In the sub-group of patients with TIMI thrombus grade ≥3 immediately pre-study 
drug administration, intracoronary alteplase is associated with lower IMR, higher 
CFR and higher RRR at the end of primary PCI, compared to placebo (Chapter 4). 
 
7) Higher IMR and TFC, and lower CFR, RRR and MPG at the end of primary PCI 
are associated with MVO and myocardial haemorrhage on CMR imaging, and are 
associated with increased rates of MACE, heart failure hospitalisation, and the 
combination of all-cause death/ heart failure hospitalisation (Chapter 5). 
 
8) Lower RRR at the end of primary PCI is more closely associated with MVO and 
myocardial haemorrhage on CMR imaging, than lower CFR (Chapter 5). 
 
9) Higher TRT at the end of emergency PCI is associated with MVO on CMR 
imaging and is associated with increased rates of MACE, and the combination of 
all-cause death/ heart failure hospitalisation (Chapter 6). 
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Chapter 2: Methods  
2.1 The T-TIME angiographic study 
2.1.1 Trial design and population 
T-TIME was an investigator-initiated, double-blind, parallel group, dose-ranging, phase 2 
randomised clinical trial of low-dose adjunctive intracoronary alteplase during primary PCI 
(Clinical trial Identifier: NCT02257294). It was funded by the Efficacy and Mechanism 
Evaluation program of the National Institute for Health Research. The trial design is 
summarised in Figure 2.1. 
 
 
Figure 2.1 Overview of the T-TIME trial design. 
 
From 17th March 2016 to 21st December 2017, patients with acute STEMI were enrolled by 
11 U.K. hospitals. Screening and study drug administration occurred during standard care 
primary PCI. Enrolment was based on prospective assessments of eligibility criteria, 
operator experience and logistical considerations.  
 
Patients were eligible for participation in the T-TIME trial if they presented with persistent 
ST-segment elevation or recent left bundle branch block, ≤6 hours from symptom onset 
and with an occluded infarct-related artery, or TIMI coronary flow grade 1 or 2, with TIMI 
thrombus grade ≥2. The rationale for limiting the ischaemic time to ≤6 hours was to 
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include patients with salvageable myocardium319. Other key inclusion criteria included 
radial artery access, and an occlusion of the proximal, or mid-segment of a major coronary 
artery, i.e. right coronary artery (RCA), left anterior descending (LAD), or circumflex 
(Cx). The rationale for including patients with impaired antegrade flow at initial 
angiography, in the presence of at least TIMI grade 2 thrombus, was to select patients at 
increased risk of distal embolization320 and no-reflow. 
 
An additional inclusion criteria for the angiographic study analysis of the T-TIME trial was 
the availability of a fluorostore or cine image, to allow TIMI coronary flow grade 
assessment immediately preceding study drug delivery. 
 
Key exclusion criteria included: a functional collateral supply to the infarct-related artery 
(Rentrop grade321 ≥2, i.e. at least partial filling of the infarct-related artery by the collateral 
vessel) and cardiogenic shock. The other exclusion criteria are shown in Figure 2.2. A 
screening log was prospectively completed to document the reasons for participation or 
not.  
 
Seven sites recruited patients outwith, in addition to within “normal working hours” (09:00 
to 17:00 on a weekday), i.e. Glasgow, Southampton, Leeds, Manchester, London, 
Middlesbrough and Wolverhampton. The other 4 sites recruited patients during “normal 












▪ Normal flow in the infarct-related coronary artery at initial angiography (TIMI flow grade 3). 
▪ Functional coronary collateral supply (Rentrop grade 2/3) to the infarct-related artery. 
▪ Previous infarction in the infarct-related artery (known or suspected clinically, e.g. wall motion  
   abnormality revealed by echocardiography). 
▪ Cardiogenic shock (Killip Class IV), or multivessel PCI intended before the day 2-7 CMR scan. 
▪ Estimated body weight <60kg, or comorbidity with expected survival <1 year. 
▪ Pacemaker, implantable defibrillator, or contra-indication to contrast-enhance CMR imaging. 
▪ Known impaired renal function (estimated glomerular filtration rate <30ml/min). 
▪ Significant bleeding disorder either presently or within the past 6 months. 
▪ Patient with current concomitant oral anticoagulation therapy (international normalised ratio >1.3),  
   including apixaban, dabigatran and rivaroxaban. 
▪ Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal  
   surgery). 
▪ Severe hypertension (blood pressure >180/110 mmHg) not controlled by medical therapy. 
▪ Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 3 months (this  
   includes any trauma associated with the current acute MI). 
▪ Recent head trauma (<2 months), or prolonged cardiopulmonary resuscitation (>2 mins) in the past  
   2 weeks. 
▪ Acute pericarditis and/ or subacute bacterial endocarditis. 
▪ Acute pancreatitis, or active peptic ulceration. 
▪ Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal  
   varices) and active hepatitis. 
▪ Arterial aneurysm and known arterial/ venous malformation. 
▪ Neoplasm with increased bleeding risk, or any known history of haemorrhagic stroke. 
▪ Known history of ischaemic stroke, or transient ischaemic attack in the preceding 6 months. 
▪ Dementia, or incapacity/ inability to provide informed consent. 
▪ Hypersensitivity to gentamicin, or natural rubber. 
▪ Previous randomisation to this study, or participation in a study with an investigational drug, or  
   medical device within 90 days prior to randomisation. 
▪ Women of child bearing potential (i.e. pre-menopausal), or breast feeding. 
▪ Immunosuppressive therapy at any time in the preceding 3 months. This would include  
   corticosteroids (but not inhaled or topical), drugs used following transplantation (e.g tacrolimus,  
   cyclosporine), anti-metabolite therapies (e.g. mycophenolic acid, azathioprine, leflunomide and    
   immunomodulators including biologics (e.g. adalimumab, or etanercept) and disease modifying  
   anti-rheumatic drugs. This list is not exhaustive. 
▪ Active/ prophylactic treatment with oral/ parenteral antibiotic, antifungal, or antiviral therapy. 
▪ Any anti-cancer treatment (excluding surgery as this is covered above) at any time during the  
   preceding 3 months, including chemotherapy, radiotherapy, and treatment with biologics, such as  
   Vascular Endothelial Growth Factor Receptor inhibitors (e.g. bevacizumab, pazopanib). This list is  
   not exhaustive. 
▪ Any significant concurrent, or recent condition(s) not listed above that in the opinion of the treating  
   clinician would pose an additional risk to the patient. 
 
Figure 2.2 Exclusion criteria for the T-TIME trial 
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2.1.2 Consent process  
Screening and study drug administration occurred during standard care primary PCI. Only 
patients who were sufficiently well to understand the information about the study, were 
eligible to participate. Patients who met the eligibility criteria (section 2.1.1) underwent 
verbal witnessed assent to participate, in the catheterisation laboratory. The investigator 
who obtained verbal assent signed the short consent form (Appendix 2). Since these were 
all emergency patients, it would have been inappropriate to delay treatment in order to 
obtain full written informed consent in the catheterisation laboratory. Written informed 
consent was obtained on the ward, within 24 hours of the hospital admission. The patient 
information sheet and a blank consent form, for patients to sign, is shown in Appendix 3.  
 
Patients were informed that they could withdraw from the study at any time. Clinicians 
could withdraw patients if knowledge of the treatment was absolutely necessary for further 
management of the patient. Ethical approval for the study (reference: 13-WS-0119) was 
obtained from the West of Scotland Research Ethics Service (Appendix 1). The trial was 
conducted in accordance with the Declaration of Helsinki322. 
2.1.3 Standard of care for primary PCI 
Standard care for initial coronary reperfusion was with balloon angioplasty, or aspiration 
thrombectomy for thrombus-containing lesions, according to the operator’s discretion. If 
balloon angioplasty was performed the balloon was sized according to the expected lumen 
diameter, and inflated to a relatively low pressure (e.g. 4 to 8 atmospheres), to minimise 
thrombus embolization. Use of an under-sized balloon was not recommended, as this could 
leave an obstructive (thrombotic) stenosis, which is a substrate for re-occlusion during 
study drug preparation and administration. Post-dilatation of implanted stents was routine. 
Anti-thrombotic therapy included oral anti-platelet drugs, i.e. 300mg aspirin, and either 
180mg ticagrelor, 60mg prasugrel, or 600mg clopidogrel, and intravenous heparin (5000 
IU, or as per standard practice) at the first medical contact.   
 
The target activated clotting time (ACT) was 250 to 300s, which was to be achieved prior 
to study drug administration. In line with optimal standard care, the ACT was checked 
every 20 minutes, to ensure therapeutic anticoagulation. As per clinical guidelines1, bail 
out glycoprotein IIb/IIIa inhibitors could be used in the event of angiographic evidence of 
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large thrombus, slow- or no-reflow, or a thrombotic complication, although there is no 
evidence from randomised clinical trials for this strategy. In line with clinical guidelines, 
multivessel PCI in the acute setting was not recommended1. 
2.1.4 Randomisation and blinding 
Patients were randomised using an interactive voice response-based system. The 
randomisation sequence was computer generated, using the method of randomised 
permuted blocks of length 6. Randomisation was stratified by the location of MI (anterior 
vs. non-anterior). The allocation sequence was on a 1:1:1 basis, between placebo and the 
alteplase groups. The researchers, clinical staff and patients were blinded to the treatment 
group allocation. Boehringer-Ingelheim U.K Ltd. Provided the study drugs (alteplase 10mg 
and 20mg), matched placebo, and sterile water for injection, but had no other involvement 
in the conduct of the study.  
2.1.5 Intervention and protocol for study drug administration 
Two doses of alteplase (10mg [one tenth of standard systemic dose] and 20mg [one fifth of 
standard systemic dose]) were compared to placebo. At the time of the study design, there 
were no other published randomised clinical trials comparing intracoronary alteplase to 
placebo, to help inform the lowest effective intracoronary dose of alteplase. In a previous 
open-label study, that compared intracoronary streptokinase to standard care, there was an 
improvement in IMR in the group that received one sixth of the standard systemic dose of 
intracoronary streptokinase, administered at the end of the primary PCI procedure260. 
Given that streptokinase is less effective than alteplase, a 10-fold lower dose (relative to 
standard systemic dose) was adopted as the lowest dose of alteplase in the T-TIME trial. 
 
The reason for selecting alteplase in preference to streptokinase is because alteplase is 
fibrin specific. Streptokinase has a higher bleeding risk than fibrin-specific fibrinolytics, 
such as alteplase and tenecteplase323.  
 
Alteplase (a second generation lytic) was selected in preference to tenecteplase (a third 
generation lytic), because alteplase has a shorter plasma half-life, compared to 
tenecteplase324 325. Therefore, there was potentially less possibility of harmful remote 
bleeds with alteplase, and if a bleeding serious adverse event did occur this could 
theoretically have been worse with tenecteplase than with alteplase. Furthermore, 
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tenecteplase is more expensive than alteplase, so is less transferable to the National Health 
Service324 325. The indicative price of one vial of tenecteplase 10000 units is £602.70325. 
The indicative price of one vial of 10mg alteplase is £172.80, and that of one vial of 20mg 
alteplase is £259.20324. 
 
The reason for adopting intracoronary rather than systemic administration of the study 
drug, was to minimise the possibility of harmful remote bleeds. Systemic administration of 
reduced dose alteplase would have diluted the drug to ineffective concentrations at the site 
of the coronary lesion.   
 
The protocol for study drug administration is provided in Appendix 4. The trial protocol 
encouraged achieving TIMI flow grade ≥2, using balloon angioplasty and/ or aspiration 
thrombectomy, prior to randomisation of participants. After randomisation, the allocated 
intervention was prepared, during which TIMI flow grade in the infarct-related artery 
deteriorated in a minority of patients, prior to administration of the study drug. The 
allocated intervention (alteplase 20mg, alteplase 10mg, or placebo) was administered 
before stent implantation. The rationale for administering the study drug before stent 
implantation was to potentially reduce the amount of thrombus present that could embolize 
distally during stent implantation, and to treat distal microvascular thrombosis, with the 
aim of achieving reperfusion to the microcirculation as early as possible. 
 
First, the study drug powder needed to be reconstituted in solvent (sterile water), made up 
to a volume of 20ml. Second, using either a flushed intracoronary catheter, or a selectively 
engaged guide catheter, the 20ml volume of study drug was infused into the infarct-related 
artery, over 5 to 10 minutes, proximal to the lesion. Finally, the catheter was flushed with 
normal saline to ensure that all of the study drug had been administered.  
 
The infusion period of up to 10 minutes was adopted based on pragmatic grounds. Bolus 
administration may have potentially limited first pass binding of alteplase with fibrin 
molecules, however, during slow manual infusion real-time thrombolysis had potential to 
further expose fibrin molecules within the thrombus as lysis progresses. Furthermore, the 
‘deep-tissue’ beta half-life of alteplase is approximately 40 minutes326, therefore persistent 
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local lysis could potentially occur within the distribution of the infarct-related artery after 
study-drug administration.  
2.1.6 Angiogram acquisition and analysis 
The angiogram acquisition protocol (Appendix 4) required stored fluoroscopy of study 
drug administration, to enable verification by the core laboratory that the guide catheter 
was selectively engaged in the infarct-related artery during study drug delivery. This also 
enabled core laboratory evaluation of TIMI coronary flow grade immediately preceding, 
and immediately after, study drug delivery. Participants were grouped according to TIMI 
flow grade (£2 vs. 3) in the infarct-related artery immediately preceding study drug 
administration. 
 
A deidentified copy of each angiogram was transferred to the Glasgow core laboratory by 
secure web-upload, or exceptionally by compact disc via courier. All the angiogram 
parameters were analysed prospectively using QAngio® XA Medis Suite software (Medis, 
Leiden, Netherlands). The angiograms were prospectively analysed by one researcher, who 
was blind to treatment allocation (i.e. alteplase 10mg, alteplase 20mg, or placebo) and 
blind to CMR, ECG, or coagulation data. A second read was performed by an experienced 
interventional cardiologist, involving combined review with the first investigator. 
Discrepancies were resolved by consensus agreement between the first and second 
reviewers, or where discrepancies remained consensus was reached after discussion with a 
third reviewer. The final angiography data, from the Glasgow core laboratory were 
submitted to the data coordination centre prior to database lock, after which no changes to 
the data were possible.  
 
Inter-rater variability for TIMI coronary flow grade, TFC, and MPG at the end of the PCI 
procedure were evaluated in 440 patients. Inter-rater variability for TIMI coronary flow 
grade immediately preceding study drug delivery was evaluated in 65 consecutive patients. 
Inter-rater variability for TIMI thrombus grade immediately preceding study drug 
administration was evaluated in 90 patients. Intra-observer variability was evaluated after a 





Identification of the cine/ fluorostore showing study drug delivery 
When a fluorostore or cine image was available showing a thrombectomy catheter 
positioned proximal to the infarct-related lesion, or a selectively engaged guide catheter 
without contrast injection, this was taken to be study-drug administration. Confirmation 
was sought by establishing that the time gap between the adjacent fluorostore/ cine images 
was sufficiently long for study drug administration. Further confirmation was sought by 
verifying that the fluorostore/ cine image identified was consistent with information 
documented on the electronic case report form, regarding the method of study drug 
delivery and duration over which the study drug was infused. 
 
When a fluorostore or cine image was not available during study drug administration, 
consecutive fluorostore/ cine images separated by a time gap sufficient for study-drug 
delivery, prior to stent deployment were identified. These were taken as the fluorostore/ 
cine images corresponding to immediately preceding and immediately after study drug 
delivery. Confirmation was sought by checking for consistency with information 
documented on the electronic case report form. 
Multivessel disease 
For the assessment of multivessel disease, a diseased non-culprit vessel was defined as 
having >50% stenosis in a major coronary artery, by angiographic visual assessment. 
TIMI coronary flow grade 
The TIMI coronary flow grade327 (Figure 2.3) was assessed in the infarct-related artery at 4 
time points: (i) on the initial image pre-reperfusion; (ii) immediately preceding study drug 
administration; (iii) immediately after study drug administration; and (iv) at the end of the 
PCI procedure after stent optimisation.  
 





The corrected TFC was assessed in the infarct-related artery at the end of the PCI 
procedure after stent optimisation. The first frame used for TFC was the frame when 
contrast entered the origin of the artery, and when the following criteria were met: (i) 
column of fully concentrated contrast extending across the entire width of the origin of the 
artery; (ii) contrast touching both borders of the artery’s origin, and; (iii) antegrade motion 
of contrast. The last frame used for TFC was when contrast entered the end-point branch of 
the infarct-related artery, as specified in the original TFC description120. For the RCA the 
distal landmark was the first branch arising from the posterior lateral extension of the RCA 
after the origin of the posterior descending artery. For the Cx artery, the distal landmark 
was the endpoint of the marginal branch with the longest total distance along which 
contrast travels in the Cx system and yet passes through the infarct-related lesion. For the 
LAD artery, the distal landmark was the distal-most branch of the LAD, conventionally at 
the apex of the heart. The frame count for the LAD was divided by 1.7 to correct for the 
relatively longer vessel length. 
MPG 
MPG was evaluated for the infarct-related artery, at the end of the PCI procedure after 
stent optimisation. The definitions used to evaluate MPG328 are shown in Figure 2.4. 
 
Figure 2.4 Definitions for myocardial perfusion grades (MPG) 
 
TIMI thrombus grade 
The TIMI classification of thrombus grade is the most widely used angiographic 
classification of coronary thrombus329. TIMI thrombus grade330 (Figure 2.5) was evaluated 
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in the infarct-related artery on the initial image pre-reperfusion, immediately preceding 
study drug administration and at the end of the PCI procedure after stent optimisation. 
 
A limitation of the TIMI thrombus grade classification is that the highest score, i.e. grade 
5, is a totally occluded vessel, consequently the actual amount of thrombus relative to 
vessel diameter is unknown, yet the assumption of the TIMI scale is that grade 5 represents 
the highest thrombus burden. With the intent of overcoming this limitation, a modification 
was introduced in 2007 that incorporated insertion of a guidewire or 1.5mm balloon for 
crossing and recanalising the occlusive grade 5 thrombus, to improve determination of the 
amount of thrombus331. On balance the TIMI thrombus grade classification shown in 
Figure 2.5 was used, because it is universally accepted329 and was user-friendly for the 
interventional cardiologists making decisions about whether or not a patient met the 
eligibility criteria for the T-TIME trial, which was important for facilitating recruitment.                    
  
 
Figure 2.5 Definitions for TIMI thrombus grades 
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Quantitative coronary angiography 
For quantitative coronary angiography (QCA), catheter calibration was performed using 
QAngio® XA Medis Suite software (Medis, Leiden, Netherlands), using information on 
the catheter size (6 or 5 French) documented in the electronic case report form. An 
angiographic projection perpendicular to the long axis of the vessel was used to avoid 
foreshortening. After selection of the end-diastolic frame, where the coronary segment was 
fully opacified with contrast, the QCA software measured different parameters, by 
automatic vessel edge detection algorithms. The parameters recorded included reference 
vessel diameter (average diameter of the coronary vessel assumed without atherosclerotic 
disease) and stent length. 
2.1.7 LVEDP 
Measurement of LVEDP was recommended in the T-TIME protocol, but was not 
mandatory, so it was measured at the discretion of the interventional cardiologist.  The 
measurement of LVEDP occurred at the end of the cardiac catheterisation procedure, by 
positioning the right coronary catheter in the LV. LVEDP was then obtained from the LV 
pressure waveform at the point when the slope of the ventricular pressure upstroke 
changes, coinciding with the R wave on the ECG (Figure 2.6). The average LVEDP from 
five LV pressure waveforms was recorded. 
 
 
Figure 2.6 LVEDP measurement 
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2.1.8 ECG acquisition and analysis 
The absolute percentage ST-segment resolution on 12-lead ECGs obtained 60 minutes 
after reperfusion, compared to pre-reperfusion were calculate centrally by the University of 
Glasgow ECG core laboratory, which is certified to ISO 9001: 2008 standards as a UKAS 
accredited organisation. The results from the ECG analyses, were submitted to the data 
coordination centre prior to database lock. 
2.1.9 CMR acquisition and analysis 
CMR was performed at 1.5 Tesla. CMR scans were acquired during the index 
hospitalisation (2 to 7 days post-STEMI), and 3 months later. MVO and myocardial 
haemorrhage were reported from the 2 to 7 day CMR scans. The other CMR parameters 
were reported from the 2 to 7 day and 3-month CMR scans. Deidentified copies of each 
CMR scan was transferred to the Glasgow core laboratory by secure web-upload, or when 
that was not feasible, then by compact disc via courier. The CMR scans were analysed 
using QMass Medis Suite MR software (Medis, Leiden, Netherlands). After the CMR 
scans underwent initial analysis by one investigator who, was blind to the angiographic 
findings and treatment allocation, there was a second read by a cardiologist with level 3 
CMR certification (who was also blind to treatment allocation), involving combined 
review with the first investigator. Discrepancies were resolved by consensus agreement. 
The final CMR data, from the Glasgow core laboratory were submitted to the data 
coordination centre prior to database lock. 
 
The CMR imaging protocol followed a standard operating procedure (Appendix 5) that 
included cine CMR imaging with steady-state free precession, T1-mapping, T2-mapping, 
T2*-maps and LGE imaging. The scan acquisitions were spatially co-registered and 
included different slice orientations to enhance diagnostic confidence.  
Microvascular obstruction 
To identify MVO, LGE CMR imaging 2 to 7 days post-STEMI was performed, and MVO 
was defined as a dark zone on early gadolinium enhancement imaging 1, 3, and 7 minutes 
after gadolinium-based contrast injection that persisted within an area of LGE at 10 to 15 
minutes89 332. A difference in signal intensity of at least x 2 SD between the hypointense 
core of MVO and surrounding hyperintense zone of infarction without MVO was required. 
The myocardial mass of the dark zone was quantified by manual delineation and expressed 
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as % of LV mass. The presence or absence of MVO was also recorded. The appearance of 
cine and LGE images in orthogonal planes (long axis and short axis images), thinning of 
the myocardium, as well as oedema and T2*-weighted imaging helped discriminate MVO 
from other pathological processes which may mimic MVO post-infarction.  
Myocardial haemorrhage 
T2*-weighted CMR imaging was used to asses infarct zone haemorrhage, 2 to 7 days post-
STEMI. A region of reduced signal intensity within the infarcted area, with a T2* value of 
<20ms was considered to confirm the presence of myocardial haemorrhage15 26 333 334. This 
area was manually delineated and expressed as a percentage of the total LV mass. The 
contours of the LV were delineated with computer assisted planimetry on the raw T2* 
image and the last corresponding T2 raw image, with echo time of 55ms335. Contours were 
then copied onto the colour-encoded spatially co-registered maps and corrected where 
necessary by consulting the steady-state free precession cine images. The presence or 
absence of myocardial haemorrhage was also recorded.  
Infarct size 
Infarct size was assessed at 3 months post-STEMI, since infarct remodelling is 
substantially complete by 3 months post-STEMI336. Infarct size was also assessed at 2 to 7 
days post-STEMI. The presence of an acute infarction was established based on 
abnormalities in cine wall motion, rest first pass myocardial perfusion, and LGE imaging. 
Acute infarction was considered present only if LGE was confirmed in 2 imaging planes, 
i.e. on both axial and long axis acquisitions. The myocardial mass of late gadolinium was 
quantified using computer assisted planimetry. The territory of infarction was delineated 
using a signal intensity threshold of >5 SD above a remote reference region337 338 and 
expressed as a percentage of the total LV myocardial mass.  
LV ejection fraction and volumes 
LV end-diastolic or systolic volumes and LV ejection fraction were quantified using 
automated planimetry, at 2 to 7 days post-STEMI and 3 months post-STEMI. The borders 
were assessed visually. Papillary muscles were not included. The LV apex was included.   
2.1.10 Coagulation blood sampling and analysis 
Peripheral intravenous blood samples were measured when site logistics permitted. The 
sampling-time points were 0, 2 and 24 hours post-PCI. Blood samples were centrifuged 
locally, with plasma separated and frozen within 2 hours of sampling. Frozen samples were 
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then transported on dry ice for central laboratory analysis, at the department of 
Haematology at the Glasgow Royal Infirmary. Plasma samples were stored at -80oC until 
analysis. The final coagulation data, were submitted to the data coordination centre prior to 
database lock. Plasminogen was measured, because it’s depletion correlates with systemic 
fibrinolysis339. Fibrin D-dimer was measured, as it is a product of fibrin lysis340. 
Prothrombin fragment F1+2 was measured, as it indicates thrombin generation and 
thrombosis341 and correlates with the procoagulant effects of fibrinolytics342. Standard 
laboratory assays: high sensitivity Fibrin D-dimer by latex immunoassay340, and 
plasminogen activity by chromogenic assay339, were performed on an IL TOP700 analyser 
using HemosIL® reagents (Instrumentation Laboratory Company, Bedford, U.S). The 
prothrombin fragment F1+2 antigen level ELISA (enzyme-linked immunosorbent assay) 
was performed on a TECAN sunrise spectrophotometer (Labtech International Ltd. U.K.), 
using the Enzygnost F1 + 2 Mono (Siemens, Marburg, Germany) commercially available 
kit.  
2.1.11 Trial management 
The Robertson Centre for biostatistics within the Glasgow Clinical Trials Unit provided the 
trial-specific electronic data collection system, and functioned as an independent 
coordination centre for randomisation and data management. The trial was co-sponsored 
by the Glasgow and Clyde Health Board and the University of Glasgow. The sponsor 
undertook feasibility assessments at each site. The independent Data and Safety 
Monitoring Committee, had responsibility for potentially recommending early 
discontinuation of the trial due to a safety concern or futility, and met before the enrolment 
began, and twice again during the active phase of the trial. The funder required an interim 









2.2 The T-TIME physiology sub-study 
2.2.1 Study design, population and ethical approval 
The T-TIME physiology sub-study was a pre-defined, prospective, sub-study, within the 
main trial, and it was funded by a British Heart Foundation clinical PhD fellowship. It was 
approved by the West of Scotland Research Ethics Service (reference: 13-WS-0119, 
Appendix 1) and complied with the Declaration of Helsinki322. 
 
Patients with STEMI were eligible for inclusion in the physiology sub-study if they 
fulfilled the eligibility criteria for the main T-TIME trial (section 2.1.1 and Figure 2.2). 
Patients were recruited to the physiology sub-study at the same time, and in the same 
manner as to the main T-TIME trial (section 2.1.2). Every centre that recruited patients 
into the main T-TIME trial was invited to participate in the physiology sub-study. Three 
sites agreed to participate (Glasgow, Leeds and Wolverhampton) and all 3 had prior 
experience of clinical research using thermodilution-derived coronary physiology 
measurements. Enrolment into the physiology sub-study within the 3 designated sites was 
at the discretion of the operating cardiologists, based on operator experience and logistical 
considerations. Two of the sites (Glasgow and Leeds) also enrolled patients into the 
physiology sub-study outwith “normal working hours”, i.e. outside 09:00 to 17:00 on a 
weekday. The dates of enrolment into the physiology sub-study were from 27th August 
2016 to 17th December 2017. 
2.2.2 Thermodilution data acquisition and analysis 
The steps for thermodilution data acquisition are detailed in the standard operating 
procedure (Appendix 6). The coronary physiology data were acquired at the end of the PCI 
procedure, i.e. after stent implantation and post-stent optimisation.  
Pressure wire preparation 
A PressureWireTM CertusTM pressure- and temperature-sensitive guidewire (Abbott, 
Vascular, California, U.S.A) was calibrated outside the body. Two hundred micrograms of 
intracoronary nitroglycerin was administered to the infarct-related artery, to minimise 
effects of potential arterial spasm on the readings. The pressure- and temperature-sensitive 
guidewire was equalised to Pa, with the pressure sensor at the ostium of the guide catheter. 
The wire was advanced down the infarct-related artery, so that the distal sensor (3cm from 
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the wire tip) was in the distal third of the artery. Care was taken to ensure that all 
radiographic contrast was flushed out of the guide catheter with saline, because 
radiographic contrast can induce submaximal hyperaemia343, which would have affected 
physiology measurements intended to be made during resting conditions. Meticulous 
attention was taken to ensure the guide catheter was appropriately engaged, and only guide 
catheters without side holes were used. 
Thermodilution and hyperaemia 
Using thermodilution, the Tmn of 3ml bolus of room temperature saline, injected briskly 
into a flushed catheter, was measured in triplicate at rest and during steady state 
hyperaemia. Caution was taken to ensure that the PressureWireTM CertusTM (Abbott, 
Vascular, California, U.S.A) was positioned similarly in the coronary artery on repeated 
measurements. In a previous study, the distance between the wire temperature-sensor and 
the guide tip was not significantly correlated with the mean hyperaemic Tmn166. 
Simultaneous measurements of mean Pa and Pd were made. Hyperaemia was induced by 
infusion of intravenous adenosine (140µg/kg/min), which is an extracellular signalling 
molecule that causes endothelium-independent coronary vasodilatation 344 345, primarily 
through activation of A2A receptors346. When the response to adenosine was inadequate 
(i.e. fall in blood pressure <20% of resting value, rise in heart rate <10% from baseline, or 
no widening of pulse pressure), the adenosine infusion was increased to 210 µg/kg/min. 
Reproducibility of IMR was assessed in 13 patients, and reproducibility of CFR and RRR 
was assessed in 9 patients. Duplicate measurements were made by either continuing the 
adenosine infusion and repeating 3 additional hyperaemic Tmn measurements, or stopping 
the adenosine infusion to repeat 3 resting Tmn measurements then restarting the adenosine 
infusion to repeat 3 hyperaemic Tmn measurements.  
Blinding 
To mitigate the possibility of bias through disclosure of coronary physiology results, the 
operators were blinded by obscuring the display of the RadiAnalyzerTMXpress screen, i.e. 
turning it 180o. The research fellow, or physiology technician quality assured the data 
acquisition, and documented the site reported IMR measurements, from the 
RadiAnalyzerTMXpress console, on a catheter laboratory worksheet (Appendix 7).  
Analysis and Coroventis software 
De-identified study number labelled files, containing the temperature- and pressure-wire 
recordings from Leeds, or Wolverhampton, were saved locally and then sent to the 
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Glasgow core laboratory for analysis. The coronary physiology data was analysed offline, 
using Coroventis software (Coroventis Research AB, Uppsala, Sweden). An example of 
coronary physiology data displayed on Coroview (Coroventis Research AB, Uppsala, 
Sweden) is provided in Figure 2.7.  
 
Evaluation of the coronary physiology data was performed prospectively, by an 
investigator blind to treatment group allocation (i.e. placebo, alteplase 10mg, or alteplase 
20mg), and blind to CMR, ECG, or coagulation data. The coronary physiology data were 
subject to a second read by an investigator, experienced in coronary physiology, involving 
combined review with the first investigator. Final data were established by consensus 
agreement between the two investigators. The final coronary physiology data, from the 
Glasgow core laboratory were submitted to the data coordination centre prior to database 
lock. Inter-rater variability for IMR, RRR and thermodilution waveforms was assessed in 
30 consecutive patients, by a third investigator, who was blinded to all other data, and 
treatment group allocation. Intra-observer variability was assessed from 30 consecutive 




Figure 2.7 An example of physiology data, displayed on Coroview (Coroventis Research 
AB, Uppsala, Sweden). Thermodilution curves are obtained in triplicate at rest (blue) and 





2.2.3 CFR analysis 
To quantify CFR, resting Tmn was divided by hyperaemic Tmn167. A threshold of 2.0 was 
used to dichotomise CFR in regression analyses, because CFR ≤2.0 is considered 
abnormal, based on published literature149. 
2.2.4 IMR analysis 
The definition of IMR was as follows: Pd x Tmn during hyperaemia140. At the end of 
primary PCI, when IMR was measured, there was no residual epicardial stenosis in the 
infarct-related artery, therefore IMR correction with wedge pressure143, or Yong’s 
formula145 was not required. Because IMR is a measure of the minimal achievable 
microvascular resistance140, the Pd value used in the IMR equation should be taken when 
there is stable maximal hyperaemia. When analysing thermodilution data, the IMR value 
can change, by varying the position of the Pd marker. Therefore, care was taken to position 
the Pd marker at the lowest stable Pd/Pa, for core lab evaluation of IMR. An IMR >40, or 
IMR >32, was used to dichotomise IMR in multivariable analyses. This is because an IMR 
>40, or ≥32 predicts all-case death or heart failure hospitalisation16, and is being used to 
select patients for clinical trials255 (Deferred stenting in STEMI patients 
[NCT03581513]271, RESTORE-MI [ACTRN12618000778280]273). Moreover, an IMR 
>32 predicts worse recovery of LV function after acute STEMI158. 
2.2.5 RRR analysis 
The RRR measures the ability of the coronary microcirculation to change from baseline to 
minimum resistance, in response to a pharmacological hyperaemic stimulus. i.e. the 
vasodilatory capacity. Therefore, RRR reflects the ability to achieve maximal hyperaemia.  
 
Baseline resistance index (BRI) is used in the equation for calculating RRR. The BRI is a 
measure of resting tone in the coronary microcirculation and was calculated using the 
following previously validated equation194: 
BRI = PdBaseline x TmnBaseline 
To measure the ability of the coronary microcirculation to undergo vasodilatation in 
response to adenosine, the RRR was calculated as previously described: 
RRR = BRI ÷ IMR 
92 
 
Because there are no established thresholds for abnormal, or normal RRR, RRR was 
dichotomised by the median in multivariable regression analyses, which is the 
conventional approach taken by previous studies197.  
2.2.6 Thermodilution waveform analysis 
A narrow unimodal waveform was defined as an acute reduction in temperature (duration 
<0.42s from the beginning of the temperature reduction to nadir temperature) followed by 
a rapid return to resting temperature198. A wide unimodal waveform was defined as a 
temperature drop to nadir >0.42s, followed by a gradual return to baseline temperature. A 
bimodal waveform was defined as having 2 distinct nadirs, with a valley deeper than 20% 
of peak temperature drop198.  
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Chapter 3: Implications of impaired coronary flow on the effects of 
adjunctive intracoronary alteplase during primary PCI: the T-TIME 
angiographic study 
3.1 Abstract 
Background: Following STEMI, MVO confers an adverse prognosis. Persistently 
impaired flow (<TIMI 3) in the infarct-related artery is a surrogate for failed myocardial 
perfusion. The aim of this chapter was to evaluate the effects of intracoronary alteplase, 
according to sub-groups of TIMI coronary flow grade immediately preceding study drug 
administration, during primary PCI. 
Methods: Patients with STEMI from 11 U.K. hospitals, presenting ≤6 hours from 
symptom onset, were randomised to alteplase 20mg, alteplase 10mg, or placebo, during 
primary PCI. The intervention was administered by infusion into the infarct-related artery, 
after initial flow restoration (by balloon angioplasty and/or thrombus aspiration), before 
stent implantation. Core laboratory evaluation of TIMI flow grade in the infarct-related 
artery was performed immediately pre- and post-study drug administration, and at the start 
and end of the procedure. MVO, myocardial haemorrhage, and infarct size were assessed 
by CMR imaging at 2 to7 days after STEMI. Follow up CMR occurred at 3 months. 
Results: TIMI flow was assessed after first treatment (balloon angioplasty and/ or 
aspiration thrombectomy) immediately before study drug administration, in 421 
participants (mean age 61 ± 10 years, 85% male), and was 3, 2, or 1, in 267, 134 and 19 
participants, respectively. Patients with TIMI flow ≤2 pre-drug had a higher incidence of 
MVO with alteplase (alteplase 20mg [53.1%] and 10mg [59.5%] combined vs. placebo 
[34.1%]; OR: 2.47 [95% CI: 1.16, 5.22] p=0.018 [interaction: p=0.005]) and increased 
incidence of myocardial haemorrhage with alteplase (alteplase 20mg [53.1%] and alteplase 
10mg [57.9%] combined vs. placebo [27.5%]; OR: 3.26 [95% CI: 1.44, 7.36] p=0.004 
[interaction: p=0.001]). Patients with TIMI flow ≤2 pre-drug had a trend towards larger 
infarct size with alteplase (alteplase 20mg [32.3 ± 13.1%] and alteplase 10mg [32.0 ± 
12.7%] combined vs. placebo [28.1 ± 15.5%]; estimated mean difference: 3.87 [95% CI: -
0.34, 8.07] p=0.072 [interaction: p=0.026]).  In participants with TIMI 3 flow pre-study 
drug, there were no associations between alteplase and MVO, myocardial haemorrhage or 
infarct size. There were no interactions between TIMI flow grade pre-drug, alteplase and 
CMR findings at 3 months. 
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Conclusion: Intracoronary alteplase was associated with increased presence of MVO and 
myocardial haemorrhage, in STEMI patients with impaired flow (<TIMI 3) in the infarct-

























Despite routinely restoring epicardial coronary patency with primary PCI, which is the 
standard of care for STEMI1, MVO affects about half of patients26 and confers an adverse 
prognosis27 86. The pathophysiology of MVO is multifactorial, however a key component is 
distal embolization and microvascular thrombi31-33, especially fibrin rich thrombi32. There 
are no evidence-based treatments for MVO91 212 347.  
 
Facilitated PCI, using full-dose, or half-dose adjunctive therapy before PCI with stenting 
improves epicardial coronary flow acutely259 306. However, facilitated PCI may cause 
paradoxical thrombus formation and bleeding290 291. 
 
The T-TIME trial tested the hypothesis that low-dose intracoronary alteplase, administered 
shortly after initial treatment (i.e. balloon angioplasty and/ or thrombus aspiration) before 
stent implantation, would reduce intracoronary and microvascular thrombosis and distal 
embolization, thereby reducing MVO. However, as assessed by contrast enhanced CMR 
imaging, MVO did not differ with intracoronary alteplase vs. placebo292. 
 
Persistently reduced flow in the infarct-related artery (TIMI flow ≤2) after first treatment, 
is termed “angiographic no-reflow”28 348, and is a surrogate for myocardial perfusion 
defects (assessed by SPECT110 or by myocardial contrast echocardiography349). TIMI flow 
≤2 in the infarct-related artery at the end of PCI in STEMI patients is associated with heart 
failure350, larger infarct size110, and mortality107 350-352. TIMI flow ≤2 early during primary 
PCI (pre-stenting) may be even more closely associated with mortality112 315 and larger 
infarct size315 than TIMI flow ≤2 post-stenting. In contrast, maintained TIMI 3 flow in the 
infarct-related artery after initial treatment may help restore microvascular function349.  
 
Persisting impaired flow in the infarct-related artery may influence the effect of 
intracoronary alteplase. Hypothetically, impaired antegrade coronary flow could 
potentially reduce the effective intracoronary delivery of alteplase to the microcirculation, 




 The following hypotheses were evaluated: 
1) In acute STEMI patients with TIMI 3 flow immediately preceding study drug 
administration, intracoronary alteplase is associated with less MVO and less 
myocardial haemorrhage on CMR imaging compared to placebo. 
 
2) In acute STEMI patients with TIMI flow ≤2 immediately before study drug 
administration, there is no difference in MVO or myocardial haemorrhage on CMR 
imaging with intracoronary alteplase vs. placebo. 
3.3 Methods 
The methods for the T-TIME angiographic study were described in detail in section 2.1. 
3.3.1 Statistical analysis 
The analysis according to TIMI flow grade immediately preceding study drug 
administration (≤2 vs. 3), was prespecified prior to database lock. Patients in whom TIMI 
flow grade was not evaluable immediately pre-drug administration, were excluded from 
this analysis. Patients were also excluded from the analysis if the study drug was not 
administered, or was administered post-stent implantation, or distal to the culprit lesion. 
The analyses were performed according to treatment received (alteplase 20mg, alteplase 
10mg, or placebo).  
 
Continuous data were generally described as mean ± SD if normally distributed, or median 
and interquartile range (IQR) if skewed. The trial endpoints were assessed using linear 
regression (continuous parameters), or logistic regression (binary parameters), to make 
treatment effect estimates. In linear regression models, logarithmic, or square root 
transformations were used where necessary to improve model residual distributions. 
Regression models were used to assess treatment effects through interactions, with 
treatment as 3-level and 2-level categorical variables. The regression analyses were 
adjusted for MI location (anterior vs. non-anterior). All tests were 2-tailed and assessed at 
the 5% significance level. Imputation for missing values was not performed, and there was 
no adjustment for multiple statistical comparisons. Data were analysed with SPSS (version 




3.4.1 Population characteristics 
One thousand five hundred and twenty-seven STEMI patients were screened (Figure 3.1). 
Four hundred and forty patients were randomised to alteplase 20mg, alteplase 10mg, or 
placebo. Nineteen patients were excluded from the analysis (Figure 3.1). Out of these 19 
excluded patients, there were 7 in whom TIMI flow grade was unevaluable immediately 
before study drug administration, 5 in whom the study drug was not administered, 3 in 
whom the study drug was administered after stent implantation, and 4 in whom the study 
drug was administered distal to the lesion.  
 
Four hundred and twenty-one patients were included in the analysis (mean age 60 ± 10 
years, 85% male). Out of the 421 participants who were included, 1 participant who was 
randomised to 10mg of alteplase received 20mg of alteplase and 1 participant randomised 
to placebo received alteplase 20mg, because of handling errors. 
 
Out of the patients with TIMI flow ≤2 pre-drug, the majority (87%) had TIMI 2 flow 
immediately preceding drug administration. The distribution of TIMI coronary flow grades 
immediately preceding drug administration were as follows: TIMI grade 0 in 1 patient 
(0.2%) who received alteplase 10mg; TIMI grade 1 in 19 patients (5%) of whom 8 
received placebo, 4 received alteplase 10mg and 7 received alteplase 20mg; TIMI grade 2 
in 134 patients (32%) of whom 42 received placebo, 44 received alteplase 10mg and 48 
received alteplase 20mg, and; TIMI grade 3 flow in 268 patients (64%) of whom 93 
received placebo, 87 received alteplase 10mg and 88 received alteplase 20mg.  
 
The population characteristics for patients with TIMI flow ≤2 (n=154) or TIMI 3 flow 
immediately before drug administration were broadly similar. There was no difference in 
glycoprotein IIbIIIa inhibitor use between patients who had TIMI flow ≤2 vs. 3 
immediately before study drug administration (p=0.476). However, LAD infarcts were 
relatively more frequent in patients with TIMI flow ≤2 pre-study drug (Tables 3.1 and 3.2). 
Anterior location of MI was the only population characteristic associated with TIMI flow 
≤2 pre-study drug, on multivariable logistic regression analysis (OR: 1.61 [95% CI: 1.07, 
2.43] p=0.023). Ischaemic time was not associated with TIMI flow ≤2 immediately pre-
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study drug administration (OR: 1.05 [95% CI: 0.91, 1.22] p=0.499). Infarct-related artery 




Figure 3.1 Flow of subjects through the T-TIME angiographic study. CMR follow up is 
reported according to treatment received. 
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 Impaired coronary flow immediately pre-drug (TIMI flow £ 2) 
 
  Normal coronary flow immediately pre-drug (TIMI 3 flow) 

















Age  59.5 ± 10.7 59.5 ± 11.3 58.7 ± 11.3 60.3 ± 9.7   61.2 ± 10.0 61.8 ± 10.7 60.1 ± 9.9 61.8 ± 9.5 
Male 134 (87%) 44 (88%) 43 (88%) 47 (86%)   224 (84%) 76 (83%) 74 (85%) 74 (84%) 
White 143 (93%) 46 (92%) 47 (96%) 50 (91%)   253 (95%) 89 (97%) 81 (93%) 83 (94%) 
Asian 9 (6%) 3 (6%) 1 (2%) 5 (9%)   14 (5%) 3 (3%) 6 (7%) 5 (6%) 
Body mass index (kg/m2) 28.4 ± 4.8 29.1 ± 5.6 28.1 ± 4.2 27.9 ± 4.4   28.1 ± 5.0 28.1 ± 5.1 28.7 ± 5.2 27.6 ± 4.5 
Heart rate at presentation, beats/ min 73.7 ± 17.2 72.1 ± 16.2 70.6 ± 15.3 78.0 ± 18.9   72.1 ± 20.1  73.5 ± 25.6 72.3 ± 16.6 70.3 ± 16.4 
Systolic blood pressure at presentation, mmHg 132.4 ± 22.9 128.8 ± 21.5 135.8 ± 23.8 132.7 ± 23.3   134.9 ± 26.6 134.8 ± 28.4 134.3± 25.6 135.5 ± 25.8 
Diastolic blood pressure at presentation, mmHg 81.1 ± 14.7 77.8 ± 15.1 81.1 ± 14.3 83.4 ± 14.5   80.0 ± 16.0 80.0 ± 17.2 80.6 ± 15.6 79.4 ± 15.1 
Infarct location:   
               Anterior 

























Hypertension 53 (34%) 18 (36%) 15 (31%) 20 (36%)   82 (31%) 27 (29%) 28 (32%) 27 (31%) 
Renal impairment * 1 (1%) 1 (2%) 0 0   5 (2%) 1 (1%) 3 (3%) 1 (1%) 
Hypercholesterolaemia 40 (26%) 15 (30%) 13 (27%) 12 (22%)   56 (21%) 25 (27%) 14 (16%) 17 (19%) 
Diabetes mellitus # 20 (13%) 5 (10%) 9 (18%) 6 (11%)   33 (12%) 13 (14%) 8 (9%) 12 (14%) 
Smoking:   
               Current 
               Former (stopped >3 months) 

































Previous PCI 4 (3%) 1 (2%) 2 (4%) 1 (2%)   14 (5%) 6 (7%) 3 (3%) 5 (6%) 
Angina 2 (1%) 1 (2%) 1 (2%) 0   13 (5%) 4 (4%) 4 (5%) 5 (6%) 
Previous MI 2 (1%) 0 2 (4%) 0   15 (6%) 5 (5%) 3 (3%) 7 (8%) 
 
Table 3.1 (page 1 of 2) Baseline characteristics from the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately before study drug 
administration. Data are reported according to treatment received (n=421). Data are mean ± SD, or n (%) unless otherwise stated. *Renal impairment was defined as 
an estimated glomerular filtration rate <59 mL/min/1.73m2. # Diabetes mellitus was defined as a history of diet-controlled or treated diabetes. Missing: body mass 
index (calculated as weight in kg divided by height in meters squared) n=2, creatinine or estimated glomerular filtration rate n=68, haemoglobin n=16, platelets n=30. 
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 Impaired coronary flow immediately pre-drug (TIMI flow £ 2) Normal coronary flow immediately pre-drug (TIMI 3 flow) 
     

















Stroke/ Transient Ischaemic Attack 0 0 0 0   5 (2%) 2 (2%) 1 (1%) 2 (2%) 
Peripheral vascular disease 3 (2%) 2 (4%) 1 (2%) 0   9 (3%) 1 (1%) 2 (2%) 6 (7%) 
Pre-existing maintenance medication:           
               Aspirin 16 (10%) 6 (12%) 5 (10%) 5 (9%)   47 (18%) 20 (22%) 11 (13%) 16 (18%) 
               P2Y12 inhibitor 
                              Clopidogrel 

























               Statin 31 (20%) 11 (22%) 11 (22%) 9 (16%)   60 (23%) 27 (29%) 17 (20%) 16 (18%) 
               Beta blocker 14 (9%) 4 (8%) 6 (12%) 4 (7%)   26 (10%) 12 (13%) 8 (9%) 6 (7%) 
               ACE inhibitor or ARB 30 (20%) 8 (16%) 10 (20%) 12 (22%)   43 (16%) 13 (14%) 16 (18%) 14 (16%) 
               Mineralocorticoid receptor antagonist 2 (1%) 0 2 (4%) 0   2 (1%) 1 (1%) 0 1 (1%) 
Symptom onset to reperfusion, median (IQR) hrs 2.7 (2.1, 3.8) 2.7 (2.1, 3.5) 2.7 (1.9, 4.2) 2.9 (2.1, 3.8)   2.6 (2.0, 3.8) 2.6 (2.0, 3.7) 2.8 (1.9, 4.0) 2.7 (2.0, 3.8) 
Initial blood results on admission:           
               Haemoglobin, g/dL 147.3 ± 13.2 144.9 ± 15.1 145.7 ± 11.0 151.0 ± 12.5   144.6 ± 13.3 144.0 ± 13.5 145.9 ± 13.6 143.8 ± 12.8 
               Platelet count, 103/μL 259.7 ± 61.2 248.7 ± 61.2 273.3 ± 64.6 257.7 ± 56.8   262.6 ± 63.6 254.2 ± 61.0 269.7 ± 75.8 263.9 ± 50.5 
               Creatinine, μmol/L 80.5 ± 17.3 83.6 ± 19.2 74.8 ± 12.3 82.7 ± 18.2   80.9 ± 18.1 78.0 ± 17.3 83.4 ± 18.7 81.2 ± 18.2 
               eGFR (ml/min/1.73m2) 92.7 ± 21.4 91.1 ± 21.6 96.4 ± 18.4 91.0 ± 23.4   88.9 ± 20.7 90.4 ± 20.9 86.9 ± 20.0 89.3 ± 21.3 
 
Table 3.1 (page 2 of 2) Baseline characteristics from the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately before study drug 
administration. Data are reported according to treatment received (n=421). Data are mean ± SD, or n (%) unless otherwise stated. *Renal impairment was defined as 
an estimated glomerular filtration rate <59 mL/min/1.73m2. # Diabetes mellitus was defined as a history of diet-controlled or treated diabetes. Missing: body mass 




 Impaired coronary flow immediately pre-drug (TIMI flow £ 2) 
 
  Normal coronary flow immediately pre-drug (TIMI 3 flow) 

















Culprit artery:  LAD 
                         Cx 


























Multivessel disease:  1 
                                  2 

























Initial TIMI coronary flow grade:  
               0 (no flow) 
               1 (minimal flow) 
               2 (slow but complete flow) 










































Initial TIMI thrombus grade:   0 - 2 
                                                    3 
                                                    4 


































QCA lesion length pre-drug (mm)  25.5 ± 11.2 26.7 ± 11.6 27.4 ± 12.4 22.7 ± 9.3   27.2 ± 11.3 26.7 ± 10.6 27.6 ± 11.6 27.5 ± 11.8 
Mode of reperfusion:           
               Aspiration thrombectomy 45 (29%) 12 (24%) 14 (29%) 19 (35%)   74 (28%) 23 (25%) 28 (32%) 23 (26%) 
               Balloon angioplasty 109 (71%) 38 (76%) 35 (71%) 36 (66%)   192 (72%) 69 (75%) 59 (68%) 64 (73%) 
               Primary stent 0 0 0 0   1 (0.4%) 0 0 1 (1%) 
Balloon angioplasty pre-stent 144 (94%) 48 (96%) 46 (94%) 50 (91%)   244 (91%) 83 (90%) 82 (94%) 79 (90%) 
Table 3.2 (page 1 of 3) Procedural characteristics from the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately preceding study drug 
administration. Data are reported according to treatment received (n=421). Data are mean ± SD, or n (%), unless otherwise stated. None of the participants received 
intravenous or intracoronary treatment with bivalirudin, metoprolol, nicorandil, or sodium nitroprusside. Missing: ACT (n=96), aspirin loading dose (n=56), 
duration of study drug infusion (n=24), glycoprotein IIbIIIa inhibitor (n=11), inhaled oxygen (n=11), infarct related artery occlusion after study drug administration 
(n=87), CMR 2 to 7 days post-PCI (n=38), CMR 3 months post-PCI (n=66). 
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 Impaired coronary flow immediately pre-drug (TIMI flow £ 2) 
 
  Normal coronary flow immediately pre-drug (TIMI 3 flow) 
















Method of study drug delivery: 
               Thrombectomy catheter 
               Guide catheter 

































PCI with stent implantation 152 (99%) 50 (100%) 48 (98%) 54 (98%)   266 (100%) 91 (99%) 87 (100%) 88 (100%) 
Total number of stents deployed: 
               0 
               1 
               2 









































Post stent dilatation 133 (86%) 48 (96%) 42 (86%) 43 (78%)   233 (87%) 76 (83%) 76 (87%) 81 (92%) 
Total length of stents deployed from 
QCA, mm  
32.7 ± 14.4 32.9 ± 13.8 35.2 ± 16.2 30.2 ± 13.1   34.5 ± 14.4 34.9 ± 13.3 34.8 ± 14.2 33.9 ± 14.7 
QCA reference vessel diameter post-
stent, mm  
3.3 ± 0.5 3.2 ± 0.5 3.3 ± 0.6 3.2 ± 0.4   3.2 ± 0.4 3.1 ± 0.4 3.2 ± 0.5 3.2 ± 0.4 
Loading with aspirin at first medical 
contact 
135 (88%) 44 (88%) 43 (88%) 48 (87%)   230 (86%) 78 (85%) 77 (89%) 75 (85%) 
Aspirin loading dose, mg, n/ total (%): 
               300 


























Table 3.2 (page 2 of 3) Procedural characteristics from the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately preceding study drug 
administration. Data are reported according to treatment received (n=421). Data are mean ± SD, or n (%), unless otherwise stated. None of the participants received 
intravenous or intracoronary treatment with bivalirudin, metoprolol, nicorandil, or sodium nitroprusside. Missing: ACT (n=96), aspirin loading dose (n=56), 
duration of study drug infusion (n=24), glycoprotein IIbIIIa inhibitor (n=11), inhaled oxygen (n=11), infarct related artery occlusion after study drug administration 





 Impaired coronary flow immediately pre-drug (TIMI flow £ 2) 
 
  Normal coronary flow immediately pre-drug (TIMI 3 flow) 
















Additional antiplatelet medication at first 
medical contact: 
                None 
                 Clopidogrel 
                 Ticagrelor 










































































ACT (s) 276.3 ± 89.8 264.3 ± 89.8 303.4 ± 97.6 263.0 ± 78.3   284.0 ± 87.4 280.8 ± 88.5 294.9 ± 88.5 276.1 ± 85.2 
Intravenous morphine 114 (74%) 37 (74%) 38 (78%) 39 (71%)   197 (74%) 62 (67%) 64 (74%) 71 (81%) 
Inhaled oxygen, n/ total (%) 28/151 (19%) 8/49 (16%) 14/48 (29%) 6/54 (11%)   32/259 (12%) 14/90 (16%) 10/85 (12%) 8/84 (10%) 
Glycoprotein IIb/IIIa inhibitor, n/ total 
(%) 
28/151 (19%) 6/49 (12%) 11/48 (23%) 11/54 (20%)   38/259 (15%) 8/90 (9%) 17/85 (20%) 13/84 (16%) 
Duration of study drug infusion, min 6.6 ± 2.0 6.9 ± 2.1 6.5 ± 2.0 6.5 ± 1.9   6.4 ± 1.9 6.2 ± 1.9 6.4 ± 1.9 6.7 ± 2.0 
Infarct-related artery occlusion after 
study drug infusion, No/total (%) 
21/121 (17%) 11/37 (30%) 5/40 (13%) 5/44 (11%)   23/213 (11%) 8/73 (11%) 6/71 (8%) 9/69 (13%) 
Days from PCI to CMR imaging 2-7 days 
post-primary PCI, median (IQR) 
4.0 (3.0, 6.0) 4.0 (3.0, 5.0) 4.0 (3.0, 6.0) 4.0 (2.8, 6.0)   4.0 (3.0, 6.0) 4.0 (2.8, 5.0) 5.0 (3.0, 6.0) 4.0 (4.0, 6.0) 
Days from PCI to CMR imaging 3 
months post-primary PCI, median (IQR) 
91.0 (85.0, 98.8) 91.0 (85.0, 97.0) 92.0 (86.0, 99.5) 90.0 (85.0, 99.0)   90.0 (86.0, 95.3) 90.0 (85.8, 94.0) 90.0 (86.0, 96.0) 91.0 (86.0, 97.0) 
 
Table 3.2 (page 3 of 3) Procedural characteristics from the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately preceding 
study drug administration. Data are reported according to treatment received (n=421). Data are mean ± SD, or n (%), unless otherwise stated. None of 
the participants received intravenous or intracoronary treatment with bivalirudin, metoprolol, nicorandil, or sodium nitroprusside. Missing: ACT 
(n=96), aspirin loading dose (n=56), duration of study drug infusion (n=24), glycoprotein IIbIIIa inhibitor (n=11), inhaled oxygen (n=11), infarct 
related artery occlusion after study drug administration (n=87), CMR imaging 2 to 7 days post-PCI (n=38), CMR imaging 3 months post-PCI (n=66). 
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One hundred and seventy-one patients (41%) were recruited on a weekend or outside 9am 
to 5pm, i.e. outwith “normal working hours”. A breakdown of the number patients enrolled 
in the angiographic study by day of the week and by time to the nearest hour is shown 
(Figure 3.2).  
 
Figure 3.2 Breakdown of the number of patients enrolled in the T-TIME angiographic 
study by day of the week (A) and by time of day to the nearest hour (B). 
 
3.4.2 Intra-observer and inter-rater reliability for angiographic parameters 
Inter-rater variability was assessed for MPG and TIMI flow grade at the end of the PCI 
procedure, in the entire T-TIME trial population (n=440). Inter-rater variability was 
assessed for TFC at the end of the procedure, in 438 patients from the T-TIME trial 
population. There was excellent inter-rater reliability for TIMI flow grade at the end of the 
PCI procedure (kappa=0.94). The inter-rater reliability for TIMI flow grade immediately 
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pre-study drug, assessed in 65 consecutive participants, was also excellent (kappa=0.94). 
There was excellent inter-rater reliability for MPG (kappa=0.88) and for TFC (intra-class 
correlation coefficient: 0.996 [95% CI: 0.995, 0.996]), at the end of the PCI procedure. 
 
There was excellent intra-observer reliability for TFC, MPG and TIMI flow grade, at the 
end of PCI in 50 consecutive participants (intra-class correlation coefficient for TFC: 0.999 
[95% CI: 0.999, 1.000], kappa for MPG=0.85, and kappa for TIMI flow grade=0.90). 
3.4.3 CMR endpoints  
Three hundred and eighty-seven patients (92%) had CMR imaging performed 2 to 7 days 
post-primary PCI, and MVO presence/ absence was evaluable in 383 patients (91%). At 3 
months post-primary PCI, CMR imaging was available in 358 participants (85%). The 
number of days from PCI to CMR imaging is shown in Table 3.2. The CMR results at 2 to 
7 days post-primary PCI are shown in Table 3.3, and the results stratified by location of MI 
are shown in Table 3.4. In participants with TIMI 3 flow pre-study drug, there were no 
associations between alteplase and CMR parameters, apart from an increase in LV end 
diastolic volume with alteplase 10mg vs. placebo (Tables 3.3 to 3.5). 
 
Due to the high proportion of participants with a 0 value for MVO extent (56% of 
participants) and myocardial haemorrhage extent (57% of participants), the median values 
for MVO and myocardial haemorrhage were 0 for all groups. Therefore, for these 
parameters the mean ± SD was reported despite not being an ideal summary for these data. 
Overall, the mean MVO extent was higher in patients who had TIMI flow ≤2 compared to 
TIMI 3 flow pre-study drug (3.7 ± 6.0% vs. 2.3 ± 4.2%; coefficient = 0.33 [95% CI: 0.05, 
0.60] p=0.022 [from linear regression using square root transformed MVO]). Overall, the 
mean myocardial haemorrhage extent was also higher in patients who had TIMI flow ≤2 
compared to TIMI 3 flow pre-study drug (2.7 ± 5.1% vs. 1.6 ± 3.4%; coefficient = 1.14 
[95% CI: 0.24, 2.03] p=0.014, from linear regression). 
MVO 
Participants with TIMI flow ≤2 pre-study drug had MVO present more often with alteplase 
(placebo: 34% [n=15/44], alteplase 10mg: 60% [n=25/42], alteplase 20mg: 53% 
[n=26/49]; OR for alteplase 10mg and 20mg combined vs. placebo, 2.47 [95% CI: 1.16, 
5.22] p=0.018) (Figure 3.3). Interactions were observed with MVO presence, between 
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TIMI flow pre-drug, and treatment analysed as 3-, or 2-level categorical variables (p=0.013 
and p=0.005 respectively) (Table 3.3). When the 19 patients with TIMI 1 flow and the one 
patient with TIMI 0 flow immediately pre-drug were excluded, significant interactions 
remained between alteplase, TIMI flow pre-drug (2 vs. 3) and the presence of MVO 
(p=0.022) (Table 3.6). 
 
Participants with TIMI flow ≤2 pre-study drug had increased extent of MVO (% LV mass) 
with alteplase 20mg compared to placebo (placebo: 2.6 ± 5.7%, alteplase 10mg: 2.7 ± 
3.9%, alteplase 20mg: 5.4 ± 7.4%; estimated mean difference alteplase 20mg and 10mg 
combined vs. placebo 0.53 [95% CI: 0.06, 1.00] p=0.027) (Table 3.3). In participants with 
TIMI 3 flow pre-study drug, there was no association between alteplase and MVO extent 
or presence (Table 3.3). There was an interaction between MVO extent, TIMI flow pre-
drug and treatment, when alteplase 10mg and 20mg were combined and compared with 
placebo (p=0.041), but not for treatment as a 3-level categorical variable (p=0.070) (Table 
3.3). 
Myocardial haemorrhage 
Myocardial haemorrhage presence/ absence was evaluable in 366 of the patients (87%), 2 
to 7 days post-PCI. Myocardial haemorrhage extent was evaluable in 348 of the patients 
(83%). 
 
In patients who had TIMI flow ≤2 pre-study drug, myocardial haemorrhage occurred more 
often with alteplase than placebo (placebo: 28% [n=11/40], alteplase 10mg: 58% 
[n=22/38], alteplase 20mg: 53% [n=26/49]; OR for alteplase 10mg and 20mg combined vs. 
placebo = 3.26 [95% CI: 1.44, 7.36] p=0.004) (Figure 3.3). There were interactions 
between myocardial haemorrhage presence, TIMI flow pre-drug and treatment, analysed as 
3- and 2-level categorical variables (p=0.004 and p=0.001 respectively) (Table 3.3). When 
the 19 patients with TIMI 1 flow pre-drug and the one patients with TIMI 0 flow 
immediately pre-drug were excluded, significant interactions remained between alteplase, 





In patients with TIMI flow ≤2 pre-study drug there was a trend towards increased extent of 
myocardial haemorrhage (% LV mass) with alteplase (placebo: 1.7 ± 5.2%, alteplase 
10mg: 2.2 ± 3.4%, alteplase 20mg: 3.8 ± 5.8%). In patients with TIMI flow ≤2 pre-study 
drug, the estimated mean difference for myocardial haemorrhage extent for alteplase 20mg 
vs. placebo was 2.15 (95% CI: 0.45, 3.85) p=0.014, however the estimated mean 
difference for myocardial haemorrhage extent for alteplase 10mg and 20mg combined vs. 
placebo was not statistically significant (Table 3.3). In participants with TIMI 3 flow pre-
study drug, there was no association between alteplase and myocardial haemorrhage extent 
or presence (Table 3.3). There were no interactions between myocardial haemorrhage 
extent, TIMI flow pre-drug and treatment, analysed as 3-, or 2-level categorical variables 
(p=0.120 and p=0.179 respectively) (Table 3.3). 
 
 
Figure 3.3 Forrest plots showing increased MVO and myocardial haemorrhage presence 
associated with alteplase vs. placebo in patients with TIMI flow ≤2 immediately before 
study drug administration 
 
Infarct size  
In patients with TIMI 3 flow pre-study drug, there were no associations between alteplase 
and infarct size (Tables 3.3 and 3.4). In patients with TIMI flow ≤2 pre-study drug, there 
was a trend towards larger infarct size (2 to 7 day) with alteplase than placebo (placebo: 
28.1 ± 15.5, alteplase 10mg: 32.0 ± 12.7, alteplase 20mg: 32.3 ± 13.1). Though no 
differences in treatment effects were detected on linear regression (Table 3.3), an 
interaction was observed for association between infarct size (2 to 7 day), TIMI flow and 
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treatment as a 2-level categorical variable (p=0.026), but not for treatment as a 3-level 
categorical variable (p=0.076) (Table 3.3). There were no associations or interactions 
between TIMI flow sub-groups, alteplase, and infarct size at 3 months post-primary PCI 
(Table 3.5). 
LV ejection fraction and volumes 
There were no interactions between sub-groups of TIMI flow pre-study drug, alteplase, and 



























Alteplase 10mg vs. placebo  Alteplase 20mg vs. placebo  
Alteplase (10mg or 20mg)  
vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
MVO present (n/ total) (a)  
TIMI flow £2  







2.86 (1.19, 6.88 p=0.019 
0.61 (0.33, 1.14) p=0.119 
 
2.18 (0.94, 5.04) p=0.069 
0.72 (0.39, 1.34) p=0.298 
 0.013          
2.47 (1.16, 5.22) p=0.018 
0.66 (0.39, 1.13) p=0.128 
0.005 
MVO extent (% of LV mass) (b)            
TIMI flow £2  
TIMI 3 flow 
2.6 ± 5.7 
2.2 ± 3.4  
2.7 ± 3.9 
2.4 ± 4.8 
5.4 ± 7.4 
2.3 ± 4.3 
0.31 (-0.24, 0.86) p=0.269 
-0.09 (-0.49, 0.31) p=0.661 
 
0.72 (0.19, 1.25) p=0.008 
-0.06 (-0.45, 0.34) p=0.777 
 0.070   
0.53 (0.06, 1.00) p=0.027 
-0.07 (-0.42, 0.27) p=0.677 
0.041 
Myocardial haemorrhage present (n/ total) (a)           
TIMI flow £2  







3.67 (1.42, 9.49) p=0.007 
0.64 (0.34, 1.21) p=0.168 
 
2.97 (1.22, 7.27) p=0.017 
0.66 (0.35, 1.23) p=0.188 
 0.004   
3.26 (1.44, 7.36) p=0.004 
0.65 (0.38, 1.11) p=0.117 
0.001 
 
Table 3.3 (page 1 of 3) Analysis of CMR parameters 2 to 7 days after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately before study 
drug administration (adjusted for MI location). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. Missing data: MVO extent or presence/ absence (n=38), 
myocardial haemorrhage extent (n=73), myocardial haemorrhage presence/ absence (n=55), infarct size (n=38), LV ejection fraction or volumes (n=34). Treatment effect estimates 
and interaction with treatment received are shown. (a) Treatment effect estimates reported as ORs between groups from a logistic regression model. (b) Treatment effect estimates 
reported as mean differences in square root transformed MVO extent between groups, from a linear regression model. (c) Treatment effect estimates reported as mean differences 
between groups, from linear regression. (d) Data analysed on a logarithmic scale, with treatment effect estimates reported as relative differences between groups. 
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as a 3-level 
categorical 
variable) 
















Alteplase 10mg vs. placebo 
 
Alteplase 20mg vs. placebo 
   
Alteplase (10mg or 20mg)  
vs. placebo 
Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value 
Myocardial haemorrhage extent (% LV mass) (c)  
TIMI flow £2  
TIMI 3 flow 
1.7 ± 5.2 
1.4 ± 2.8 
2.2 ± 3.4 
1.8 ± 3.6 
3.8 ± 5.8 
1.5 ± 3.8 
0.55 (-0.31, 2.42) p=0.562 
0.29 (-1.00, 1.58) p=0.656 
 
2.15 (0.45, 3.85) p=0.014 
0.11 (-1.16, 1.38) p=0.867 
 0.120   
0.50 (-0.04, 3.04) p=0.057 
0.20 (-0.91, 1.31) p=0.726 
0.179 
Infarct size (% LV mass) (c)     
TIMI flow £2  
TIMI 3 flow 
28.1 ± 15.5 
26.0 ± 12.6 
32.0 ± 12.7 
24.7 ± 11.7 
32.3 ± 13.1 
22.8 ± 12.3 
3.87 (-1.08, 8.81) p=0.126 
-1.35 (-4.92, 2.22) p=0.460 
 
3.87 (-0.90, 8.63) p=0.112 
-2.68 (-6.22, 0.86) p=0.138 
 0.076   
3.87 (-0.34, 8.07) p=0.072 
-2.03 (-5.09, 1.03) p=0.195 
0.026 
LV ejection fraction (%) (c)     
TIMI flow £2  
TIMI 3 flow 
43.4 ± 10.5 
44.8 ± 7.9 
41.5 ± 8.8 
44.7 ± 7.4 
42.6 ± 8.8 
45.4 ± 7.9 
-1.85 (-5.18, 1.48) p=0.276 
-0.03 (-2.43, 2.37) p=0.982 
 
-0.67 (-3.88, 2.53) p=0.681 
0.40 (-1.98, 2.79), p=0.740 
 0.681   
-1.22 (-4.05, 1.62) p=0.400 
0.19 (-1.87, 2.25) p=0.856 
0.431 
 
Table 3.3 (page 2 of 3) Analysis of CMR parameters 2 to 7 days after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately before study 
drug administration (adjusted for MI location). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. Missing data: MVO extent or presence/ absence (n=38), 
myocardial haemorrhage extent (n=73), myocardial haemorrhage presence/ absence (n=55), infarct size (n=38), LV ejection fraction or volumes (n=34). Treatment effect estimates & 
interaction with treatment received are shown. (a) Treatment effect estimates reported as ORs between groups from a logistic regression model. (b) Treatment effect estimates 
reported as mean differences in square root transformed MVO extent between groups, from a linear regression model. (c) Treatment effect estimates reported as mean differences 
between groups, from linear regression. (d) Data analysed on a logarithmic scale, with treatment effect estimates reported as relative differences between groups. 
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as a 3-level 
categorical 
variable) 
















Alteplase 10mg vs. placebo 
 
Alteplase 20mg vs. placebo 
   
Alteplase (10mg or 20mg)  
vs. placebo 
Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value 
LV end-systolic volume (ml) (d)            
TIMI flow £2  
TIMI 3 flow 
96.2 [80.2, 118.9] 
90.2 [75.9, 108.0] 
105.3 [85.6, 124.3] 
92.9 [79.0, 113.4] 
95.5 [80.8, 113.6] 
92.5 [72.3, 109.0] 
1.05 (0.93, 1.19) p=0.392 
1.08 (0.99, 1.18) p=0.070 
 
0.95 (0.85, 1.07) p=0.425 
1.01 (0.93, 1.10) p=0.819 
 0.739   
1.00 (0.90, 1.11) p=0.984 
1.05 (0.97, 1.13) p=0.242 
0.480 
LV end-diastolic volume (ml) (d)            
TIMI flow £2  
TIMI 3 flow 
174.2 [153.9, 214.1] 
162.2 [141.8, 190.1] 
177.3 [163.9, 212.3] 
176.5 [155.5, 205.8] 
161.6 [142.6, 200.0] 
170.5 [136.6, 194.3] 
1.02 (0.93, 1.12) p=0.721 
1.08 (1.01, 1.16) p=0.021 
 
0.94 (0.86, 1.03) p=0.171 
1.02 (0.95, 1.09) p=0.601 
 0.340   
0.97 (0.90, 1.06) p=0.525 
1.05 (0.99, 1.11) p=0.105 
0.141 
 
Table 3.3 (page 3 of 3) Analysis of CMR parameters 2 to 7 days after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately before study 
drug administration (adjusted for MI location). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. Missing data: MVO extent or presence/ absence (n=38), 
myocardial haemorrhage extent (n=73), myocardial haemorrhage presence/ absence (n=55), infarct size (n=38), LV ejection fraction or volumes (n=34). Treatment effect estimates & 
interaction with treatment received are shown. (a) Treatment effect estimates reported as ORs between groups from a logistic regression model. (b) Treatment effect estimates 
reported as mean differences in square root transformed MVO extent between groups, from a linear regression model. (c) Treatment effect estimates reported as mean differences 
































Alteplase 10mg vs placebo  Alteplase 20mg vs. placebo  
Alteplase (10mg or 20mg)  
vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
MVO present (n/ total) (a)            
Anterior MI:            TIMI flow £2  







1.88 (0.57, 6.21) p=0.304 
0.80 (0.31, 2.03) p=0.633 
 
2.34 (0.75, 7.37) p=0.145 
0.84 (0.32, 2.19) p=0.720 
 0.354   
2.12 (0.77, 6.13) p=0.151 
0.82 (0.36, 1.84) p=0.625 
0.150 
Non-anterior MI:    TIMI flow £2  







4.67 (1.30, 18.65) p=0.022 
0.48 (0.21, 1.14) p=0.095 
 
2.00 (0.58, 6.87) p=0.271 
0.65 (0.29, 1.45) p=0.292 
 0.014   
2.94 (0.98, 8.81) p=0.054 
0.57 (0.28, 1.15) p=0.116 
0.012 
MVO extent (% LV mass) (b)             
Anterior MI:            TIMI flow £2  
                                TIMI 3 flow 
3.7 ± 7.4  
3.0 ± 4.1 
2.5 ± 3.4  
2.9 ± 4.6 
6.3 ± 8.0  
3.1 ± 5.6 
0.00 (-0.85, 0.86) p=0.993 
-0.12 (-0.80, 0.57) p=0.738 
 
0.73 (-0.09, 1.54) p=0.080 
-0.10 (-0.80, 0.60) p=0.778 
 0.261   
0.40 (-0.32, 1.13) p=0.277 
-0.11 (-0.70, 0.49) p=0.072 
0.284 
Non-anterior MI:    TIMI flow £2  
                                TIMI 3 flow 
1.4 ± 2.9  
1.5 ± 2.6 
3.1 ± 4.5  
2.1 ± 4.9 
4.2 ± 6.5  
1.8 ± 3.3 
0.65 (-0.07, 1.37) p=0.079 
-0.07 (-0.54, 0.40) p=0.775 
 
0.71 (0.00, 1.41) p=0.050 
-0.02 (-0.49, 0.44) p=0.922 
 0.156   
0.68 (0.07, 1.29) p=0.031 
-0.04 (-0.45, 0.36) p=0.828 
0.053 
 
Table 3.4 (page 1 of 3) Analysis of CMR parameters 2 to 7 days after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately before study 
drug administration, and by sub-groups of MI location (anterior [n=187], non-anterior [n=234]). Data are mean ± SD, or n (%), unless otherwise stated. Missing data: infarct size 
(n=66), LV ejection fraction or volumes (n=63). Treatment effect estimates and interaction with treatment received are shown. (a) Treatment effect estimates reported as ORs between 
groups from a logistic regression model. (b) Treatment effect estimates reported as mean differences in square root transformed MVO extent between groups, from a linear regression 
model. (c) Treatment effect estimates reported as mean differences between groups, from linear regression.  
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as a 3-level 
categorical 
variable) 
















Alteplase 10mg vs. placebo 
 
Alteplase 20mg vs. placebo 
   
Alteplase (10mg or 20mg) 
vs. placebo 
Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value 
Myocardial haemorrhage present (n/ total) (a)           
Anterior MI:             TIMI flow £2  







2.22 (0.62, 7.98) p=0.221 
0.83 (0.32, 2.18) p=0.710 
 
2.50 (0.77, 8.16) p=0.129 
0.71 (0.26, 1.92) p=0.494 
 0.245   
2.38 (0.83, 7.32) p=0.114 
0.77 (0.33, 1.79) p=0.544 
0.102 
Non-anterior MI:     TIMI flow £2  







6.43 (1.62, 30.35) p=0.012 
0.51 (0.21, 1.20) p=0.129 
 
3.75 (0.99, 16.56) p=0.061 
0.63 (0.28, 1.40) p=0.254 
 0.007   
4.79 (1.45, 19.13) p=0.015 
0.57 (0.28, 1.17) p=0.124 
0.003 
Myocardial haemorrhage extent (% LV mass) (c)            
Anterior MI:             TIMI flow £2  
                                 TIMI 3 flow 
2.9 ± 7.1  
1.6 ± 3.0 
2.8 ± 4.0  
2.0 ± 3.4 
4.6 ± 6.4  
2.2 ± 5.2 
-0.08 (-3.22, 3.05) p=0.959 
0.39 (-2.08, 2.87) p=0.757 
 
1.77 (-1.10, 4.64) p=0.230 
0.55 (-2.01, 3.10) p=0.676 
 0.671   
1.01 (-1.59, 3.61) p=0.447 
0.46 (-1.71, 2.64) p=0.677 
0.752 
Non-anterior MI:    TIMI flow £2  
                                TIMI 3 flow 
0.4 ± 1.1 
1.3 ± 2.7 
1.6 ± 2.5 
1.6 ± 3.8 
2.9 ± 4.9 
1.1 ± 2.8 
1.21 (-0.94, 3.36) p=0.272 
0.28 (-1.04, 1.60) p=0.679 
 
2.52 (0.56, 4.47) p=0.010 
-0.16 (-1.43, 1.11) p=0.804 
 0.072   
1.99 (0.23, 3.75) p=0.028 
0.04 (-1.08, 1.16) p=0.944 
0.067 
Table 3.4 (page 2 of 3) Analysis of CMR parameters 2 to 7 days after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3)  immediately before study 
drug administration, and by sub-groups of MI location (anterior [n=187], non-anterior [n=234]). Data are mean ± SD, or n (%), unless otherwise stated. Missing data: infarct size 
(n=66), LV ejection fraction or volumes (n=63). Treatment effect estimates and interaction with treatment received are shown. (a) Treatment effect estimates reported as ORs between 
groups from a logistic regression model. (b) Treatment effect estimates reported as mean differences in square root transformed MVO extent between groups, from a linear regression 




             




as a 3-level 
categorical 
variable) 
















Alteplase 10mg vs. placebo 
 
Alteplase 20mg vs. placebo 
   
Alteplase (10mg or 20mg) 
vs. placebo 
Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value 
Infarct size (% LV mass) (c)     
Anterior MI:            TIMI flow £2  
                                 TIMI 3 flow 
33.4 ± 17.0 
33.1 ± 12.7 
37.6 ± 11.5 
31.3 ± 12.0 
35.3 ± 15.4 
28.4 ± 14.5 
4.13 (-3.97, 12.23) p=0.319 
-1.75 (-8.24, 4.75) p=0.598 
 
1.91 (-5.80, 9.61) p=0.628 
-4.71 (-11.36, 1.95) p=0.167 
 0.382   
2.91 (-3.94, 9.75) p=0.407 
-3.16 (-8.79, 2.47) p=0.272 
0.180 
Non-anterior MI:    TIMI flow £2  
                                TIMI 3 flow 
22.3 ± 11.4 
20.8 ± 9.8 
25.8 ± 11.3 
19.8 ± 8.8 
28.5 ± 8.3 
19.5 ± 9.4 
3.57 (-2.35, 9.49) p=0.238 
-1.06 (-4.95, 2.83) p=0.595 
 
6.23 (0.45, 12.01) p=0.036 
-1.34 (-5.11, 2.43) p=0.488 
 0.097   
4.96 (-0.08, 10.01) p=0.055 
-1.21 (-4.51, 2.10) p=0.475 
0.045 
 
Table 3.4 (page 3 of 3) Analysis of CMR parameters 2 to 7 days after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3)  immediately before study 
drug administration, and by sub-groups of MI location (anterior [n=187], non-anterior [n=234]). Data are mean ± SD, or n (%), unless otherwise stated. Missing data: infarct size 
(n=66), LV ejection fraction or volumes (n=63). Treatment effect estimates and interaction with treatment received are shown. (a) Treatment effect estimates reported as ORs between 
groups from a logistic regression model. (b) Treatment effect estimates reported as mean differences in square root transformed MVO extent between groups, from a linear regression 





 Treatment Group                                        Treatment Effect Interaction 
p-value  
(treatment 




Treatment Effect Interaction 
p-value 
(treatment 











Alteplase 10mg vs placebo  Alteplase 20mg vs. placebo  Alteplase (10mg or 20mg) vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
Infarct size (% LV mass) (a)  
TIMI flow £2  
TIMI 3 flow 




23.9 ± 13.0 
16.2±10.3 
1.11 (-3.61, 5.83) p=0.645 
-1.09 (-4.57, 2.39) p=0.539 
 
2.73 (-1.84, 7.30) p=0.242 
-0.74 (-4.17, 2.70) p=0.675 
 0.488   
1.97 (2.07, 6.01 p=0.339 
-0.91 (-3.90, 2.08) p=0.552 
0.261 
 
LV ejection fraction (%) (a)     
TIMI flow £2  
TIMI 3 flow 
47.4 ± 11.9 
50.8 ± 6.8 
47.3 ± 8.7 
49.1 ± 7.3 
46.8 ± 9.2 
49.9 ± 7.9 
1.03 (0.88, 1.20) p=0.729 
1.10 (0.99, 1.23) p=0.085 
 
0.99 (0.85, 1.15) p=0.878 
1.03 (0.92, 1.15) p=0.640 
 0.762   
1.01 (0.88, 1.15) p=0.923 
1.06 (0.97, 1.17) p=0.210 
0.508 
LV end-systolic volume (ml) (b)     
TIMI flow £2  
TIMI 3 flow 
81.6 [72.8, 114.7] 
77.5 [60.7, 99.5] 
88.9 [71.4, 116.5] 
85.9 [71.7, 103.3] 
92.1 [71.5, 110.1] 
78.5 [65.8, 102.1] 
1.03 (0.88, 1.20) p=0.729 
1.10 (0.99, 1.23) p=0.085 
 
0.99 (0.85, 1.15) p=0.878 
1.03 (0.92, 1.15) p=0.640 
 0.762   
1.01 (0.88, 1.15) p=0.923 
1.06 (0.97, 1.17) p=0.210 
0.508 
 
Table 3.5 (page 1 of 2) Analysis of CMR parameters 3 months after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately 
before study drug administration (adjusted for MI location). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. Missing data: infarct size (n=66), 
LV ejection fraction or volumes (n=63). Treatment effect estimates and interaction with treatment received are shown. (a) Treatment effect estimates reported as mean 





 Treatment Group Treatment Effect  Interaction 
p-value 
(treatment 
as a 3-level 
categorical 
variable) 
  Treatment Effect Interaction 
p-value 
(treatment 












Alteplase 10mg vs. placebo 
 
Alteplase 20mg vs. placebo 
   
Alteplase (10mg or 20mg) 
vs. placebo 
Estimate (95% CI), p-value Estimate (95% CI), p-value Estimate (95% CI), p-value 
LV end-diastolic volume (ml) (b)     
TIMI flow £2  
TIMI 3 flow 
170.2 [158.8, 207.1] 
157.9 [138.9, 188.5] 
170.0 [152.9, 206.4] 
173.6 [153.7, 205.6] 
174.0 [150.5, 195.1] 
162.9 [140.4, 194.3] 
1.01 (0.91, 1.12) p=0.796 
1.08 (1.00, 1.16) p=0.045 
 
0.95 (0.86, 1.05) p=0.349 





0.98 (0.90, 1.07) p=0.673 
1.04 (0.98, 1.11) p=0.213 
0.281 
 
Table 3.5 (page 2 of 2) Analysis of CMR parameters 3 months after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately 
before study drug administration (adjusted for MI location). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. Missing data: infarct size (n=66), 
LV ejection fraction or volumes (n=63). Treatment effect estimates and interaction with treatment received are shown. (a) Treatment effect estimates reported as mean 




























Alteplase 10mg vs. placebo  Alteplase 20mg vs. placebo  
Alteplase (10mg or 20mg)  
vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
MVO present (n/ total) (a)  
TIMI 2 flow  







2.58 (1.00, 6.65) p=0.051 
0.61 (0.33, 1.14) p=0.119 
 
1.66 (0.67, 4.13) p=0.257 
0.72 (0.39, 1.34) p=0.298 
 0.153          
2.06 (0.92, 4.62) p=0.081 
0.66 (0.39, 1.13) p=0.128 
0.022 
MVO extent (% of LV mass) (b)            
TIMI 2 flow 
TIMI 3 flow 
3.0 ± 6.2 
2.2 ± 3.4  
2.8 ± 3.9 
2.4 ± 4.8 
5.2 ± 7.2 
2.3 ± 4.3 
0.26 (-0.36, 0.89) p=0.405 
-0.09 (-0.49, 0.31) p=0.661 
 
0.55 (0.18, 1.27) p=0.136 
-0.06 (-0.45, 0.34) p=0.777 
 0.243   
0.43 (0.17, 1.02) p=0.158 
-0.07 (-0.42, 0.27) p=0.677 
0.107 
Myocardial haemorrhage present (n/ total) (a)           
TIMI 2 flow 







3.05 (1.12, 8.31) p=0.029 
0.64 (0.34, 1.21) p=0.168 
 
2.14 (0.82, 5.62) p=0.121 
0.66 (0.35, 1.23) p=0.188 
 0.054   
2.55 (1.07, 6.06) p=0.034 
0.65 (0.38, 1.11) p=0.117 
0.009 
 
Table 3.6 (page 1 of 2) Analysis of CMR parameters 2 to 7 days after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (2 vs. 3) 
immediately before study drug administration (adjusted for MI location). Data are mean ± SD, or n (%), unless otherwise stated. Missing data: MVO extent or 
presence/ absence (n=78), myocardial haemorrhage extent (n=68), myocardial haemorrhage presence/ absence (n=51), infarct size (n=37). Treatment effect estimates 
and interaction with treatment received are shown. (a) Treatment effect estimates reported as ORs between groups from a logistic regression model. (b) Treatment 
effect estimates reported as mean differences in square root transformed MVO extent between groups, from a linear regression model. (c) Treatment effect estimates 









as a 3-level 
categorical 
variable) 
















Alteplase 10mg vs. placebo 
 
Alteplase 20mg vs. placebo 
   
Alteplase (10mg or 20mg)  
vs. placebo 
Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value 
Myocardial haemorrhage extent (% LV mass) (c)  
TIMI 2 flow 
TIMI 3 flow 
2.0 ± 5.7 
1.4 ± 2.8 
2.0 ± 2.9 
1.8 ± 3.6 
4.2 ± 6.0 
1.5 ± 3.8 
1.95 (-0.33, 4.24) p=0.093 
0.29 (-1.00, 1.58) p=0.656 
 
1.98 (-0.74, 4.69) p=0.151 
0.11 (-1.16, 1.38) p=0.867 
 0.132   
0.50 (-0.04, 3.04) p=0.287 
0.20 (-0.91, 1.31) p=0.726 
0.362 
Infarct size (% LV mass) (c)     
TIMI 2 flow 
TIMI 3 flow 
28.5 ± 16.4 
26.0 ± 12.6 
30.5 ± 12.7 
24.7 ± 11.7 
31.9 ± 13.5 
22.8 ± 12.3 
2.46 (-3.91, 8.82) p=0.445 
-1.35 (-4.92, 2.22) p=0.460 
 
3.00 (-3.48, 9.48) p=0.359 
-2.68 (-6.22, 0.86) p=0.138 
 0.158   
2.69 (-2.67, 8.04) p=0.322 
-2.03 (-5.09, 1.03) p=0.195 
0.085 
 
Table 3.6 (page 2 of 2) Analysis of CMR parameters 2 to 7 days after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (2 vs. 3) 
immediately before study drug administration (adjusted for MI location). Data are mean ± SD, or n (%), unless otherwise stated. Missing data: MVO extent or 
presence/ absence (n=78), myocardial haemorrhage extent (n=68), myocardial haemorrhage presence/ absence (n=51), infarct size (n=37). Treatment effect estimates 
and interaction with treatment received are shown. (a) Treatment effect estimates reported as ORs between groups from a logistic regression model. (b) Treatment 
effect estimates reported as mean differences in square root transformed MVO extent between groups, from a linear regression model. (c) Treatment effect estimates 
reported as mean differences between groups, from linear regression. 
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3.4.4 LVEDP, angiographic and ECG endpoints 
LVEDP was measured in 272 of the 421 patients (65%). In patients with TIMI flow ≤2 
pre-study drug, there were no associations between alteplase and the following: LVEDP, 
TFC, MPG ≤1 and TIMI flow grade ≤2 at the end of PCI, and % ST-segment resolution 
(Table 3.7). In patients with TIMI 3 flow pre-study drug, alteplase was not associated with 
any of these parameters, apart from TFC and LVEDP (Table 3.7). In patients with TIMI 3 
flow immediately pre-drug, LVEDP was lower with alteplase 20mg vs. placebo (mean 
difference: -0.16 (95% CI: -0.30, -0.02) p=0.025) (Table 3.7). 
 
There were no interactions between sub-groups of TIMI flow pre-drug, alteplase, and 
LVEDP, TFC, MPG or TIMI flow grade at the end of the PCI procedure (Table 3.7). There 
were no interactions between sub-groups of TIMI flow pre-study drug, alteplase, and 
absolute % ST-segment resolution at 60 minutes post-reperfusion compared to baseline 
(Table 3.6).  
3.4.5 Coagulation variables 
There were no interactions between sub-groups of TIMI flow pre-study drug, alteplase, and 
fibrin D-dimers, prothrombin fragment F1+2, or plasminogen (Table 3.8). There was an 
increase in systemic fibrin D-dimers (a product of fibrin lysis) and decrease in 
plasminogen 2 hours post-primary PCI relative to baseline, in patients with TIMI flow ≤2 
or 3, pre-study drug. This is consistent with what is expected following intra-arterial 
fibrinolysis. 
 
There was a significant increase in systemic prothrombin fragment F1+2 (a measure of 
thrombin activation) two hours post-primary PCI relative to baseline, with alteplase 



























Alteplase 10mg vs. placebo  Alteplase 20mg vs. placebo 
 
Alteplase (10mg or 20mg) 
vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value   Estimate (95% CI), p-value 
Absolute % ST-segment resolution 60 min post-reperfusion relative to baseline(a)  
TIMI flow £2  
TIMI 3 flow 
45.0 ± 44.3 
50.7± 36.4 
40.6 ± 52.1 
44.4 ± 41.8 
37.7 ± 43.3 
50.5 ± 46.0 
-4.43 (-21.96, 13.10) p=0.621 
-6.89 (-20.50, 6.73) p=0.322 
 
-7.37 (-24.21, 9.47) p=0.392 





-6.02 (-20.91, 8.87) p=0.429 
-3.44 (-14.99, 8.11) p=0.560 
0.789 
 
TIMI flow grade post-PCI ≤2 (b)  
TIMI flow £2  







0.72 (0.31, 1.66) p=0.432 
2.80 (0.95, 8.34) p=0.064 
 
1.09 (0.50, 2.39) p=0.838 





0.90 (0.45, 1.81) p=0.762 
2.66 (0.98, 7.27) p=0.056 
0.071 
 
TFC (c):                
TIMI flow £2  
TIMI 3 flow 
26.5 [17.4, 39.4] 
17.7 [12.0, 24.0] 
22.4 [15.5, 35.9] 
20.0 [14.0, 26.0] 
28.0 [21.8, 40.5] 
17.4 [12.9, 24.0] 
0.91 (0.73, 1.13) p=0.372 
1.18 (1.00, 1.39) p=0.049 
 
1.07 (0.87, 1.32) p=0.534 





0.99 (0.82, 1.19) p=0.902 




Table 3.7 (page 1 of 2) Analysis of ECG and angiographic parameters at the end of primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 
vs. 3) immediately before study drug administration (adjusted for location of MI). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. Missing data: 
% ST-segment resolution (n=43), TFC (n=2), LVEDP (n=154). Treatment effect estimates and interaction with treatment received are shown. (a) Treatment effect 
estimates reported as mean differences between groups. (b) Treatment effect estimates reported as ORs between groups from a logistic regression model. (c) Data 
analysed on a logarithmic scale, treatment effect estimates reported as relative differences between groups. (d) Data analysed on a logarithmic scale, with treatment 
effects reported as mean differences between groups. 
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Alteplase 10mg vs. placebo 
 
Alteplase 20mg vs. placebo 
   
Alteplase (10mg or 20mg) 
vs. placebo 
Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value 
MPG £1 (b):                         
TIMI flow £2  







0.95 (0.42, 2.13) p=0.895 
1.43 (0.77, 2.65) p=0.264 
 
1.65 (0.75, 3.66) p=0.214 





1.27 (0.63, 2.54) p=0.501 
1.02 (0.59, 1.77) p=0.932 
0.634 
 
LVEDP mmHg (d):             
TIMI flow £2  







0.14 (-0.09, 0.38) p=0.220 
-0.02 (-0.16, 0.13) p=0.841 
 
0.04 (-0.20, 0.28) p=0.740 
-0.16 (-0.30, -0.02) p=0.025 
 0.221   
0.09 (-0.11, 0.29) p=0.384 
-0.09 (-0.21, 0.04) p=0.173 
0.118 
 
Table 3.7 (page 2 of 2) Analysis of ECG and angiographic parameters at the end of primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI 
flow (≤2 vs. 3) immediately before study drug administration (adjusted for location of MI). Data are mean ± SD, median [IQR], or n (%), unless 
otherwise stated. Missing data: % ST-segment resolution (n=43), TFC (n=2), LVEDP (n=149). Treatment effect estimates and interaction with treatment 
received are shown. (a) Treatment effect estimates reported as mean differences between groups. (b) Treatment effect estimates reported as ORs between 
groups from a logistic regression model. (c) Data analysed on a logarithmic scale, treatment effects reported as relative differences between groups. (d) 




























Alteplase 10mg vs. placebo  Alteplase 20mg vs. placebo  
Alteplase (10mg or 20mg)   
vs. placebo 
Estimate (95% CI) p-value  Estimate (95% CI) p-value    Estimate (95% CI), p-value 
Plasminogen (U/dL) 2 hours post-PCI (a)     
TIMI flow £2  
TIMI 3 flow 
95.0 [88.3, 101.0] 
96.0 [87.0, 104.5] 
91.0 [81.5, 100.8] 
88.0 [80.0, 98.0] 
83.5 [74.8, 92.0] 
84.0 [77.0, 92.0] 
-2.66 (-8.56, 3.25) p=0.378 
-6.90 (-11.20, -2.66) p=0.002 
 
-10.88 (-16.52, -5.25) p<0.001 





-7.16 (-12.23, -2.09) p=0.006 
-8.74 (-12.45, -5.03) p<0.001 
0.623 
Fibrin D-dimer (ng/mL) 2 hours post-PCI (b)     
TIMI flow £2  
TIMI 3 flow 
101.0 [69.5, 138.3] 
117.0 [74.8, 169.0] 
319.5 [215.5, 633.0] 
354.0 [224.0, 593.0] 
513.5 [266.8, 831.5] 
421.0 [275.5, 641.5] 
3.64 (2.53, 5.22) p<0.001 
3.15 (2.43, 4.09) p<0.001 
 
4.91 (3.48, 6.93) p<0.001 
3.88 (3.00, 5.03) p<0.001 
 0.563   
4.29 (3.15, 5.83) p<0.001 
3.50 (2.80, 4.39) p<0.001 
0.299 
Prothrombin fragment F1+2 (pmol/L) 2 hours post-PCI (b)      
TIMI flow £2  
TIMI 3 flow 
165.0 [134.0, 220.8] 
155.5 [124.1, 267.0] 
161.1 [124.9, 260.8] 
200.3 [144.0, 328.2] 
201.5 [147.4, 303.0] 
199.1 [153.2, 303.0] 
1.20 (0.92, 1.57) p=0.183 
1.26 (1.04, 1.53) p=0.019 
 
1.22 (0.94, 1.57) p=0.136 
1.19 (0.98, 1.44) p=0.078 
 0.909   
1.21 (0.96, 1.52) p=0.103 
1.23 (1.04, 1.45) p=0.017 
0.925 
 
Table 3.8 (page 1 of 2) Analysis of coagulation variables after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) immediately before 
study drug administration (adjusted for MI location). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. Missing data: coagulation variables 2 hours 
post-PCI (n=75), change in coagulation parameters at 2 hours relative to baseline (n=80). Treatment effect estimates and interaction with treatment received are shown. 
(a) Treatment effect estimates reported as mean differences between groups. (b) Data analysed on a logarithmic scale, with treatment effect estimates reported as relative 
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Alteplase 10mg vs. placebo 
 
Alteplase 20mg vs. placebo 
   
Alteplase (10mg or 20mg)  
vs. placebo 
Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value 
Change in plasminogen (U/dL) at 2 hours relative to baseline (a)          
     TIMI flow £2 
     TIMI 3 flow 
1.0 [-2.0, 3.0] 
1.0 [-3.3, 5.0] 
-3.0 [-9.5, 4.5] 
-5.0 [-11.0, -0.8] 
-10.0 [-15.0, -6.0] 
-9.5 [-16.0, -4.0] 
-4.30 (-8.20, -0.40) p=0.034 
-6.10 (-8.90, -3.30) p<0.001 
 
-13.40 (-17.10, -9.60) p<0.001 
-10.20 (-13.00, -7.40) p<0.001 
 0.110   
-9.30 (-12.80, -5.80) p<0.001 
-8.20 (-10.07, -5.60) p<0.001 
0.609 
Ratio of fibrin D-dimer at 2 hours relative to baseline (b)          
     TIMI flow £2 
     TIMI 3 flow 
1.1 [1.0, 1.3] 
1.1 [0.9, 1.5] 
3.2 [2.2, 6.0] 
3.4 [2.2, 4.6] 
3.8 [2.0, 6.2] 
4.9 [3.2, 7.4] 
3.27 (2.47, 4.32) p<0.001 
2.86 (2.35, 3.50) p<0.001 
 
3.52 (2.70, 4.59) p<0.001 
4.16 (3.41, 5.08) p<0.001 
 0.213   
3.40 (2.67, 4.32) p<0.001 
3.46 (2.91, 4.12) p<0.001 
0.907 
Ratio of prothrombin fragment F1+2 at 2 hours relative to baseline (b)          
     TIMI flow £2 
     TIMI 3 flow 
1.1 [0.9, 1.3] 
1.1 [0.9, 1.4] 
1.3 [1.1, 1.6] 
1.2 [0.9, 1.5] 
1.2 [1.0, 1.6] 
1.3 [1.1, 1.6] 
1.46 (1.16, 1.85) p=0.002 
1.18 (1.00, 1.39) p=0.057 
 
1.20 (0.96, 1.51) p=0.104 
1.20 (1.02, 1.42) p=0.030 
 0.242   
1.31 (1.08, 1.60) p=0.008 
1.19 (1.03, 1.38) p=0.018 
0.432 
 
Table 3.8 (page 2 of 2) Analysis of coagulation variables after primary PCI, in the T-TIME angiographic study, by sub-groups of TIMI flow (≤2 vs. 3) 
immediately before study drug administration (adjusted for MI location). Data are mean ± SD, median [IQR], or n (%), unless otherwise stated. Missing 
data: coagulation variables 2 hours post-PCI (n=75), change in coagulation parameters at 2 hours relative to baseline (n=80). Treatment effect 
estimates and interaction with treatment received are shown. (a) Treatment effect estimates reported as mean differences between groups. (b) Data 




In this prespecified analysis, low-dose intracoronary alteplase given early during primary 
PCI, was associated with increased presence of MVO and myocardial haemorrhage in 
participants who had TIMI flow ≤2 pre-drug administration (Figure 3.3). On the other 
hand, patients with TIMI 3 flow immediately pre-study drug administration had no 
difference in MVO or myocardial haemorrhage with alteplase compared to placebo. 
Furthermore, the relationship of intracoronary alteplase with infarct size 2 to 7 days 
following primary PCI depended on TIMI flow grade pre-drug administration.  
 
The findings contrast with a previous study, which reported smaller 6-month infarct size 
(assessed by SPECT) in patients given adjunctive intracoronary streptokinase at the end of 
primary PCI (n=51) compared to standard primary PCI without streptokinase (n=44)260. In 
the previous study, intracoronary streptokinase was delivered post-stent, at the end of the 
PCI procedure, when 89% of the population had TIMI 3 flow260, whereas in the T-TIME 
trial intracoronary alteplase was administered early after re-establishment of flow in the 
infarct-related artery pre-stenting, when only 63% of the population had TIMI 3 flow. The 
previous study was not double-blind, so it had an open design with unmasked 
interventions260, and it is plausible that those findings might have been a consequence of 
type 1 statistical error, i.e. a false positive result.  
 
The speculation that TIMI flow ≤2 at the time of study drug administration would in turn 
lead to inadequate drug delivery to the microcirculation, does not appear to be supported 
by the data. In fact, increased fibrin D-dimer, and lower plasminogen concentrations, were 
observed with alteplase in patients with TIMI flow ≤2 pre-drug, which indicates that 
fibrinolysis did indeed occur in this group of participants (Table 3.7).  
 
An explanation for the findings presented in this chapter may be that in circumstances of 
slow microvascular flow, the undesired procoagulant effects of fibrinolytic therapy288 353-358 
were potentially augmented, thereby promoting microvascular thrombosis and worsening 
MVO (Figure 3.4). Indeed, increased prothrombin F1+2 concentrations were observed with 
alteplase (Table 3.7), despite therapeutic anticoagulation with heparin, which indicates 
thrombin generation and thrombosis341. Slow blood flow is one of the factors postulated by 
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Rudolph Virchow to propagate thrombus formation, the other 2 factors being vascular wall 
injury and hypercoagulable state due to abnormalities in coagulation, or fibrinolytic 
pathways, or platelet function359. The mechanism of the paradoxical procoagulant effect of 
alteplase, is that alteplase actives plasmin formation, and plasmin paradoxically increases 
thrombogenesis, due to the activation of factor V to Va288.   
 
Another explanation for the findings presented in this chapter may be that is circumstances 
of reduced antegrade flow myocardial perfusion is reduced, leading to higher local 
concentrations of alteplase, due to reduced “washout” of alteplase from the 
microcirculation. Alteplase activates plasmin formation, which degrades fibrin, and 
therefore increases bleeding propensity. Patients with TIMI flow ≤2 immediately pre-drug 
may have had move extensive microvascular injury, as evidenced by these patients having 
significantly more MVO and myocardial haemorrhage than the patients with TIMI 3 flow 
pre-drug. Myocardium with extensive microvascular damage from coronary occlusion is 
characterised by endothelial degradation, loss of capillary integrity and myocyte necrosis. 
In these circumstances, intracoronary alteplase appears to worsen extravasation of 
erythrocytes, resulting in myocardial haemorrhage in the infarct core (the secondary and 
irreversible manifestation of persistent MVO). An increase in extravasation of blood into 
the interstitial space of the infarct core results in external compression of capillaries, with 
an associated increase in microvascular resistance, thereby worsening MVO (Figure 3.4). 
 
Insights from previous studies of glycoprotein IIbIIIa inhibitors are consistent with the 
findings reported in this chapter155 360. In a porcine model, with MI induced by balloon 
occlusion of the LAD (n=23), there was an increased incidence of myocardial haemorrhage 
when intracoronary  glycoprotein IIbIIIa inhibitors were added to intravenous bivalirudin 
therapy361. In humans, peri-procedural glycoprotein IIbIIIa inhibitor use during STEMI 
(n=410) was an independent predictor myocardial haemorrhage, as assessed on T2-
weighted CMR imaging360. Although a causal relationship cannot be assumed, because of 
the observational nature of that study, it is conceivable that more aggressive anti-
thrombotic treatment may promote myocardial haemorrhage, especially in the context of 
extensive microvascular injury. Further support for this theory is from another study in 49 
STEMI patients, which showed that more potent inhibition of platelet aggregation 





Figure 3.4 Potential mechanisms for the association of intracoronary alteplase with 
increased MVO and myocardial haemorrhage presence, in patients with TIMI flow ≤2 
immediately preceding study drug administration. 
In patients with reduced antegrade flow in the infarct-related artery, there may have been 
increased microvascular exposure to higher local concentrations of alteplase for longer. In 
patients with slow microvascular flow, intracoronary alteplase potentially promoted the 
undesired procoagulant effects of fibrinolytic therapy. TIMI flow ≤2 may indicate ongoing 
impaired myocardial reperfusion, due to extensive microvascular damage. In these 
circumstance, intracoronary fibrinolysis appears to worsen MVO and extravasation of 
erythrocytes, resulting in myocardial haemorrhage in the infarct core and potentially 
promotes microvascular thrombosis. An increased in extravasation of blood into the 
interstitial space results in external compression of capillaries with an associated increase 
in microvascular resistance. This leads to a further reduction in myocardial blood flow, 
and exacerbates myocardial necrosis and capillary destruction, which promotes further 
myocardial haemorrhage. 
 
The observation that participants with TIMI flow ≤2 early after balloon angioplasty were 
more likely to have infarct-related lesions in the LAD is consistent with previous reports in 
the medical literature363. A potential explanation for this finding is that the LAD artery 
supplies a relatively larger territory of myocardium, thus LAD occlusion would likely have 
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resulted in relatively more extensive myocardial necrosis, making persistent TIMI flow ≤2 
more likely during PCI. Analyses for interactions between TIMI flow pre-study drug, 
alteplase, and CMR parameters were performed separately for patients who had anterior 
MI and patients who had non-anterior MI (Table 3.4). In the group that had non-anterior 
MI (n=234) there were interactions between TIMI flow, alteplase and MVO presence, 
myocardial haemorrhage presence, or infarct size, consistent with the findings in the entire 
population studied (n=421). In the group that had anterior MI (n=187) these interactions 
were not observed, likely because the smaller number of patients limited statistical power 
to detect interactions. 
 
The findings presented in this chapter are relevant as a disincentive to clinicians when 
considering bail-out lytic therapy for acute STEMI patients with high thrombus burden and 
angiographic “no reflow”. The findings are also very relevant to ongoing clinical trials. 
Notably, the RESTORE-MI trial [ACTRN12618000778280]273 is randomising STEMI 
patients undergoing primary PCI (n=800) to adjunctive intracoronary tenecteplase or 
placebo, in a double-blind design, and a key inclusion criteria for that trial is a post-stent 
IMR >32 in the infarct-related artery, which signifies incomplete microvascular perfusion 
and microvascular dysfunction156. Importantly, the findings presented in this chapter 
suggest that low-dose intracoronary lytic therapy in STEMI patients who have incomplete 
perfusion after initial balloon angioplasty may be harmful. Therefore, the risk-based 
selection strategy used in the RESTORE-MI trial [ACTRN12618000778280]273, which 
targets patients with microvascular dysfunction evidenced by abnormal invasive coronary 
physiology, may enrol patients at risk of myocardial haemorrhage, which may be 
exacerbated by lytic therapy. Nonetheless, there are important differences in the design of 
T-TIME as compared to RESTORE-MI, notably, in relation to the timing of study drug 
administration (before, or after stent implantation, respectively) and the lytic agent 
(alteplase, or tenecteplase), which is relevant since tenecteplase is less procoagulant than 
alteplase318. 
 
The findings suggest that normal antegrade coronary flow is important for fibrinolytic 
therapy to be safe and effective. Therefore, future studies evaluating the effects of 
intracoronary lytic therapy should limit recruitment to patients with TIMI 3 flow at the 
time of study drug administration, which would be post-stent implantation for most 




The strengths of this study are: (i) the analyses of source data were conducted in a double-
blind manner to minimise the potential risk of bias, (ii) core-lab analyses were performed, 
(iii) the randomised design and (iv) CMR was available in almost all of the participants. 
Even though randomisation was not stratified according to TIMI flow grade post-
reperfusion, the randomisation was stratified according to MI location (anterior vs. non-
anterior), which was the only independent associate of TIMI flow pre-study drug. The 
regression analyses were adjusted for MI location, to limit the potential influence of 
confounding.  
 
Because of the potential for type 1 statistical error (false positive) the findings should be 
interpreted as exploratory/ hypothesis generating, and causality should not be inferred. 
Nonetheless, whilst the results may be due to play of chance, the mechanism is plausible 
and type 1 statistical error appears less likely given that the findings for MVO and 
myocardial haemorrhage were consistent with infarct size at 2 to 7 days post-PCI. A 
potential limitation of not adjusting for multiple statistical comparisons is that the 
probability of a false positive result is increased364. Adjusting for multiple statistical 
comparisons, for example with the Bonferroni method, generally requires more stringent 
significance thresholds for p-values365. There is a danger that by correcting for multiplicity 
the probability of type 2 statistical error (false negative) is increased. The results from the 
analyses presented in this chapter include some very low interaction p-values, for example 
the interaction p-value for alteplase, coronary flow and myocardial haemorrhage presence 
was 0.001 (Table 3.3), which would likely remain significant even after adjustment for 
multiple statistical comparisons.  
 
Lastly, TIMI 3 flow is not synonymous with optimal tissue perfusion, because MVO can 
be demonstrated in a substantial number of acute STEMI patients with TIMI 3 flow at the 
end of PCI113. Approximately 50% of acute STEMI patients with TIMI 3 flow at the end of 
PCI have MVO on CMR imaging26 103. In the present study, 42% of participants with TIMI 
3 flow immediately pre-study drug administration had MVO present, and 40% of 
participants with TIMI 3 flow at the end of the PCI procedure had MVO present.  
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3.7 Future work 
Future research is of interest to determine whether low-dose intracoronary tenecteplase 
(which has less unwanted procoagulant effects than alteplase318) administered after stent 
implantation, at the end of the primary PCI procedure (when TIMI 3 flow is routinely 
achieved), might have beneficial effects on the coronary microcirculation. 
3.8 Conclusions 
In conclusion, low-dose intracoronary alteplase administered pre-stent implantation was 
associated with an increased incidence of MVO and myocardial haemorrhage, in STEMI 
patients with impaired coronary flow (<TIMI 3) immediately pre-drug administration. 
Potential explanations include increased local exposure to alteplase enhancing endothelial 
damage and haemorrhagic transformation in the infarct core, and augmented procoagulant 
effects of alteplase promoting microvascular thrombosis. In patients with TIMI 3 flow in 
the infarct-related artery, pre-drug administration, alteplase was not associated with MVO 
or myocardial haemorrhage.  
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Chapter 4: Effects of intracoronary alteplase during primary PCI on 
IMR, CFR and RRR: the T-TIME physiology sub-study 
This work has been published (Maznyczka AM et al. Effects of intracoronary alteplase on 
microvascular function in acute myocardial infarction. JAHA. 2020.9(3): e014066. Doi: 
10.1161/JAHA.119.014066 [available from: jaha.ahajournals.org]366. The open access 
journal did not require permission to reproduce Tables and Figures from this publication, 
for use in the thesis. 
4.1 Abstract 
Background: Impaired microcirculatory perfusion worsens prognosis following acute 
STEMI. The aim of the study presented in this chapter was to evaluate the effects of 
intracoronary alteplase, during primary PCI, on IMR, CFR and RRR. 
Methods: The T-TIME coronary physiology study was a pre-defined, prospective, double-
blind, sub-study, within the main T-TIME trial. From 2016 to 2017 patients with STEMI 
≤6 hours from symptom onset were randomised, to receive alteplase 20mg, alteplase 
10mg, or placebo infused into the infarct-related artery, after initial balloon angioplasty 
and/ or thrombus aspiration, but pre-stenting. IMR, CFR and RRR were measured at the 
end of the PCI procedure. CMR was performed at 2 to 7 days and 3 months post-PCI. Sub-
group analyses in relation to ischaemic time ([i] <2 hours, [ii] ≥2, <4 hours and [iii] ≥4 
hours), TIMI coronary flow grade immediately preceding study drug administration (≤2, 
and 3), and TIMI thrombus grade immediately before study drug administration (≤2 and 
≥3) were prespecified. 
Results: 144 patients (mean age: 59 ± 11 years, 80% male) were prospectively enrolled 
into the physiology sub-study, representing 33% of the overall population (n=440). The 
median IMR was 29.5 (IQR: 17.0 - 55.0), median CFR was 1.4 (IQR: 1.1 - 2.0) and 
median RRR was 1.7 (IQR: 1.3 - 2.3). Overall, IMR, CFR or RRR did not differ between 
alteplase and placebo groups. Interactions were observed between ischaemic time and 
alteplase for CFR (p=0.013), RRR (p=0.026) and MVO (p=0.022), but not for IMR. In 
patients with ischaemic time <2 hours, CFR was higher with alteplase 20mg vs. placebo 
(relative difference: 1.59 [95% CI: 1.11, 2.27] p=0.012), and RRR was also higher with 
alteplase 20mg vs. placebo (relative difference 1.52 [95% CI: 1.05, 2.22] p=0.028). In 
patients with ischaemic times ≥4 hours, MVO extent was higher with alteplase 20mg vs. 
placebo (mean difference: 1.47 [95% CI: 0.40, 0.54] p=0.007). There was no interaction 
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between TIMI flow, or thrombus grade, immediately preceding study drug administration, 
with alteplase, and IMR, CFR or RRR. 
Conclusion: There was overall no difference in IMR, CFR or RRR with adjunctive 
intracoronary alteplase vs. placebo, during primary PCI. The results from sub-group 
analyses suggest that CFR and RRR may be improved with alteplase in patients presenting 
with an ischaemic time ≤2 hours, and that MVO extent may be worse with alteplase in 
























Failed myocardial perfusion following STEMI, revealed as MVO on CMR imaging, 
confers a worse prognosis27. There are no evidence-based treatments for MVO, so it is a 
clinical problem of unmet need. A key component for the pathophysiology of MVO is 
distal embolization and microvascular thrombi31-33.  
 
In contrast to CMR imaging, which is not readily available at the time of primary PCI, 
invasive coronary physiology parameters can quantify the immediate efficacy of 
microcirculatory reperfusion16. Among these parameters, IMR measures the minimal 
achievable microvascular resistance during maximal hyperaemia140. RRR reflects the 
microvascular vasodilator capacity, i.e. the ability of the coronary microcirculation to 
change from baseline to hyperaemia, reflecting the ability to achieve maximal 
hyperaemia194 197. RRR is the ratio between basal resting tone and resistance at maximal 
hyperaemia, and is lower when microvasodilatory capacity is impaired.  
 
The aim of the present study was to evaluate the effects of low-dose intracoronary alteplase 
during primary PCI, on acute invasive coronary physiology measurements. The effects of 
ischaemic time on any associations between alteplase and IMR, CFR, or RRR was also 
assessed. The rationale for investigating this sub-group is that longer ischaemic time 
diminishes the efficacy of primary reperfusion therapies, including systemic fibrinolysis367 
and primary PCI319. The effects of TIMI coronary flow grade immediately before study 
drug administration, on any associations between alteplase and IMR, CFR, or RRR was 
also evaluated. The rationale for investigating this sub-group was the speculation that 
impaired antegrade flow in the infarct-related artery could influence the effects of 
intracoronary alteplase on the microcirculation. Lastly, the effects of TIMI thrombus grade 
immediately before study drug administration, on any associations between alteplase IMR, 
CFR or RRR was evaluated, to assess whether intracoronary alteplase might be effective 
compared to placebo, when administered to the most thrombus-laden lesions. 
 
The following hypotheses were evaluated: 
1) Intracoronary alteplase administered pre-stenting, is associated with lower IMR, 
higher CFR and higher RRR at the end of primary PCI, compared to placebo. 
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2) In the sub-group of patients with shorter ischaemic time (≤2 hours), intracoronary 
alteplase administered pre-stenting is associated with lower IMR, higher CFR and 
higher RRR at the end of primary PCI, compared to placebo. 
 
3) In the sub-group of patients with TIMI 3 flow immediately preceding study drug 
administration, intracoronary alteplase is associated with lower IMR, higher CFR 
and higher RRR at the end of primary PCI, compared to placebo. 
 
4) In the sub-group of patients with TIMI thrombus grade ≥3 immediately pre-study 
drug administration, intracoronary alteplase is associated with lower IMR, higher 
CFR and higher RRR at the end of primary PCI, compared to placebo. 
4.3 Methods 
Details of the specific methods used in the T-TIME physiology sub-study are described in 
section 2.2. The T-TIME physiology sub-study design is depicted in Figure 4.1.  
4.3.1 Sample size calculation 
The sample size calculation for the T-TIME physiology sub-study was based on data from 
patients in the British Heart Foundation MR-MI study149 156 who fulfilled the eligibility 
criteria for T-TIME. For a comparison of IMR between the 3 treatment groups (placebo vs. 
alteplase 10mg vs. alteplase 20mg), assuming a mean IMR of 33.9 and SD of 25.2, and 
assuming mean differences in IMR for the10mg and 20mg alteplase groups vs. placebo of 
10 and 20 respectively, then 108 subjects were needed for 85% power and a significance 
level of 0.05. For a comparison of CFR between the 3 treatment groups (placebo vs. 
alteplase 10mg vs. alteplase 20mg), assuming a mean CFR of 1.65 and SD of 0.8, and 
assuming mean differences in CFR between the 10mg and 20mg alteplase groups vs. 












Figure 4.1 Summary of study design for the T-TIME physiology sub-study. Adapted and 
reproduced with permission from: Maznyczka A et al. Effects of intracoronary alteplase on 





4.3.2 Statistical analyses 
There was a prespecified statistical analysis plan (Appendix 8), which was finalised prior 
to database lock. Continuous data were summarised using mean ± SD, or median (IQR). 
MVO and myocardial haemorrhage extent were presented as mean ± SD, because the high 
proportion of patients with a 0 value for MVO or myocardial haemorrhage extent resulted 
in median values of 0 in each treatment group for MVO or myocardial haemorrhage. 
Categorical variables were reported as frequency and percentages. All the analyses were 
performed according to treatment received (alteplase 10mg, alteplase 20mg, or placebo).  
 
Association analyses were performed using linear regression for continuous outcomes, 
logistic regression for binary outcomes, or proportional odds logistic regression for ordinal 
outcomes. Logarithmic or square root transformations were used where necessary, in linear 
regression models, to improve model residual distributions. The regression analyses were 
adjusted for the location of MI (anterior vs. non-anterior).  Regression models were used to 
assess treatment effects with treatments as a 3-level categorical variable, and treatment as a 
2-level categorical variable (alteplase 10mg and 20mg combined vs. placebo).  
 
Post-hoc analyses were performed in prespecified sub-groups of interest, according to 
patient characteristics, i.e. ischaemic time ([i] <2 hours, [ii] > 2, ≤ 4 hours and [iii] ≥ 4 
hours), TIMI coronary flow grade immediately pre-study drug (≤2, and 3) and TIMI 
thrombus grade immediately pre-study drug (≤2, and ≥3). The sub-groups were based on a 
priori concern that they are clinically relevant patient characteristics, which potentially 
could impact on associations of alteplase with IMR, CFR and RRR. Regression models 
were used to assess treatment effects within prespecified sub-groups through the use of 
treatment-by-sub-group interactions. 
 
There was no imputation for missing values and no adjustments for multiple statistical 
comparisons were made. All tests were 2-tailed and assessed at the 5% significance level. 
Data were analysed using R (version 3.4.3, R Development Core Team, California, U.S.A) 





4.4.1 Population characteristics 
The flow of subjects through the study is shown in Figure 4.2. One hundred and forty-four 
patients were enrolled into the physiology sub-study, which represented one third of the 
overall T-TIME population (n = 440) and their characteristics were broadly similar. The 
characteristics of the population are shown in Table 4.1 and procedure characteristics are 
shown in Table 4.2. The mean age was 59.4 ± 10.5 years, 80% were male, and the median 
ischaemic time was 2.5 hours (IQR: 2.0 – 3.5). The infarct-related artery was the RCA in 
66 patients (46%), LAD in 54 patients (38%) and Cx in 24 patients (17%). 
 
At the start of the coronary angiogram, TIMI coronary flow grade was 0 in 114 patients 
(79%), 1 in 14 patients (10%) and 2 in 16 patients (11%). The thrombus grade at the start 
of the angiogram was 5 in 116 patients (81%), 4 in 25 patients (17%) and 3 in 3 patients 
(2%) (Table 4.2).  
 
All of the patients included in the physiology sub-study analysis, except for one, received 
the study drug according to the protocol. The one patient who did not receive the study 
drug according to protocol had the study drug delivered distal to the infarct-related lesion, 






















Alteplase 10mg  
[n=41] 
Alteplase 20mg  
[n=50] 
Demographics 
Age, years 59.4 ± 10.5 56.8 ± 11.3 61.2 ± 9.4 60.6 ± 10.3 
Male 115 (80%) 45 (85%) 31 (76%) 39 (78%) 
Body mass index, kg/m2 28.4 ± 5.1 28.8 ± 5.3 29.0 ± 5.2 27.4 ± 4.6 
Ischaemic time, h:mm, median (IQR) 2:47 (2:03, 3:50) 2:40 (2:03, 3:52) 2:43 (1:53, 4:10) 2:54 (2:10, 3:36) 
Medical history 
Hypertension 41 (28%) 14 (26%) 11 (27%) 16 (32%) 
Hypercholesterolaemia 21 (15%) 11 (21%) 6 (15%) 4 (8%) 
Diabetes mellitus* 16 (11%) 6 (11%) 6 (15%) 4 (8%) 
Smoking:  
                  Current 
                  Former 

















Previous PCI 9 (6%) 3 (6%) 1 (2%) 5 (10%) 
Previous MI 8 (6%) 2 (4%) 1 (2%) 5 (10%) 
Angina 4 (3%) 2 (4%) 0 (0%) 2 (4%) 
Stroke/ Transient Ischaemic Attack 3 (2%) 2 (4%) 0 (0%) 1 (2%) 
Pre-existing maintenance medication 
Aspirin 20 (14%) 8 (15%) 4 (10%) 8 (16%) 
P2Y12 inhibitor:  
                       Clopidogrel 













Statin 25 (17%) 13 (25%) 6 (15%) 6 (12%) 
Βeta-blocker 14 (10%) 4 (8%) 4 (10%) 6 (12%) 
Angiotensin converting enzyme 
inhibitor/ angiotensin receptor blocker 
18 (12%) 7 (13%) 4 (10%) 7 (14%) 
Mineralocorticoid receptor antagonist 3 (2%) 1 (2%) 2 (5%) 0 (0%) 
Haemodynamic measures and baseline blood results on admission 
Heart rate, beats per minute 73.0 ± 15.1 74.4 ± 16.1 71.5 ± 13.0 72.7 ± 15.8 
Systolic blood pressure, mmHg 140 ± 26 140 ± 28 141 ± 23 138 ± 27 
Diastolic blood pressure, mmHg 82 ± 15 84 ± 17 82 ± 13 81 ± 16 
Creatinine†, µmol/L 79 ± 16 79 ± 16 80 ± 14 79 ± 17 
Estimated glomerular filtration rate† 91 ± 21 94 ± 22 88 ± 18 92 ± 22 
Haemoglobin†, g/L 145.8 ± 13.7 145.4 ± 13.8 146.2 ± 12.6 146.0 ± 14.6 
Platelet count†, 109/L 264.2 ± 62.1 252.4 ± 53.6 280.9 ± 73.5 262.9 ± 58.1 
Table 4.1 Population characteristics, from the T-TIME physiology sub-study366. Data are 
reported according to treatment received (n=144). Data are mean ± SD, or n (%), unless 
otherwise stated. † Missing data: Creatinine, estimated glomerular filtration rate, 
haemoglobin and platelets, one subject (alteplase 20mg group) * Diabetes mellitus was 
defined as a history of diet-controlled or treated diabetes. 
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 All Placebo Alteplase 10mg Alteplase 20mg 
 [n=144] [n=53] [n=41] [n=50] 
Infarct-related artery:   LAD 
                                     Cx 













Number of vessels diseased:  1 
                                               2 













Balloon angioplasty pre-stent 141 (98%) 51 (96%) 41 (100%) 49 (98%) 
Initial angiography pre-reperfusion     
TIMI coronary flow grade: 0 
                                            1 
                                            2 

















TIMI thrombus grade: 3 
                                     4 













Immediately pre-study drug administration    
TIMI coronary flow grade: 1 
                                             2 





























Post- study drug 
PCI with stent implant 144 (100%) 53 (100%) 41 (100%) 50 (100%) 
QCA total stent length, mm 35.6 ± 13.2 33.6 ± 12.2 38.1 ± 14.6 35.8 ± 13.0 
QCA post-stent infarct-related artery diameter, mm 3.2 ± 0.4 3.2 ± 0.5 3.2 ± 0.5 3.2 ± 0.4 
Post stent dilatation 133 (92%) 46 (87%) 41 (100%) 46 (92%) 
Acute therapy following first medical contact† 
Aspirin loading dose:  300mg 









Additional antiplatelet medication: 
     None 
     Clopidogrel 
     Ticagrelor 































Intravenous morphine 134 (93%) 48 (91%) 38 (93%) 48 (96%) 
Inhaled oxygen 20 (14%) 8 (15%) 7 (17%) 5 (10%) 
Glycoprotein IIb/IIIa inhibitor 8 (6%) 1 (2%) 5 (12%) 2 (4%) 
Aspiration thrombectomy 23 (16%) 8 (15%) 8 (20%) 7 (14%) 
Table 4.2 Procedural characteristics, from the T-TIME physiology sub-study366. Data are 
reported according to treatment received (n=421). Data are mean ± SD, or n (%), unless 
otherwise stated. Missing data: TIMI coronary flow grade immediately pre-study drug 
administration (3 subjects [2 placebo, 1 alteplase 20mg group]). † None of the patients 
received intravenous or intracoronary treatment with bivalirudin, metoprolol, nicorandil, 
or sodium nitroprusside. 
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Sixty-seven patients (47%) were recruited on a weekend or outside 9am to 5pm, i.e. 
outwith “normal working hours”. A breakdown of the number patients enrolled in the 
physiology sub-study by day of the week and by time to the nearest hour is shown (Figure 
4.3). 
 
Figure 4.3 Breakdown of the number patients enrolled in the T-TIME physiology sub-study 
by day of the week (A) and by time of day to the nearest hour (B). 
 
4.4.2 Correlations between site reported and core laboratory IMR data 
There was excellent correlation between the 144 site-reported IMR values and IMR values 
reported by the core-laboratory (r=0.99, p<0.0001). The intra-class correlation coefficient 
was 0.993 (95% CI: 0.990, 0.995). 
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4.4.3 Intra-observer and inter-rater reliability for IMR, RRR, CFR thermodilution 
waveforms and TIMI thrombus grade 
The intra-observer reliability for IMR assessed from 30 consecutive patients was excellent, 
with an intra-class correlation coefficient of 0.998 (95% CI: 0.997, 0.999). The inter-rater 
reliability for IMR assessed from 30 consecutive patients was also excellent (intra-class 
correlation coefficient: 0.999 [95% CI: 0.998, 0.999]). 
 
For RRR there was excellent intra-observer reliability from 30 consecutive patients (intra-
class correlation coefficient: 0.988 [95% CI: 0.974, 0.994]). The inter-rater reliability for 
RRR assessed from 30 consecutive patients was also excellent, with an intra-class 
correlation coefficient of 0.988 (95% CI: 0.975, 0.994). For CFR, the intraclass correlation 
coefficient was 1.0 for intra- and inter-rater reliability (assessed from 30 consecutive 
patients). 
 
From 30 consecutive patients there was concordance in intra-observer reporting of 
thermodilution waveforms in 97% of patients (n=29), with a kappa value of 0.95 consistent 
with excellent intra-observer agreement368. There was concordance in inter-rater reporting 
of thermodilution waveforms in 26 out of 30 patients (87%) (kappa=0.79). 
 
From 90 patients there was substantial, but imperfect, inter-rater reliability for TIMI 
thrombus grade assessed immediately before study drug administration (kappa=0.75). The 
intra-rater reliability for TIMI thrombus grade assessed in 50 patients immediately before 
study drug administration, was also substantial (kappa=0.72). 
4.4.4 Repeatability of IMR, CFR and RRR 
Paired IMR measurements, obtained 0.5 to 8 minutes apart, post-primary PCI by 4 
cardiologists in 13 patients were correlated (r=0.80, p=0.001), with a mean difference 
between duplicate IMR measurements of 2.90 ± 8.69 (p=0.252). The coefficient of 
variation from duplicate IMR measurements was 15.5%. The Bland-Altman plot is shown 
in Figure 4.4. The mean difference between duplicate CFR measurements from 9 patients 
was 0.07 ± 0.44 (p=0.659) and the coefficient of variation was 24.1%. The mean difference 
between duplicate RRR measurements from 9 patients was -0.04 ± 0.73 (p=0.860) and the 




Figure 4.4 Bland-Altman plots for duplicate IMR (A), CFR (B) and RRR (C) 




4.4.5 Physiology endpoint: IMR 
The median IMR for the entire population was 29.5 (IQR: 17.0 – 55.0). IMR >40 occurred 
in 57 patients (40%), and IMR >32 occurred in 69 patients (48%). Overall, IMR did not 
differ between the alteplase 20mg group (median IMR: 37.0 [IQR: 20.0 – 57.8]), alteplase 
10mg group (median IMR: 22.0 [IQR: 17.0 – 42.0]) and placebo group (median IMR: 33.0 
[IQR: 20.0 – 57.8]). The relative difference in IMR between patients who received 
alteplase 20mg vs. placebo was 1.04 (95% CI: 0.78, 1.38) p=0.801. The relative difference 
in IMR between patients who received alteplase 10mg vs. placebo was 0.79 (95% CI: 0.58, 
1.07) p=0.125. Table 4.3 shows the treatment effects on IMR for alteplase 10mg and 20mg 
combined vs. placebo. 
4.4.6 Physiology endpoints: CFR and RRR 
The median CFR for the whole population was 1.4 (IQR: 1.1 – 2.0). CFR ≤2.0 occurred in 
115 patients (88%). Overall, CFR did not differ between the alteplase 20mg group (median 
CFR: 1.4 [IQR: 1.1 – 2.0]), alteplase 10mg group (median CFR: 1.4 [IQR: 1.1 - 1.9]) and 
placebo group (median CFR: 1.3 [IQR: 1.1 – 1.8]). The relative difference in CFR between 
patients who received alteplase 20mg vs. placebo was 1.03 (95% CI: 0.88, 1.20) p=0.732. 
Treatment effects on CFR did not differ for alteplase 10mg vs. placebo, or for alteplase 
10mg and 20mg combined vs. placebo (Table 4.3). 
 
The median RRR for the population was 1.7 (IQR: 1.2 – 2.3). Overall, RRR did not differ 
between treatment groups (median for the alteplase 20mg group: 1.8 [IQR: 1.3 – 2.4], 
alteplase 10mg group: 1.6 [IQR: 1.4 – 2.6]), placebo group: 1.6 [IQR: 1.3 - 2.2]). The 
relative difference in RRR between patients who received alteplase 20mg vs. placebo was 
1.02 (95% CI: 0.87, 1.20) p=0.795. Treatment effects on RRR did not differ for alteplase 
10mg vs. placebo, or for alteplase 10mg and 20mg combined vs. placebo (Table 4.3).  
4.4.7 Physiology endpoint: thermodilution waveforms 




   
 Treatment Group Treatment Effect 
 All Placebo Alteplase 10mg Alteplase 20mg 10mg vs. placebo  20mg vs. placebo 10 or 20mg vs. placebo 
 [n = 144] [n = 53]  [n = 41] 
 
 [n = 50] Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value 
IMR 
 
29.5 (17.0, 55.0) 33.0 (17.0, 57.0) 22.0 (17.0, 42.0) 37.0 (20.0, 57.8) 0.79 (0.58, 1.07) p=0.125 1.04 (0.78, 1.38) p=0.801 0.92 (0.71, 1.18) p=0.505 
IMR >40 
 
57 (40%) 24 (45%) 11 (27%) 22 (44%) 0.42 (0.17, 1.02) p=0.054  0.93 (0.42, 2.05) p=0.864 0.66 (0.33, 1.34) p=0.251 
IMR >32  
 
69 (48%) 27 (51%) 15 (37%) 27 (54%) 0.54 (0.23, 1.24) p=0.147 1.12 (0.51, 2.44) p=0.774 0.81 (0.41, 1.60) p=0.546 
CFR  
 
1.4 (1.1, 2.0) 1.3 (1.1, 1.8) 1.4 (1.1, 1.9) 1.4 (1.1, 2.0) 1.01 (0.86, 1.19) p=0.900 1.03 (0.88, 1.20) p=0.732 1.02 (0.89, 1.17) p=0.777 
CFR £2.0  
 
115 (80%) 44 (83%) 31 (76%) 40 (80%) 1.62 (0.59, 3.36) p=0.680 1.23 (0.45, 3.36) p=0.680 1.40 (0.58, 3.36) p=0.451 
RRR  1.6 (1.3, 2.3) 1.6 (1.3, 2.2) 1.6 (1.4, 2.6) 1.8 (1.3, 2.4) 1.04 (0.88, 1.23) p=0.658 1.02 (0.87, 1.20) p=0.795 1.03 (0.90, 1.18) p=0.685 
Waveform: 
    Unimodal (narrow) 
    Unimodal (wide) 


















1.00 (0.45, 2.20) p=0.999 
 
0.98 (0.46, 2.06) p=0.956 
 
0.99 (0.52, 1.89) p=0.972 
 
Table 4.3 Coronary physiology endpoints, from the T-TIME physiology sub-study, according to treatment received366. Data are median (IQR), or n (%). 
IMR, CFR and RRR were analysed on a logarithmic scale. Treatment effect estimates for IMR, CFR and RRR were derived from linear regression, with 
treatment effects reported as relative differences between groups, with 95% CIs and p-values (adjusted for location of MI). Treatment effect estimates for 
IMR >40, IMR >32 and CFR ≤2.0 were reported as odds ratios between groups, with 95% CIs and p-values, from logistic regression models (adjusted for 
location of MI). Treatment effect estimates for thermodilution waveforms were reported as odds ratio between groups, with 95% CIs and p-values, from a 
proportional odds logistic regression model (adjusted for location of MI). 
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4.4.8 LVEDP, angiographic and ECG endpoints 
One hundred and thirty-one patients had both LVEDP and IMR measured. There were no 
statistically significant correlations between LVEDP and IMR (r=0.2, p=0.087), CFR (r= -
0.1, p=0.485), RRR (r= -0.1, p=0.475), or MVO (r=0.1, p=0.284). LVEDP did not differ 
with alteplase vs. placebo (Table 4.4). 
 
TIMI flow grade or TFC at the end of PCI did not differ between treatment groups (Table 
4.4). MPG was higher in the alteplase 20mg group vs. placebo (OR: 2.16 [95% CI: 1.04, 
4.49] p=0.039). However, there was no difference in treatment effects on MPG for 
alteplase 10mg vs. placebo, or for alteplase 10mg and 20mg combined vs. placebo (Table 
4.4). 
 
As in the main T-TIME trial, there was no difference in absolute % ST-segment resolution 
60 minutes post-reperfusion relative to baseline, between treatment groups (mean for the 
alteplase 20mg group: 48.8 ± 42.4%, alteplase 10mg group: 45.7 ± 43.8%, placebo group: 















   
 Treatment Group Treatment Effect 
 All Placebo Alteplase 10mg Alteplase 20mg 10mg vs. placebo  20mg vs. placebo 10 or 20mg vs. placebo 
 [n=144] [n=53]  [n=41] [n=50] Estimate (95% CI) p-value  Estimate (95% CI) p-value Estimate (95% CI) p-value 








1.05 (0.88, 1.25) p=0.579 0.89 (0.75, 1.05) p=0.172 0.96 (0.83, 1.12) p=0.609 
TIMI flow grade post-PCI  
     1 
     2 

















1.43 (0.42, 4.84) p=0.565 1.70 (0.51, 5.69) p=0.391 1.57 (0.57, 4.32) p=0.387 
MPG post-PCI  
     0 
     1 
     2 


































0.89 (0.72, 1.11) p=0.311 1.03 (0.84, 1.27) p=0.774 0.97 (0.80, 1.16) p=0.713 
Absolute % ST-segment  
resolution 60 min post-
reperfusion relative to 
baseline 
46.6 ± 40.9 45.1 ± 37.8 45.7 ± 43.8 48.8 ± 42.4 1.32 (-15.53, 18.16) p=0.878 4.15 (-11.71, 20.02) p=0.608 2.89 (-11.04, 16.83) p=0.684 
 
Table 4.4 LVEDP, angiographic and ECG endpoints, from the T-TIME physiology sub-study, according to treatment received366. Data are reported as 
mean ± SD, n (%), or median (IQR). Treatment effect estimates for TIMI flow grade, and MPG are reported as odds ratios, with 95% CIs and p-values, 
from proportional odds logistic regression (models adjusted for MI location).  Treatment effects for TFC and LVEDP (analysed on a logarithmic scale) 
are reported as relative differences, with 95% CIs and p-values, from linear regression (models adjusted for MI location).  Treatment effects for % ST-
segment resolution are reported as mean differences, with 95% CIs and p-values, from linear regression (models adjusted for MI location). Missing data: 
LVEDP, 13 subjects (6 placebo, 1 alteplase 10mg, 6 alteplase 20mg); ST-segment resolution, 3 subjects (2 placebo, 1 alteplase 10mg group).
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4.4.9 CMR endpoints 
Ninety seven percent of patients (n=140) had CMR imaging performed 2 to 7 days post-
PCI, with MVO evaluable in all 140 patients. Ninety four percent of patients (n=135) had 
CMR imaging performed at 3 months post-PCI, with infarct size evaluable in 133 patients.  
 
The number of days from PCI to CMR imaging is shown in Table 4.5. Given the high 
proportion of patients with a value of 0 for MVO (n=83 [59%]), the median MVO extent 
was 0.0 (IQR: 0.0 – 3.3). As in the main T-TIME trial, there was overall no difference 
between treatment groups for MVO, myocardial haemorrhage, infarct size, LV ejection 
fraction or LV volumes (Tables 4.6 and 4.7). 
 
 All Placebo Alteplase 10mg Alteplase 20mg 
 [n=144] [n=53] [n=41] [n=50] 
 
Days from PCI CMR imaging 2-7 
days following primary PCI 
 
4.0 (3.0 – 5.0) 4.0 (3.0 – 5.0) 5.0 (4.0 – 6.0) 4.0 (3.0 – 5.0) 
 
Days from PCI to CMR imaging 3 
months following primary PCI 
90.0 (84.0 – 97.0) 89.0 (84.0 – 97.0) 90.5 (84.5 – 95.8) 90.0 (85.0 – 97.0) 
 
Table 4.5 Number of days from PCI to CMR imaging, in the T-TIME physiology sub-
study366. Data are median (IQR). Missing data: 2 to 7 day CMR imaging (4 subjects [2 
placebo, 2 alteplase 20mg group]); 3-month CMR imaging (9 subjects [5 placebo, 1 
alteplase 10mg, 3 alteplase 20mg group]). 
 
4.4.10 Coagulation variables 
The effects of alteplase on coagulation variables 2 hours post-PCI are shown in Table 4.8. 
Systemic concentrations of fibrin D-dimer were increased, and systemic concentrations of 
plasminogen were reduced in patients who received alteplase compared to placebo, 
reflecting fibrinolysis. Systemic concentrations of prothrombin fragment F1+2 were 






    
 Treatment Group  Treatment Effect 
 All Placebo Alteplase 10mg Alteplase 20mg 10mg vs. placebo  20mg vs. placebo 10 or 20mg vs. placebo 
 [n=144] 
 
[n=53] [n=41] [n=50] Estimate (95% CI) p-value  Estimate (95% CI) p-value Estimate (95% CI) p-value 
MVO extent (% LV)  
 
2.5 ± 4.5 2.0 ± 3.1 2.5 ± 4.2 2.9 ± 5.7 0.03 (-0.50, 0.56) p=0.908 0.08 (-0.43, 0.59) p=0.766 0.06 (-0.50, 0.50) p=0.804 
MVO present  
 
57 (41%) 23 (45%) 16 (39%) 18 (38%) 0.78 (0.34, 1.81) p=0.566 0.73 (0.33, 1.64) p=0.449 0.76 (0.38, 1.52) p=0.432 
Myocardial haemorrhage extent (% LV)  2.0 ± 3.9 1.6 ± 2.8 2.1 ± 3.8 2.4 ± 4.8 0.44 (-1.28, 2.16) p=0.619 0.72 (-0.87, 2.31) p=0.373 0.60 (-0.81, 2.01) p=0.403 
Myocardial haemorrhage present  56 (41%) 22 (45%) 16 (41%) 18 (38%) 0.85 (0.36, 2.00) p=0.713 0.73 (0.33, 1.66) p=0.458 0.79 (0.38, 1.60) p=0.506 
Acute infarct size (% LV)  
 
24.1 ± 12.7 23.3 ± 12.9 26.6 ± 12.5 23.1 ± 12.8 2.57 (-2.29 7.42) p=0.300  -0.70 (-5.35, 3.94) p=0.767 0.80 (-3.27, 4.87) p=0.700 
LV ejection fraction (%)  
 
43.9 ± 8.3 44.3 ± 7.6 43.6 ± 7.6 43.7 ± 9.7 -0.25 (-3.55, 3.05) p=0.882 -0.32 (-3.48, 2.84) p=0.844 -0.29 (-3.04, 2.47) p=0.838 










1.00 (0.88, 1.12) p=0.946 0.94 (0.84, 1.06) p=0.306 0.97 (0.87, 1.07) p=0.503 










0.99 (0.90, 1.09) p=0.850 0.94 (0.86, 1.03) p=0.189 0.96 (0.89, 1.04) p=0.360 
 
Table 4.6 CMR endpoints at 2 to 7 days post-PCI, from the T-TIME physiology sub-study, according to treatment received.366 Data are mean ± SD, or n (%), or 
median (IQR). Treatment effect estimates for MVO extent (on square root transformed scale) were reported as mean difference in square root of MVO extent between 
groups, with 95% CIs and p-values from linear regression (adjusted for MI location).Treatment effect estimates for myocardial haemorrhage infarct size and LV 
ejection fraction, were reported as mean differences between groups, with 95% CIs and p-values, from linear regression (adjusted for MI location). Treatment effect 
estimates for MVO presence or myocardial haemorrhage presence were reported as odds ratios, with 95% CIs and p-values from logistic regression (adjusted for MI 
location). Treatment effect estimates for LV volumes (on a log-transformed scale) were reported as relative differences between groups, with 95% CIs and p-values 
from linear regression (adjusted for MI location). Missing data: MVO presence/ absence or extent, Infarct size, LV ejection fraction (4 subjects [2 placebo, 2 alteplase 
20mg group]). LV end diastolic/ systolic volumes (4 subjects [2 placebo, 2 alteplase 20mg]). Myocardial haemorrhage extent (13 subjects [6 placebo [5 alteplase 
10mg, 2 alteplase 20mg group]). Myocardial haemorrhage presence/ absence (8 subjects [8 placebo, 2 alteplase 10mg, 2 alteplase 20mg group]).  
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 Treatment Group Treatment Effect 
 All Placebo Alteplase 10mg Alteplase 20mg 10mg vs. placebo  20mg vs. placebo 10 or 20mg vs. placebo 
 [n=144] 
 
[n=53] [n=41] [n=50] Estimate (95% CI) p-value  Estimate (95% CI) p-value Estimate (95% CI) p-value 
Infarct size (% LV)  
 
17.0 ±  11.5 17.0 ± 11.9 17.7 ± 11.0 16.5 ± 11.7 0.45 (-4.16, 5.06) p=0.848   -0.62 (-5.04, 3.80) p=0.782 -0.13 (-4.00, 3.74) p=0.947 
LV ejection fraction  
 
49.1 ± 8.4 49.5 ± 8.4 49.0 ± 6.5 48.9 ± 9.8 -0.32 (-3.79, 3.14) p=0.855 -0.45 (-3.77, 2.88) p=0.793 -0.39 (-3.29, 2.51) p=0.792 
LV end systolic volume 










0.97 (0.84, 1.12) p=0.687 0.95 (0.83, 1.09) p=0.484 0.96 (0.85, 1.08) p=0.513 
LV end diastolic volume 










0.96 (0.87, 1.06) p=0.403 0.93 (0.85, 1.02) p=0.140 0.95 (0.87, 1.02) p=0.170 
 
Table 4.7 CMR endpoints at 3 months post-PCI, from the T-TIME physiology sub-study, according to treatment received366. Data are mean ± SD, or 
median (IQR). Treatment effect estimates for infarct size and LV ejection fraction, were reported as mean differences between groups, with 95% CIs and 
p=values, from linear regression (adjusted for MI location). Treatment effect estimates for LV volumes (on a log-transformed scale) were reported as 
relative differences between groups, with 95% CIs and p-values from linear regression (adjusted for MI location). Missing data: LV ejection fraction (9 
subjects [5 placebo, 1 alteplase 10mg, 3 alteplase 20mg group]). Infarct size (11 subjects [7 placebo, 1 alteplase 10mg, 3 alteplase 20mg group]). LV 
end diastolic/ systolic volume (9 subjects [5 placebo, 1 alteplase 10mg, 3 alteplase 20mg]).  
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 Treatment Group Treatment effect 
 All Placebo Alteplase 10mg Alteplase 20mg 10mg vs. placebo 20mg vs. placebo 10 or 20mg vs. placebo 
 [n=144] [n=53] [n=41] [n=50] Estimate (95% CI) p-value  Estimate (95% CI) p-value Estimate (95% CI) p-value 
 
ACT 2 hrs post-PCI (mean ± SD) 
 
288.9 ± 92.0 302.3 ± 103.3 298.3 ± 83.1 266.9 ± 83.5 1.00 (0.89, 1.13) p=0.940 0.89 (0.80, 1.00) p=0.046 0.94 (0.85, 1.04) p=0.230 
Plasminogen (U/dL) 2 hrs post-PCI   
 
89.0 (78.2, 98.0) 96.0 (87.0, 106.0) 89.0 (82.5, 98.0) 81.5 (74.2, 91.8) -5.20 (-11.00, 0.60) p=0.076 -12.9 (-18.4, -7.30) p<0.001 -9.40 (-14.30, -4.40) p<0.001 
Change in plasminogen (U/dL) 2 
hrs post-PCI relative to baseline 
 
-6.0 (-11.0, 0.0)  0.0 (-5.0, 2.5) -5.0 (-9.8, -2.0) -11.0 (-15.2, -8.0) -4.60 (-7.80, -1.30) p=0.006 -11.30 (-14.40, -8.10) p<0.001 -8.20 (-11.10, -5.30) p<0.001 
D-dimers (ng/ml) 2 hrs post-PCI 
 
245.5 (117.0, 455.8) 107.0 (66.0, 149.0) 287.0 (213.5, 587.5) 367.5 (228.8, 557.5) 3.23 (2.28, 4.58) p<0.001 3.49 (2.50, 4.87) p<0.001 3.37 (2.52, 4.50) p<0.001 
Ratio of D-dimers 2 hrs post-PCI 
relative to baseline 
 
2.11 (1.05, 3.72) 1.01 (0.95, 1.19) 2.96 (2.14, 4.06) 3.14 (2.16, 6.32) 2.78 (2.10, 3.68) p<0.001 3.24 (2.48,4.25) p<0.001 3.02 (2.39, 3.82) p<0.001 
Prothrombin fragment F1+2 
(pmol/L) 2 hrs post-PCI  
 
178.8 (133.1, 244.2) 152.0 (118.6, 211.4) 183.0 (141.9, 291.9) 187.3 (150.5, 244.9) 1.27 (1.02, 1.58) p=0.034 1.24 (1.00, 1.52) p=0.048 1.25 (1.04, 1.50) p=0.017 
Ratio of prothrombin fragment F1+2 
2hrs post-PCI relative to baseline 
1.16 (1.02, 1.43) 1.07 (0.96, 1.44) 1.17 (1.03, 1.42) 1.18 (1.06, 1.40) 1.08 (0.87, 1.33) p=0.477 1. 08 (0.88, 1.32) p=0.466 1.08 (0.90 1.29) p=0.398 
 
Table 4.8 Coagulation and haematology variables, from the T-TIME physiology sub-study, according to treatment received366. Data are median (IQR) 
unless otherwise stated. Treatment effect estimates for ACT, plasminogen, and change in variables at 2 hours compared to baseline, are reported as mean 
differences between groups, with 95% CIs and p-values, from linear regression (adjusted for MI location). Treatment effects for D-dimers and prothrombin 
fragment F1+2 (analysed on logarithmic scales) reported as relative difference between groups, with 95% CIs and p-values, from linear regression (adjusted 
for MI location). Missing data: ACT (6 subjects [5 from placebo, 1 from alteplase 10mg group]), prothrombin fragment F1+2 two hours post-PCI (15 
subjects [6 placebo, 3 alteplase 10mg, 4 alteplase 20mg group]). Plasminogen 2 hours post-PCI (10 subjects [4 placebo, 2 alteplase 10mg. 4 alteplase 20mg 
group]).  Change in plasminogen, d-dimers, or prothrombin fragment F1+2 2 hours post-PCI compared to baseline (15 subjects [6 placebo, 3 alteplase 
10mg, 6 alteplase 20mg group]). 
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4.4.11 Sub-group analyses 
The results from the sub-group analyses are shown in Figures 4.5 to 4.8, and Tables 4.9 to 
4.11. There was no interaction between TIMI flow grade immediately before drug 
administration, alteplase and IMR, CFR or RRR (Figure 4.5 and Table 4.9). Patients with 
TIMI 3 flow pre-study drug administration had numerically higher RRR and CFR with 
alteplase 20mg compared to placebo, and patients with TIMI flow ≤2 pre-study drug had 
numerically lower RRR and CFR with alteplase 20mg (Figure 4.5). However, there were 
no significant differences in treatment effects on linear regression (Table 4.9).  
 
There was no interaction between ischaemic time, alteplase and IMR (Figure 4.6 and Table 
4.10). There was an interaction between ischaemic time, alteplase and CFR, with treatment 
as a 3-level categorical variable (p=0.013) (Table 4.10). For patients with ischaemic times 
<2 hours, median CFR was higher with alteplase (alteplase 20mg: 2.0 [IQR:1.8 – 2.3], 
alteplase 10mg: 1.4 [IQR: 1.0 – 1.8], placebo: 1.2 [IQR: 1.1 – 1.7]) (Table 4.10). In 
patients with an ischaemic time ≥4 hours, median CFR was 1.2 (IQR: 1.0 - 1.6) for 
alteplase 20mg, 1.8 (IQR:1.3 – 2.6) for alteplase 10mg and 1.7 (IQR: 1.4 – 2.0) for 
placebo. An interaction occurred between ischaemic time, alteplase and RRR with 
treatment as a 3-level categorical variable (p=0.026) (Table 4.10). For patients with 
ischaemic times <2 hours, median RRR was higher with alteplase (alteplase 20mg: 2.2 
[IQR:2.0 – 2.6], alteplase 10mg: 1.6 [IQR: 1.1 – 2.2], placebo: 1.5 [IQR: 1.3 – 1.9]). In 
patients with an ischemic time ≥4 hours median RRR was as follows: alteplase 20mg (1.4 
[IQR: 1.0 – 2.5]), alteplase 10mg (2.3 [IQR:1.6 – 2.8]), placebo (2.0 [IQR: 1.4 – 2.7]). 
 
Interaction occurred between ischaemic time, alteplase and MVO extent with treatment as a 
3-level categorical variable (p=0.039). The interaction effect was driven by an increase in 
mean MVO extent with alteplase in patients with ischaemic times ≥4 hours (Figure 4.7 and 
Table 4.10): alteplase 20mg (5.97 ± 6.58%), alteplase 10mg (2.77 ± 4.54%), placebo (0.89 
± 1.65%). 
 
There was no interaction between TIMI thrombus grade immediately before study drug 





Figure 4.5 IMR (A), CFR (B) and RRR (C), by treatment received, in sub-groups of TIMI 
coronary flow grade (≤2, 3) immediate before study drug administration. Boxes represent 
the median and IQR (values provided), with whiskers at the 10th and 90th percentiles. 
Values outside the 10th and 90th percentiles are presented as individual data points.
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TIMI flow pre-study drug  Treatment Effect Interaction p-value 
(treatment as 3-level  
categorical variable) 
Treatment Effect Interaction p-value 
(treatment as 2-level 
categorical variable) 
10mg vs. placebo 
Estimate (95% CI) p-value 
20mg vs. placebo 
Estimate (95% CI) p-value 
10 or 20mg vs. placebo 
Estimate (95% CI) p-value 
IMR  




1.03 (0.61, 1.77) p=0.903  
0.72 (0.51, 1.02) p=0.835 
 
1.05 (0.65, 1.71) p=0.835 
1.02 (0.72, 1.45) p=0.896 
 
0.481  
1.05 (0.68, 1.62) p=0.834 
0.86 (0.64, 1.16) p=0.335 
0.473 
CFR  




0.88 (0.65, 1.18) p=0.396 
1.07 (0.88, 1.31) p=0.472 
 
 
0.84 (0.64, 1.10) p=0.198 
1.16 (0.95, 1.41) p=0.139 
0.159  
0.85 (0.67, 1.09) p=0.201 
1.12 (0.95, 1.32) p=0.192 
0.074 
RRR  
≤ 2  
3  
 
0.90 (0.66, 1.23) p=0.502 
1.10 (0.90, 1.35) p=0.341 
 
0.82 (0.62, 1.08) p=0.158 
1.16 (0.95, 1.41) p=0.154 
0.140  
0.85 (0.66, 1.09) p=0.203 
1.13 (0.95, 1.34) p=0.160 
0.065 
 
Table 4.9 Treatment effect estimates reported as relative differences and 95% CIs with p-values from linear regression and interactions with treatment 
received, for IMR, CFR and RRR, in sub-groups of TIMI coronary flow grade (≤2, 3) immediately before study drug administration.366 Data analysed on 







Figure 4.6 IMR (A), CFR (B) and RRR (C), by treatment received, in sub-groups of 
ischaemic time (<2 hours, ≥ 2, < 4 hours, ≥4 hours). Boxes represent the median and IQR 
(values provided), with whiskers at the 10th and 90th percentiles. Values outside the 10th 








Figure 4.7 Mean MVO extent (± SD), by treatment received, in sub-groups of ischaemic 
time (<2 hours, ≥2, < 4 hours, ≥4 hours). 
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Ischaemic time  
 
 
Treatment Effect Interaction p-value 
(treatment as 3-level  
categorical variable) 
Treatment Effect Interaction p-value 
(treatment as 2-level  
categorical variable) 10mg vs. placebo  20mg vs. placebo 10 or 20mg vs. placebo 
IMR   
<2 hrs 




0.79 (0.43, 1.46) p=0.454 
0.82 (0.53, 1.27) p=0.364 
0.70 (0.39, 1.27) p=0.238 
 
 
0.52 (0.26, 1.04) p=0.064 
1.24 (0.86 1.79) p=0.250 
1.07 (0.58, 1.96) p=0.837 
0.172  
0.68 (0.39, 1.19) p=0.173 
1.07 (0.76, 1.51) p=0.685 
0.86 (0.51, 1.44) p=0.556 
0.367 
CFR   
<2 hrs 




0.94 (0.68, 1.29) p=0.686 
1.03 (0.82, 1.30) p=0.791 
1.08 (0.79, 1.47) p=0.636 
 
 
1.59 (1.11, 2.27) p=0.012 
1.00 (0.82, 1.21) p=0.987 
0.82 (0.60, 1.13) p=0.224 
0.013  
1.14(0.85, 1.55) p=0.379 
1.01 (0.84, 1.21) p=0.915 
0.95 (0.72, 1.25) p=0.697 
0.652 
RRR   
<2 hrs 
≥2, <4 hrs 
≥4 hrs 
 
0.93 (0.66, 1.29) p=0.647 
1.10 (0.87, 1.40) p=0.435 
1.11 (0.80, 1.54) p=0.518 
 
 
1.52 (1.05, 2.22) p=0.028 
0.98 (0.80, 1.20) p=0.848 
0.86 (0.61, 1.20) p=0.367 
0.026  
1.12 (0.82, 1.53) p=0.481 
1.02 (0.85, 1.23) p=0.833 
0.98 (0.74, 1.31) p=0.907 
0.827 
MVO (% LV)    
<2 hrs  
≥2, <4 hrs  
≥4 hrs  
 
 
-0.03 (-1.10, 1.03) p=0.950 
-0.14 (-0.90, 0.61) p=0.715 
0.49 (-0.52, 1.50) p=0.337 
 
 
-0.87 (-2.07, 0.33) p=0.155 
-0.14 (-0.77, 0.50) p=0.676 
1.47 (0.40, 0.54) p=0.007 
0.039  
-0.35 (-1.34, 0.64) p=0.484 
-0.14 (-0.72, 0.45) p=0.643 
0.93 (0.05, 1.82) 0.039 
0.089 
Myocardial haemorrhage (% LV) 
<2 hrs 
≥2, <4 hrs 
≥4 hrs 
 
0.20 (-2.48, 4.87) p=0.523 
 0.41 (-2.04, 2.86) p=0.741 
0.80 (-2.46, 4.06) p=0.632 
 
-0.51 (-4.44, 3.42) p=0.800 
-0.06 (-2.05, 1.92) p=0.950 
4.25 (0.88, 7.61) p=0.013 
0.153  
0.48 (-2.91, 3.86) p=0.783 
0.09 (-1.75, 1.93) p=0.926 
2.42 (-0.41, 5.25) p=0.094 
0.392 
 
Table 4.10 Treatment effect estimates and interactions with treatment received, for IMR, CFR, RRR, MVO extent and myocardial haemorrhage extent, in sub-groups of 
ischaemic time (<2 hours, ≥2 <4 hours, ≥4 hours). Coronary physiology data were analysed on a logarithmic scale, with treatment effect estimates reported as relative 
differences and 95% CIs, derived from linear regression.
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 MVO extent (% LV) were analysed on a square root scale, with treatment effect estimates reported as mean 
differences and 95%, derived from linear regression. For myocardial haemorrhage extent (% LV) treatment effect estimates were reported as mean differences 




Figure 4.8 IMR (A), CFR (B) and RRR (C), by treatment received, in sub-groups of TIMI 
thrombus grade (≤2, ≥3) immediate preceding study drug administration. Boxes represent 
the median and IQR (values provided), with whiskers at the 10th and 90th percentiles. 




     
TIMI thrombus grade pre-
study drug  
Treatment Effect Interaction p-value 
(treatment as 3-level  
categorical variable) 
Treatment Effect Interaction p-value 
(treatment as 2-level 
categorical variable) 
10mg vs. placebo 
Estimate (95% CI) p-value 
20mg vs. placebo 
Estimate (95% CI) p-value 
10 or 20mg vs. placebo 
Estimate (95% CI) p-value 
IMR  
≤ 2  
≥ 3  
 
 
1.24 (0.67, 2.29) p=0.498 
0.69 (0.48, 0.98) p=0.036 
 
 
1.33 (0.72, 2.44) p=0.363 
0.97 (0.70, 1.36) p=0.865 
0.260  
1.28 (0.77, 2.13) p=0.348 
0.83 (0.62, 1.12) p=0.231 
0.158 
CFR  
≤ 2  
≥ 3  
 
 
0.86 (0.62, 1.21) p=0.393 
1.05 (0.87, 1.28) p=0.595 
 
 
1.06 (0.76, 1.48) p=0.737 
1.03 (0.86, 1.23) p=0.753 
0.506  
0.96 (0.73, 1.26) p=0.759 
1.04 (0.89, 1.22) p=0.637 
0.616 
RRR  
≤ 2  
≥ 3  
 
0.87 (0.61, 1.23) p=0.424 
1.09 (0.89, 1.33) p=0.412 
 
1.05 (0.75, 1.48) p=0.767 
1.02 (0.85, 1.23) p=0.840 
0.440  
0.96 (0.72, 1.27) p=0.768 
1.05 (0.89, 1.24) p=0.580 
0.595 
 
Table 4.11 Treatment effect estimates reported as relative differences and 95% CIs with p-values from linear regression and interactions with treatment 
received, for IMR, CFR and RRR, in sub-groups of TIMI thrombus grade (≤2, ≥3) immediately before study drug administration.366 Data analysed on 




In this prespecified, physiology sub-study of the T-TIME trial, there was overall no 
difference in microvascular function, measured by IMR, CFR and RRR, between alteplase 
and placebo groups.  
 
The lack of an overall effect of adjunctive intracoronary alteplase on microvascular 
function in the infarct-related artery contrasts with the findings reported from a previous 
study, which used adjunctive intracoronary streptokinase during primary PCI259 260. In that 
study, low-dose intracoronary streptokinase (n=51) was infused into the infarct-related 
artery over 3 minutes through a guide catheter at the end of primary PCI, and when 
compared to standard care (n=44) the patients who received streptokinase had higher CFR 
(2.5 vs. 1.7, p<0.001) and lower IMR (20.2 vs. 34.3, p<0.001)260. 
 
There are differences between the study described in the above paragraph by Sezer et al260 
and the T-TIME physiology sub-study. First, the study by Sezer et al260 was not double-
blinded. Second, unlike alteplase, streptokinase is not fibrin specific. Third, in the study by 
Sezer et al260 intracoronary streptokinase was administered after stent implantation, when 
89% of the cohort had TIMI 3 flow in the infarct-related artery, whereas in the T-TIME 
physiology sub-study intracoronary alteplase was administered before stent implantation, 
when only 68% of the patients had TIMI 3 flow. Fourth, in the T-TIME physiology sub-
study, IMR, CFR and RRR were measured immediately after stent optimisation at the end 
of the PCI procedure, whereas Sezer et al260 measured IMR and CFR 48-hours after 
primary PCI, when IMR and CFR may have undergone partial recovery163 275 276. 
 
The prespecified sub-group analyses were exploratory and were intended to be interpreted 
as hypothesis generating, and to provide mechanistic insights. The reason for the absence 
of interaction between ischaemic time and alteplase with IMR, even though interactions 
were observed with CFR and RRR, could potentially be because IMR reflects different 
aspects of microvascular function than RRR or CFR, or due to type 2 statistical error (i.e. a 
false negative result), due to the relatively small number of patients in the sub-groups, 
which limited statistical power to detect differences. IMR measures the minimum 
achievable microvascular resistance with hyperaemia140, but unlike RRR194 and CFR156 191, 
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IMR does not measure the “ability” of the microcirculation to vasodilate, i.e. vasodilator 
capacity, and therefore IMR might not reflect the full potential for the microcirculation to 
recover following reperfusion.  
 
There are plausible potential mechanisms to explain the interactions that were observed 
between ischaemic time and alteplase, with CFR and RRR. The improvements in CFR and 
RRR with alteplase in patients with brief ischaemic times (<2 hours) may reflect those 
patients having an intact microcirculation, with preserved vasodilator capacity, which was 
modifiable by therapy. On the other hand, in patients with ischaemic times ≥4 hours, there 
may have been irreversible microvascular damage. Therefore, the microcirculation may 
have been resistant to modification by therapy in patients with longer ischaemic times. 
Indeed, patients with ischaemic times ≥4 hours had numerically lower CFR and RRR with 
alteplase 20mg, suggesting a trend to worse microvascular function with alteplase in 
patients with longer ischaemic times. This is consistent with the observation that alteplase 
was associated with more MVO in patients with ischaemic times ≥4 hours. The underlying 
mechanism is uncertain, but a potential explanation could be that in the setting of 
prolonged ischaemia with associated capillary degradation, alteplase may have promoted 
haemorrhage of erythrocytes into the interstitial space of the infarct core, with consequent 
external compression of capillaries, thereby worsening MVO. The findings suggest the 
possibility of alteplase having a detrimental effect on myocardial reperfusion in patients 
with ischaemic times ≥4. This is especially relevant to the ongoing RESTORE-MI trial 
(ACTRN12618000778280)273, which is including STEMI patients with ischaemic times up 
to 12 hours, for adjunctive intracoronary tenecteplase or placebo during primary PCI.  
 
Whilst the observed interactions between ischaemic time, alteplase and CFR, RRR and 
MVO could potentially be a consequence of type 1 statistical error (false positive result), 
the findings are supported by consistent effects of ischaemic time on the extent of MVO in 
the main T-TIME trial (n=440)303. In the main T-TIME trial population (n=440), patients 
with ischaemic times ≥4 had significantly more MVO and myocardial haemorrhage with 
alteplase compared to placebo, and there was a significant interaction between ischaemic 
time, alteplase and MVO (and myocardial haemorrhage) with treatment analysed as a 





With regards to the lack of interaction between TIMI flow grade immediately before drug 
administration, alteplase, and IMR, CFR or RRR, type 2 statistical error cannot be 
excluded (i.e. a false negative). The patient numbers in the treatment groups, for sub-
groups of TIMI flow pre-drug, were relatively small, which limited power to detect 
significant interactions.  
 
A possible explanation for the lack of interaction between TIMI thrombus grade 
immediately before study drug administration, alteplase and IMR, CFR or RRR, may be 
because distal embolization of thrombus to the microcirculation could have occurred at 
initial low-pressure balloon inflation, prior to the assessment of thrombus grade pre-study 
drug administration. Therefore, some of the patients assessed as having thrombus grade ≤2 
immediately before study drug administration may have had very high thrombus burden 
that wasn’t apparent angiographically at the time of study drug administration, because 
distal embolization of thrombus to the microcirculation had already occurred. A second 
consideration is that angiography is a relatively insensitive means of assessing thrombus 
burden, and intra-observer, and inter-rater variability was demonstrated in this study. 
Optical coherence tomography is a superior method, with high-resolution (10-20 µm)369, 
for accurate determination of thrombus burden369-372. Furthermore, optical coherence 
tomography allows white thrombi (composed largely of platelets and leukocytes), which 
produce high signal intensity to be distinguished from red thrombi (composed mainly of 
fibrin and erythrocytes), which produce high backscattering protrusions in the artery lumen 
with signal attenuation373. It is not possible to distinguish red from white thrombus using 
the TIMI thrombus grade classification.  
4.6 Limitations 
The study presented in this chapter has many strengths, including: (i) multicentre 
enrolment, (ii) blinding of coronary physiology measurements during acquisition to 
minimise bias, (iii) double-blind, randomised design, (iv) excellent inter-rater and intra-
observer reliability for physiology measurements, and (v) excellent follow up rates with 
CMR at 3 months (94%). However, the limitations need to be considered. 
 
First, coronary physiology measurements were not performed consecutively in patients 
enrolled into the main T-TIME trial. Out of the 440 patients in the T-TIME trial, about two 
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thirds did not have coronary physiology measurements performed, due to logistical 
reasons, or operator inexperience with coronary physiology. Seven patients had failed 
attempts at coronary physiology measurements, due to haemodynamic instability or no 
detectable thermodilution transit times.  
 
The most prevalent infarct-related artery in the T-TIME physiology study was the RCA 
(46%), followed by the LAD (38%), whereas for the main T-TIME trial the most prevalent 
infarct-related artery was the LAD (41%) and second most prevalent was the RCA 
(39%)292. In general, it may be easier and quicker to pass wires in the RCA than the LAD, 
which in circumstances of logistical pressures for catheterisation laboratory access may 
have led to slightly fewer pressure wire measurement being performed in the LAD. 
 
Another limitation, is the potential for type 1 statistical error (false positive) in the sub-
group analyses, therefore these should be interpreted as exploratory. Furthermore, 
duplicate IMR measurements were available in only 13 patients and duplicate CFR and 
RRR measurements were only available in 9 patients. Finally, there was some variability in 
angiographic thrombus assessment pre-study drug. 
4.7 Future work 
Further research is needed to validate the findings from the sub-group analyses, because of 
the potential for type 1 statistical error. In addition, analysis of the results from the T-
TIME optical coherence tomography sub-study is of interest to determine whether low-
dose intracoronary alteplase may have a differential effect in patients with the largest 
thrombus burden compared to lower thrombus burden pre-drug, assessed by optical 
coherence tomography. Lastly, it would be interesting to investigate whether intracoronary 
tenecteplase administered at the end of primary PCI, i.e. post-stent implantation, may result 
in improvement in invasive coronary physiology parameters measured before and after 
drug administration compared to placebo, in patients with short ischaemic times. The T-
TIME physiology sub-study protocol did not include pressure wire studies pre-drug, 
because the drug was administered before stent implantation, and in that setting the infarct-




In conclusion, acute STEMI patients with ischaemic times ≤6 hours had no overall 
difference in infarct-related artery microvascular function (IMR, CFR, or RRR) at the end 
of PCI with alteplase (administered following initial reperfusion and before stent 
implantation) compared to placebo. Interactions were observed between ischaemic time 
and alteplase on CFR, RRR and MVO, suggesting potential therapeutic benefit in patients 
presenting with a shorter ischaemic time, and a detrimental effect in patients with a longer 
ischaemic time.  
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Chapter 5: Comparison of acute invasive parameters for predicting 
microvascular injury and clinical outcomes after primary PCI 
This work has been published (Maznyczka AM et al. Comparative significance of invasive 
measures of microvascular injury in acute myocardial infarction. Circ Cardiovasc Interv. 
2020.13(5) [Epub ahead of print]374. Doi: 10.1161/CIRCINTERVENTIONS.119.008505 
[available from: https://www.ahajournals.org/journal/circinterventions]. The journal 
provided permission to reproduce Tables and Figures from this publication, for use in the 
thesis. 
5.1 Abstract 
Background: Parameters that detect failed microvascular perfusion during primary PCI 
have potential for early risk stratification of patients, and to identify patients likely to 
benefit from adjunctive treatments. The aim of the research presented in this chapter was to 
compare IMR, CFR, RRR, MPG and TFC, for predicting MVO, myocardial haemorrhage 
and clinical outcomes. 
Methods: In the T-TIME trial, 440 acute STEMI patients from 11 U.K. hospitals were 
prospectively enrolled. In a subset of 144 patients, IMR, CFR and RRR were measured at 
the end of primary PCI. In addition, MPG and TFC were measured at the end of the PCI 
procedure. MVO extent (% LV mass) was determined by CMR imaging performed 2 to 7 
days after primary PCI. Myocardial haemorrhage was determined by T2* mapping. One 
year major adverse cardiac events (MACE), heart failure hospitalisations, and all-cause 
death/ heart failure hospitalisations were assessed. 
Results: In these 144 patients (mean age 59 ± 11 years, 80% male), IMR >40 was 
multivariably associated with more MVO (coefficient: 0.54 [95% CI: 0.05, 1.03] p=0.030) 
and myocardial haemorrhage presence (OR: 2.67 [95% CI: 1.10, 6.51] p=0.031), 
independently of CFR ≤2.0, RRR ≤1.7, MPG ≤1 and TFC >27. Lower RRR was 
multivariably associated with more MVO (coefficient: -0.61 [95% CI: -0.98, -0.23] 
p=0.002) and myocardial haemorrhage presence (OR: 0.34 [95% CI: 0.15, 0.75] p=0.008). 
MPG ≤1 was also multivariably associated with more MVO (coefficient: 0.53 [95% CI: 
0.07, 1.00] p=0.026) and myocardial haemorrhage presence (OR: 3.15 [95% CI: 1.35, 
7.35] p=0.008), whereas CFR ≤2.0 and TFC >27 were not. IMR >40 was associated with 
heart failure hospitalisation (OR: 5.34 [95% CI: 1.80, 15.81] p=0.002), MACE (OR: 4.46 
[95% CI: 1.70, 11.70] p=0.002), and all-cause death/ heart failure hospitalisation (OR: 4.08 
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[95% CI: 1.55, 10.79] p=0.005). Lower RRR was associated with heart failure 
hospitalisation (OR: 0.44 [95% CI:0.19, 0.99] p=0.047). TFC >27 and MPG ≤1 were also 
associated with clinical outcomes, whereas CFR ≤2.0 was not. 
Conclusion: In acute STEMI, IMR >40, lower RRR and MPG ≤1, were associated with 
MVO, myocardial haemorrhage and clinical outcomes. TFC >27 was associated with 
clinical outcomes, but not MVO or myocardial haemorrhage. CFR ≤2.0 was not associated 
with MVO, myocardial haemorrhage, or clinical outcomes. Compared with CFR, RRR 























Invasive parameters, measured acutely in the infarct-related artery, during primary PCI can 
potentially be used to enable stratified medicine, which is the identification of patient sub-
groups that are distinguishable from a heterogenous population by disease severity and 
potential response to treatments269. Early and accurate identification of acute microvascular 
injury in the catheterisation laboratory allows potential for early administration of targeted 
adjunctive therapies to the highest risk patients, before irreversible microvascular damage 
occurs. Furthermore, during primary PCI, invasive parameters measured acutely in the 
infarct-related artery, have potential to refine future clinical trial design, by enabling 
selection of higher risk STEMI patients with evidence of microvascular injury for 
adjunctive treatments292. 
 
In STEMI patients, MPG ≤1 at the end of PCI is associated with the presence of MVO on 
CMR imaging131 and with mortality125 132. However, MPG as an angiographic surrogate 
measure of failed myocardial reperfusion has limitations: (i) it requires evaluation by an 
experienced observer for accurate interpretation116, (ii) it has relatively high inter-rater 
variability116, and (iii) it has limited specificity, since MPG ≥2 is not synonymous with 
adequate microvascular perfusion103 131. Increased TFC provides a quantitative, measure to 
assess coronary flow, and has relatively good inter-rater reproducibility117 118 126. A TFC 
≤27 in the infarct-related artery is considered normal120-123. A limitation is that the 
prognostic value of TFC is unclear. A higher TFC following thrombolysis for STEMI 
independently predicted mortality in some studies121 124, whereas in other studies higher 
TFC was not multivariably associated with mortality125 126. Moreover, TFC is increased 
(confounded) by the use of intracoronary nitrates118 119. 
 
Higher IMR values indicate greater degrees of microvascular dysfunction156 164, and an 
IMR >40 predicts death, heart failure hospitalisations and MI149 164. CFR reflects epicardial 
and microcirculatory vasodilator capacity, as well as residual epicardial stenosis. A lower 
CFR predicts MVO, however, when compared to IMR >40, the combination of IMR>40 
and CFR ≤2.0 did not add incremental prognostic value149. RRR is a newer invasive 
coronary physiology parameter, with no established cut-off value for normal/ abnormal. 
RRR evaluates the vasodilatory capacity of the coronary microcirculation and, therefore, 
the ability of the microcirculation to appropriately increase myocardial blood flow. 
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Specifically, RRR reflects the ability of the coronary microcirculation to vary its resistance 
in response to adenosine, i.e. a hyperaemic stimulus194. Higher RRR values signify greater 
vasodilatation of the microcirculation in response to hyperaemia, whereas lower RRR 
values signify poor vasodilator capacity of the coronary microcirculation. Lower RRR is 
associated with more MVO on CMR imaging197. Furthermore, lower RRR measured in 
patients with stable ischaemic heart disease is associated with a composite of all-cause 
mortality, MI, or any revascularisation events during 5-year follow up195. The prognostic 
significance of RRR in acute STEMI is unknown. 
 
The aim of the present study was to compare the associations of IMR, CFR, RRR, MPG 
and TFC, with MVO (a reference surrogate measure of failed myocardial perfusion), 
myocardial haemorrhage (a secondary irreversible manifestation of persistent MVO) and 
clinical outcomes.  
 
The following hypotheses were evaluated: 
1) Higher IMR and TFC, and lower CFR, RRR and MPG at the end of primary PCI 
are associated with MVO and myocardial haemorrhage on CMR imaging. 
 
2) Lower RRR at the end of primary PCI is more closely associated with MVO and 
myocardial haemorrhage on CMR imaging, than lower CFR. 
 
3) Higher IMR and TFC, and lower CFR, RRR and MPG at the end of primary PCI 
are associated with increased rates of MACE, heart failure hospitalisation, and the 
combination of all-cause death/ heart failure hospitalisation 
5.3 Methods 
The design, population, data acquisition, and angiographic, ECG and CMR analyses for the 
T-TIME physiology sub-study was described in sections 2.1, 2.2, and Figure 2.2. 
5.3.1 Clinical outcomes 
All serious adverse events were prospectively reported to the Pharmacovigilance Unit, by 
site research staff. These events were initially screened by blinded investigators for 
forwarding to the clinical events committee. The events were then reviewed and 
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adjudicated by the clinical events committee, comprising 3 cardiologists who were blinded 
and independent of the trial. There was a pre-defined clinical events committee charter 
(Appendix 9). Clinical events were assessed at 1-year and clinical follow up was 
completed for all patients. 
 
The prespecified clinical outcomes for this study were pathophysiologically linked with the 
natural history of STEMI. The clinical outcomes were: hospitalisation for heart failure; all-
cause death/ hospitalisation for heart failure, and; MACE, defined as cardiac death, non-
fatal MI, or hospitalisation for heart failure.  
 
Hospitalisation for heart failure was defined as follows: (i) new/ worsening heart failure 
signs/ symptoms requiring initiation of, or increase in heart failure directed treatment, or 
occurring in a patient already receiving maximal heart failure therapy, or; (ii) confinement 
to bed predominantly due to heart failure symptoms, or; (iii) pulmonary oedema sufficient 
to cause increased respiratory rate and distress (not occurring concurrently with an acute 
MI, or worsening kidney function [that is not completely explained by worsening heart 
failure], or as the consequence of arrythmia without worsening heart failure), or; (iv) 
cardiogenic shock. 
5.3.2 Statistical analysis 
Categorical variables were reported as frequency and percentages. Continuous data were 
summarised using means if normally distributed, or medians if skewed. The associations 
between invasive parameters and MVO or myocardial haemorrhage extent were assessed 
by linear regression and were adjusted for the following covariates: CFR ≤2, RRR ≤1.7 
(median value), IMR >40, TFC >27 and MPG ≤1 (all measured at the end of the primary 
PCI procedure). There was a priori concern that these covariates were clinically relevant 
confounders. The reason for not including continuous coronary physiology parameters as 
covariates together in the same model was due to collinearity. In linear regression models, 
square root transformation was applied to MVO to improve model residual distributions. 
The regression coefficients reported from linear regression represent mean change in the 
extent of the endpoint for a 1-unit increase in the predictor. The incremental predictive 
ability of RRR was assessed using the continuous net reclassification improvement375. 
Spearman rank coefficients were used to assess correlations. 
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Receiver operating characteristic (ROC) curve analysis was undertaken to investigate the 
relationships between IMR, CFR, RRR, or TFC, with MVO, and myocardial haemorrhage 
absence/ presence, and clinical outcomes. Optimal thresholds for predicting MVO, 
myocardial haemorrhage and clinical outcomes were derived from the ROC curves. In this, 
sensitivity and specificity were considered equally important, therefore the optimal cut-off 
was considered as the one giving the maximum Youden index. ROC comparisons were 
made using the DeLong method376.  
 
The associations with clinical outcomes were evaluated by calculating ORs, derived from 
logistic regression. A preponderance of heart failure episodes occurred during the index 
hospitalisation, therefore the assumptions for the Cox proportional hazards regression 
model for constant effects over time was not met.  
 
All tests were 2-tailed and a p-value of <0.05 was considered statistically significant. There 
was no imputation for missing values and no adjustments for multiple statistical 
comparisons. Statistical analyses were performed in SPSS (version 25.0, SPSS IBM, 
Armonk, NY, USA), and MedCalc Statistical Software version 18 (MedCalc Software, 
Ostend, Belgium). The net reclassification improvement was calculated using the package 
PredictABEL in R (version 3.4.3, R Development Core Team, California, USA). 
5.4 Results 
The population and procedure characteristics for the T-TIME coronary physiology sub-
study have been described in section 4.4.2, Tables 4.1 to 4.3 and Figure 4.2. 
5.4.1 Associations with invasive parameters 
Among the 144 patients, 57 (40%) had IMR>40, 115 (80%) had CFR ≤2, 77 (54%) had 
RRR ≤1.7, 29 (20%) had TFC >27 and 45 (31%) had MPG ≤1. 
 
The characteristics that were associated with higher IMR, on multivariable linear 
regression, were: TIMI flow grade post-PCI ≤2 (p=0.026), MPG ≤1 post-PCI (p=0.016) 
and RRR ≤1.7 (p=0.009). The characteristics that were associated with lower RRR were: 
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CFR ≤2.0 (p<0.001) and IMR >40 (p=0.034). The only characteristic that was associated 
with lower CFR, on multivariable linear regression analysis, was RRR ≤1.7 (p<0.001).  
 
The characteristics that were associated with higher TFC, on multivariable linear 
regression, were hypertension (p=0.028), lower estimated glomerular filtration rate 
(p=0.011), and TIMI flow grade post-PCI ≤2 (p<0.001). The characteristics that were 
associated with MPG ≤1 on multivariable logistic regression were lower estimated 
glomerular filtration rate (p=0.019), infarct-related artery (LAD vs. LCx vs. RCA) 
(p<0.001), TIMI flow grade post-PCI ≤2 (p=0.043) and IMR >40 (p=0.023). 
 
IMR was correlated with RRR (r= -0.32, p=0.0001), CFR (r= -0.30, p=0.0002) and TFC 
(r=0.59, p<0.0001). CFR was correlated with RRR (r=0.94, p<0.001) (Figure 5.1), but not 
with TFC (r= -0.05, p=0.549). There was no statistically significant correlation between 
RRR and TFC (r= -0.06, p=0.465) (Figure 5.2). 
 
When CFR was dichotomized by 2, RRR by 1.7 and IMR by 40, discordance between CFR 
and RRR occurred in 38 patients (26.4%), discordance between CFR and IMR occurred in 
66 patients (45.9%), and discordance between RRR and IMR occurred in 50 patients 
(34.7%) (Figure 5.1). When RRR was dichotomised by 2 the results were broadly similar 












Figure 5.1 Scatterplots showing correlations between: A, CFR and RRR; B, IMR and CFR; and C, 
IMR and RRR. Also shown is discordance between dichotomised coronary physiology parameters 
(CFR ≤2.0, RRR ≤1.7, IMR >40) and presence/ absence of MVO. Reproduced with permission 
from Maznyczka AM et al. Comparative significance of invasive measures of microvascular injury 





Figure 5.2 Scatterplots showing correlations between: (i) TFC and IMR, (ii) TFC and 





Figure 5.3 Scatterplots showing correlations between: A, CFR and RRR; and B, IMR and 
RRR. Also shown is discordance between dichotomised coronary physiology parameters 
(CFR ≤2.0, RRR ≤2.0, IMR >40) and presence/ absence of MVO. Reproduced with 
permission from Maznyczka AM et al. Comparative significance of invasive measures of 
microvascular injury in acute myocardial infarction. Circ Cardiovasc Interv. 2020.13(5) 




5.4.2 Association of invasive parameters with MVO 
IMR 
Higher IMR measured acutely correlated with more MVO (Figure 5.4). Among the 140 
patients who had CMR imaging 2 to 7 days post-PCI, IMR was >40 in 55, of whom 32 
(58%) had MVO present, and IMR was ≤40 in 85, of whom 25 (29%) had MVO present.  
 
The optimal IMR threshold from the AUC for predicting MVO presence was >40 (Figure 
5.5). IMR >40 was multivariably associated with larger MVO extent (coefficient: 0.54 
[95% CI: 0.05, 1.03]) p=0.030) and higher incidence of MVO (OR: 2.67 [95% CI: 1.11, 
6.39] p=0.028), independently of CFR ≤2.0, RRR ≤1.7, TFC >27 and MPG ≤1 (Table 5.1). 
Continuous IMR, or IMR dichotomised by 30 (median value) were not multivariable 
predictors of MVO (Tables 5.1 and 5.2). 
CFR 
Lower CFR measured acutely correlated with more MVO (Figure 5.4). Among the patients 
who had CMR imaging 2 to 7 days post-PCI, CFR was ≤2.0 in 112, of whom 47 (42%) 
had MVO present, and CFR was >2.0 in 28, of whom 10 (36%) had MVO present.  
 
Continuous CFR, CFR ≤2.0 or CFR dichotomised by median value (1.4) were not 
multivariable predictors of MVO (Tables 5.1 and 5.2). The optimal CFR threshold from 
the AUC for predicting MVO presence was ≤1.2 (Figure 5.5). CFR ≤1.2 was multivariably 
associated with larger MVO extent (coefficient: 0.60 [95% CI: 0.03, 1.17] p=0.039) and 
MVO presence (OR: 3.12 [95% CI: 1.06, 9.19) p=0.039) (Table 5.2).  
RRR 
Lower RRR measured acutely correlated with more MVO (Figure 5.4). Among the patients 
who had CMR imaging 2 to 7 days post-PCI, RRR was ≤1.7 (median value) in 75, of 
whom 37 (49%) had MVO present, and RRR was >1.7 in 65, of whom 20 (31%) had 
MVO present.  
 
The optimal RRR threshold from the AUC for predicting MVO presence was ≤1.5 (Figure 
5.5). RRR ≤1.5 was multivariably associated with larger MVO extent (coefficient: 0.91 
[95% CI: 0.46, 1.35] p<0.001) and MVO presence (OR: 4.66 [95% CI: 1.89, 11.47) 
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p=0.001) (Table 5.2). Lower continuous RRR was also multivariably associated with 
larger MVO extent (coefficient: -0.61 [95% CI: -0.98, -0.23] p=0.002) and MVO presence 
(OR: 0.32 [95% CI: 0.14, 0.73) p=0.006) (Table 5.1). RRR ≤1.7 was a multivariable 
associate of larger MVO extent, but not MVO presence (Table 5.1).  
 
The overall net reclassification improvement, reflecting the incremental predictive 
accuracy for detecting the presence of MVO, was 0.34 (95% CI: 0.06, 0.61, p=0.018) when 
RRR ≤1.7 was added to a baseline model containing CFR ≤2.0. When continuous RRR 
was added to a baseline model containing CFR ≤2.0 the net reclassification improvement 
for detecting MVO presence was 0.66 (95% CI: 0.36, 0.95, p<0.001). When the baseline 
model incorporated IMR >40, the overall net reclassification improvement for detecting 
the presence of MVO was 0.38 (95% CI: 0.05, 0.70, p=0.025) when RRR ≤1.7 was added, 
and was 0.29 (95% CI: -0.02, 0.59, p=0.068) when continuous RRR was added. 
RRR and CFR in Combination 
Compared with RRR >1.7 and CFR ≤2.0 combined (reference group), the group with the 
combination of RRR ≤1.7 and CFR ≤2.0 was associated with an increased odds of MVO 
presence (37/75 [40.3%] vs. 10/37 [27.0%]; OR, 2.63 [95% CI, 1.12, 6.18] p=0.027), and 
increased MVO extent (0.0 [IQR: 0.0 – 5.3] vs. 0.0 [IQR: 0.0-0.8]; coefficient, 0.74 [95% 
CI, 0.22, 1.25] p=0.006). 
TFC 
There was no statistically significant correlation between TFC and MVO (Figure 5.4). 
Among the patients who had CMR imaging 2 to 7 days post-PCI, TFC was >27 in 28, of 
whom 14 (50%) had MVO present. Among the patients who had CMR imaging 2 to 7 days 
post-PCI, TFC was ≤27 in 112, of whom 43 (38%) had MVO present.  
 
The optimal TFC threshold from the AUC for predicting MVO presence was >22 (Figure 
5.5).  Continuous TFC, or TFC dichotomised by 22 (median value), 18, or 27 was not 
multivariably associated with MVO (Tables 5.1 and 5.2). 
MPG 
Among the patients who had CMR imaging 2 to 7 days post-PCI, MPG was ≤1 in 44 
patients, of whom 28 (64%) had MVO present. Among the patients who had CMR imaging 
2 to 7 days post-PCI, MPG was >1 in 96 patients, of whom 29 (30%) had MVO present. 
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MPG ≤1 was multivariably associated with larger MVO extent (coefficient: 0.53 [95% CI: 




Figure 5.4 Scatterplots showing correlations between IMR, RRR, CFR and TFC, with 





Figure 5.5 ROC curves showing the performance of IMR, CFR, RRR and TFC for 




    
    
       Association with MVO extent (% LV) (n=140)  Association with MVO presence (n=140) 
 Univariable Multivariable  Univariable Multivariable 
Continuous IMR* 0.01 (0.01, 0.02) p=0.001 0.01 (-0.00, 0.01) p=0.077  1.01 (1.00, 1.02) p=0.024 1.01 (0.99, 1.02) p=0.460 
IMR >40*  0.78 (0.36, 1.20) p<0.001 0.54 (0.05, 1.03) p=0.030  3.34 (1.64, 6.80) p=0.001 2.67 (1.11, 6.39) p=0.028 
Continuous CFR† -0.50 (-0.81, -0.18) p=0.002 -0.11 (-0.60, 0.38) p=0.654  0.52 (0.29, 0.93) p=0.028 0.92 (0.35, 2.40) p=0.856 
CFR £2.0† 0.35 (-0.19, 0.88) p=0.200 -0.30 (-0.90, 0.30) p=0.325  1.30 (0.55, 3.07) p=0.548 0.45 (0.14, 1.42) p=0.173 
Continuous RRR‡ -0.45 (-0.69, -0.20) p<0.001 -0.61 (-0.98, -0.23) p=0.002  0.51 (0.31, 0.83) p=0.007 0.32 (0.14, 0.73) p=0.006 
RRR £1.7 (median)‡ 0.67 (0.26, 1.09) p=0.002 0.60 (0.11, 1.09) p=0.017  2.19 (1.09, 4.39) p=0.027 2.35 (0.92, 5.97) p=0.074 
Continuous TFC 0.01 (-0.01, 0.03) p=0.208 -0.01 (-0.02, 0.01) p=0.520  1.01 (0.99, 1.04) p=0.389 0.98 (0.95, 1.01) p=0.203 
TFC >27 § 0.38 (-0.15, 0.91) p=0.162 -0.19 (-0.75, 0.37) p=0.493  1.61 (0.70, 3.69) p=0.266 0.56 (0.20, 1.58) p=0.275 
MPG £1 || 0.71 (0.27, 1.16) p=0.002 0.53 (0.07, 1.00) p=0.026  4.04 (1.90, 8.59) p<0.001 3.61 (1.56, 8.38) p=0.003 
 
Table 5.1 Associations of invasive parameters with the extent of MVO, from linear regression and with MVO presence from logistic regression. Results 
are reported as regression coefficient or OR (95% CI) and p-value. MVO extent (2 to 7 days post-PCI) was analysed on a square root scale.                                                                                                                                                                                                                                                
* Covariates in multivariable analyses for association of IMR with MVO: CFR ≤2.0, RRR ≤1.7, TFC >27 and MPG £1.                                                             
† Covariates in multivariable analyses for association of CFR with MVO: IMR >40, RRR ≤1.7, TFC >27 and MPG £1.                                                               
‡ Covariates in multivariable analyses for association of RRR with MVO: IMR >40, CFR ≤2.0, TFC >27 and MPG£1.                                                               
§ Covariates in multivariable analyses for association of TFC with MVO: IMR >40, CFR ≤2.0, RRR ≤1.7 and MPG £1.                                                                




    
 Association with MVO extent (% LV) (n=140)  Association with MVO presence (n=140) 
 Univariable Multivariable  Univariable Multivariable 
IMR>30 (median)* 0.43 (0.01, 0.85) p=0.045 0.10 (-0.37, 0.56) p=0.687  1.76 (0.89, 3.47) p=0.105 1.11 (0.48, 2.53) p=0.814 
      
CFR£1.2 (optimal threshold from AUC)† 0.85 (0.44, 1.27) p<0.001 0.60 (0.03, 1.17) p=0.039  3.31 (1.62, 6.75) p=0.001 3.12 (1.06, 9.19) p=0.039 
CFR£1.4 (median)† 0.65 (0.23, 1.06) p=0.002 0.35 (-0.74, 1.43) p=0.528  2.09 (1.04, 4.18) p=0.038 1.65 (0.24, 11.15) p=0.610 
      
RRR£1.5 (optimal threshold from AUC)‡ 0.98 (0.57, 1.38) p<0.001 0.91 (0.46, 1.35) p<0.001  3.86 (1.89, 7.88) p<0.001 4.66 (1.89, 11.47) p=0.001 
      
TFC >22 (Optimal threshold from AUC) § 0.60 (0.17, 1.03) p=0.007 0.17 (-0.33, 0.66) p=0.508  1.84 (0.92, 3.69) p=0.087 0.77 (0.31, 1.92) p=0.772 
TFC >18 (median) § 0.44 (0.02, 0.86) p=0.040 0.06 (-0.39, 0.51) p=0.797  1.52 (0.77, 3.00) p=0.224 2.25 (0.89, 5.68) p=0.451 
 
Table 5.2 Associations of invasive parameters with the extent of MVO, from linear regression and with MVO presence from logistic regression. Different 
dichotomisations for IMR, CFR, RRR and TFC are shown, including according to median values and according to the optimal thresholds from AUCs. 
Results are reported as regression coefficient or OR (95% CI) and p-value. MVO extent (2 to 7 days post-PCI) was analysed on square root scales.                                                                                                                                                                                                                        
* Covariates in multivariable analyses for association of IMR with MVO: CFR ≤2.0, RRR ≤1.7, TFC >27 and MPG £1.                                                              
† Covariates in multivariable analyses for association of CFR with MVO: IMR >40, RRR ≤1.7, TFC >27 and MPG £1.                                                             
‡ Covariates in multivariable analyses for association of RRR with MVO: IMR >40, CFR ≤2.0, TFC >27 and MPG £1.                                                              
§ Covariates in multivariable analyses for association of corrected TFC post-PCI with MVO: IMR >40, CFR ≤2.0, RRR ≤1.7 and MPG £1. 
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5.4.3 Association of invasive parameters with myocardial haemorrhage 
IMR 
There was no statistically significant correlation between IMR and myocardial 
haemorrhage extent (Figure 5.4). IMR >40 was multivariable associated with myocardial 
haemorrhage presence (OR: 2.67 [95% CI: 1.10, 6.51] p=0.031], but not myocardial 
haemorrhage extent (coefficient: 0.96 [95% CI: -0.67, 2.60] p=0.246) (Table 5.3). 
Continuous IMR, or IMR dichotomised by 30 (median value) were not multivariably 
associated with myocardial haemorrhage (Tables 5.3 and 5.4). 
CFR 
Lower CFR was correlated with more myocardial haemorrhage (Figure 5.4).  However, 
CFR ≤2.0, CFR ≤1.2 (optimal threshold from AUC), CFR ≤1.4 (median value) and 
continuous CFR were not multivariably associated with myocardial haemorrhage (Tables 
5.3and 5.4). 
RRR 
Lower RRR was correlated with more myocardial haemorrhage (Figure 5.4). RRR ≤1.5 
(optimal threshold from AUC) was multivariably associated with larger myocardial 
haemorrhage extent (coefficient: 2.30 [95% CI: 0.77, 3.83] p=0.004) and myocardial 
haemorrhage presence (OR: 4.06 [95% CI: 1.65, 10.04] p=0.002).  
 
Lower continuous RRR was also multivariably associated with larger myocardial 
haemorrhage extent (coefficient: -1.49 [95% CI: -2.71, -0.27] p=0.017) and myocardial 
haemorrhage presence (OR: 0.34 [95% CI: 0.15, 0.75] p=0.008). RRR ≤1.7 was 
multivariably associated with larger myocardial haemorrhage extent, but not myocardial 
haemorrhage presence (Table 5.3). 
 
The overall net reclassification improvement, reflecting the incremental predictive 
accuracy for detecting the presence of myocardial haemorrhage was 0.34 (95% CI: 0.05, 
0.52 [p=0.021]), when RRR ≤1.7 was added to a baseline model containing CFR ≤2.0. 
When continuous RRR was added to a baseline line incorporating CFR ≤2.0, the net 
reclassification improvement for detecting myocardial haemorrhage presence was 0.62 
(95% CI: 0.32, 0.91 [p<0.001]).  
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When the baseline model incorporated IMR >40, the overall net reclassification 
improvement for detecting the presence of myocardial haemorrhage was 0.39 (95% CI: 
0.04, 0.72 [p=0.026]) when RRR ≤1.7 was added, and was 0.25 (95% CI: -0.07,0.56 
[p=0.131]) when continuous RRR was added. 
CFR and RRR in combination 
Compared with RRR >1.7 and CFR ≤2.0 combined (reference group), the group with the 
combination of RRR ≤1.7 and CFR ≤2.0 was associated with increased odds of myocardial 
haemorrhage presence (36/72 [50.0%] vs. 10/36 [27.8%]; OR, 2.60 [95% CI, 1.10, 6.17] 
p=0.030), and with increased myocardial haemorrhage extent (0.00 [IQR: 0.0 - 4.6] vs. 0.0 
[IQR: 0.0 - 0.2]; coefficient, 1.85 [95% CI: 0.11, 3.58] p=0.037). 
TFC 
There was no statistically significant correlation between TFC and myocardial 
haemorrhage extent (Figure 5.4). Neither continuous TFC, TFC >27, TFC >22 (optimal 
from AUC), or TFC >18 (median value) were associated with myocardial haemorrhage 
(Tables 5.3 and 5.4). 
MPG 
MPG ≤1 was multivariably associated with the presence of myocardial haemorrhage (OR: 
3.15 [95% CI: 1.35, 7.35] p=0.008), but not with myocardial haemorrhage extent 
(coefficient: 0.43 [95% CI: -1.16, 2.01] p=0.594) (Table 5.3).
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   Association with myocardial haemorrhage extent (% LV) (n=131)    Association with myocardial haemorrhage presence (n=136) 
 Univariable Multivariable  Univariable Multivariable 
Continuous IMR* 0.03 (0.01, 0.05) p=0.014 0.02 (-0.01, 0.04) p=0.132  1.01 (1.00, 1.02) p=0.090 1.00 (0.99, 1.01) p=0.901 
IMR >40*  1.46 (0.09, 2.83) p=0.037 0.96 (-0.67, 2.60) p=0.246  3.27 (1.59, 6.72) p=0.001 2.67 (1.10, 6.51) p=0.031 
Continuous CFR† -1.32 (-2.32, -0.33) p=0.009 -0.50 (-2.09, 1.10) p=0.539  0.52 (0.29, 0.93) p=0.028 0.90 (0.34, 2.37) p=0.835 
CFR £2.0†  1.16 (-0.48, 2.80) p=0.165 -0.30 (-2.26, 1.67) p=0.766  1.34 (0.56, 0.32) p=0.511 0.48 (0.15, 1.51) p=0.207 
Continuous RRR‡ -1.13 (-1.90, -0.36) p=0.004 -1.49 (-2.71, -0.27) p=0.017  0.51 (0.31, 0.83) p=0.007 0.34 (0.15, 0.75) p=0.008 
RRR £1.7 (median)‡ 1.82 (0.50, 3.14) p=0.007 1.66 (0.30, 3.28) p=0.046  2.20 (1.09, 4.44) p=0.028 2.29 (0.90, 5.83) p=0.083 
Continuous TFC 0.02 (-0.04, 0.08) p=0.491 -0.02 (-0.09, 0.05) p=0.589  1.01 (0.98, 1.04) p=0.397 0.97 (0.93, 1.01) p=0.091 
TFC >27 § 0.73 (-1.05, 2.50) p=0.420 -0.32 (-2.24, 1.60) p=0.743  1.56 (0.66, 3.68) p=0.312 0.54 (0.18, 1.56) p=0.253 
MPG £1 || 0.90 (-0.58, 2.37) p=0.231 0.43 (-1.16, 2.01) p=0.594  3.72 (1.75, 7.95) p=0.001 3.15 (1.35, 7.35) p=0.008 
 
Table 5.3 Associations of invasive parameters with the extent of myocardial haemorrhage (2 to 7 days post-PCI), from linear regression and with 
myocardial haemorrhage presence from logistic regression. Results are reported as regression coefficient or OR (95% CI) and p-value.   
* Covariates in multivariable analyses for association of IMR with myocardial haemorrhage: CFR ≤2.0, RRR ≤1.7, TFC >27 and MPG £1.                                            
† Covariates in multivariable analyses for association of CFR with myocardial haemorrhage: IMR >40, RRR ≤1.7, TFC >27 and MPG £1.                                            
‡ Covariates in multivariable analyses for association of RRR with myocardial haemorrhage: IMR >40, CFR ≤2.0, TFC >27 and MPG£1.                                             
§ Covariates in multivariable analyses for association of TFC with myocardial haemorrhage: IMR >40, CFR ≤2.0, RRR ≤1.7 and MPG £1.                                           




    
 Association with myocardial haemorrhage extent (% LV) (n=131)  Association with myocardial haemorrhage presence (n=136) 
 Univariable Multivariable  Univariable Multivariable 
IMR>30 (median)* 0.64 (-0.72, 1.99) p=0.353 -0.15 (-1.70, 1.40) p=0.848  1.68 (0.84, 3.34) p=0.141 1.05 (0.45, 2.44) p=0.907 
      
CFR£1.2 (optimal threshold from AUC)† 2.00 (0.63, 3.37) p=0.005 1.16 (-0.76, 3.08) p=0.234  3.24 (1.57, 6.69) p=0.001 2.85 (0.96, 8.48) p=0.059 
CFR£1.4 (median)† 1.76 (0.44, 3.08) p=0.010 0.76 (-2.73, 4.25) p=0.667  2.09 (1.04, 4.22) p=0.039 1.58 (0.24, 10.59) p=0.638 
      
RRR£1.5 (optimal threshold from AUC)‡ 2.44 (1.12 3.76) p<0.001 2.30 (0.77, 3.83) p=0.004  3.56 (1.73, 7.30) p=0.001 4.06 (1.65, 10.04) p=0.002 
      
TFC >22 (optimal threshold from AUC) § 1.76 (0.39, 3.13) p=0.012 1.29 (-0.36, 2.93) p=0.124  1.77 (0.87, 3.60) p=0.112 0.74 (0.29, 1.88) p=0.530 
TFC >18 (median) § 1.20 (-0.15, 2.54) p=0.080 0.62 (-0.87, 2.11) p=0.412  1.45 (0.73, 2.89) p=0.286 0.69 (0.30, 1.61) p=0.396 
 
Table 5.4 Associations of invasive parameters with the extent of myocardial haemorrhage (2 to 7 days post-PCI), from linear regression and with 
myocardial haemorrhage presence from logistic regression. Different dichotomisations for IMR, CFR, RRR and TFC are shown, including according to 
median values and according to the optimal thresholds from AUCs. Results are reported as regression coefficient or OR (95% CI) and p-value.  
* Covariates in multivariable analyses for association of IMR with myocardial haemorrhage: CFR ≤2.0, RRR ≤1.7, TFC >27 and MPG £1.                                                              
† Covariates in multivariable analyses for association of CFR with myocardial haemorrhage: IMR >40, RRR ≤1.7, TFC >27 and MPG £1.                                                             
‡ Covariates in multivariable analyses for association of RRR with myocardial haemorrhage: IMR >40, CFR ≤2.0, TFC >27 and MPG £1.                                                              




5.4.4 Association of invasive parameters with clinical outcomes 
At 1-year follow up, there were 19 adjudicated hospitalisations for heart failure, 22 for all-
cause death/ heart failure hospitalisations, and 23 MACE events.  
IMR 
In patients with IMR >40, heart failure hospitalisations occurred in 14 patients (24.6%) at 
1 year, death/ heart failure hospitalisation occurred in 15 patients (26.3%), and MACE 
occurred in 16 (28.1%) patients. The optimal IMR threshold from the AUC for predicting 
clinical outcomes was 44 (Figure 5.6). Higher continuous IMR, IMR >40, IMR >44, and 
IMR >30 (median value), were all associated with heart failure hospitalisations, all-cause 
death/ heart failure hospitalisation, and MACE (Table 5.5).  
CFR 
In patients with CFR ≤2.0, heart failure hospitalisations occurred in 18 patients (15.7%), 
death/ heart failure hospitalisation occurred in 20 patients (17.4%) and MACE occurred in 
21 patients (18.3%). Neither continuous CFR, CFR ≤2.0, nor CFR ≤1.4 (median value) 
were associated with clinical outcomes. The optimal CFR threshold was ≤1.8 for 
predicting heart failure hospitalisation (OR: 8.47 [95% CI: 1.09, 65.70] p=0.041). The 
optimal CFR threshold was ≤1.3 for predicting all-cause death/ heart failure hospitalisation 
(OR: 2.89 [95% CI: 1.1.0, 7.58] p=0.032) (Figure 5.6). The optimal CFR threshold from 
the AUC for predicting MACE was ≤1.3 (Figure 5.6), however on logistic regression 
analysis CFR ≤1.3 was not associated with MACE (OR: 2.49 [95% CI: 0.98, 6.31] 
p=0.055).  
RRR 
In patients with RRR ≤1.7, heart failure hospitalisations occurred in 14 (18.2%) patients, 
death/ heart failure hospitalisation occurred in 16 (20.8%) patients, and MACE occurred in 
16 (20.8%) patients. The optimal RRR threshold from the AUC for predicting heart failure 
hospitalisations was ≤1.6 (Figure5.5) (OR: 3.23 [95% CI: 1.10, 9.52] p=0.033). The 
optimal RRR threshold for predicting all-cause death/ heart failure hospitalisations was 
also ≤1.6 (OR: 3.14 [95% CI:1.15, 8.57] p=0.025). The optimal RRR threshold for 
predicting MACE was ≤2.2 (OR: 4.99 [95% CI: 1.12, 22.37] p=0.036). Lower continuous 
RRR was associated with heart failure hospitalisations, but was not associated with all-
cause death/ heart failure hospitalisations, or MACE (Table 5.5). RRR ≤1.7 was not 
associated with clinical outcomes. 
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CFR and RRR in combination 
RRR ≤1.7 and CFR ≤2.0 combined did not enhance the prognostic significance of RRR 
>1.7 and CFR ≤2.0 combined, for association with heart failure hospitalisations (14/77 
[18.2%] vs. 4/38 [10.5%]; OR, 1.89 [95% CI: 0.58, 6.19] p=0.294), death/ heart failure 
hospitalisations (16/77 [20.8%] vs. 4/38 [10.5%]; OR, 2.23 [95% CI: 0.69, 7.21] p=0.180), 
or MACE (16/77 [20.8%] vs. 5/38 [13.2%]; OR, 1.73 [95% CI: 0.58, 5.15] p=0.324). 
TFC 
Higher continuous TFC, TFC >27, TFC >26 (optimal threshold from AUC), and TFC >18 
(median value) were all associated with heart failure hospitalisations, all-cause death/ heart 
failure hospitalisation, and MACE (Table 5.5).  
MPG 
MPG <1 was associated with heart failure hospitalisations, all-cause death/ heart failure 




Figure 5.6 ROC curves showing the performance of IMR, CFR, RRR and TFC for 





      
 Heart failure hospitalisation 
 (n=19 events) 
 All-cause death & heart failure hospitalisation combined 
(22 events) 
 Major adverse cardiac events  
(n=23 events) 
 Crude OR (95% CI) p-value  Crude OR (95% CI) p-value  Crude OR (95% CI) p-value 
Continuous IMR 1.02 (1.01, 1.04) p<0.001  1.02 (1.01, 1.03) p=0.001  1.02 (1.01, 1.03) p=0.001 
IMR >40  
IMR >44 (optimal threshold from AUC) 
5.34 (1.80, 15.81) p=0.002 
6.92 (2.32, 20.63) p=0.001 
 4.08 (1.55, 10.79) p=0.005 
5.33 (2.00, 14.18) p=0.001 
 4.46 (1.70, 11.70) p=0.002  
5.85 (2.21, 15.47) p<0.001 
IMR >30 (median) 3.56 (1.21, 10.50) p=0.021  2.70 (1.03, 7.09) p=0.044  2.93 (1.13, 7.64) p=0.028 
Continuous CFR 0.39 (0.15, 1.04) p=0.060  0.48 (0.20, 1.14) p=0.097  0.57 (0.26, 1.28) p=0.174 
CFR £2.0 5.20 (0.66, 40.65) p=0.116  0.35 (0.08, 1.60) p=0.177  3.02 (0.67, 13.68) p=0.152 
CFR£ optimal threshold from AUC* 8.47 (1.09, 65.70) p=0.041  2.89 (1.10, 7.58) p=0.032  2.49 (0.98, 6.31) p=0.055 
CFR £1.4 (median) 2.67 (0.91, 7.86) p=0.075  2.58 (0.95, 7.04) p=0.064  2.18 (0.84, 5.66) p=0.112 
Continuous RRR 0.44 (0.19, 0.99) p=0.047  0.55 (0.28, 1.10) p=0.092  0.59 (0.31, 1.14) p=0.119 
RRR £optimal threshold from AUC† 3.23 (1.10, 9.52) p=0.033  3.14 (1.15, 8.57) p=0.025  4.99 (1.12, 22.37) p=0.036 
RRR £1.7 (median) 2.76 (0.94, 8.11) p=0.066  2.67 (0.98, 7.27) p=0.055  2.25 (0.86, 5.85) p=0.097 
Continuous TFC 1.04 (1.01, 1.07) p=0.007  1.05 (1.02, 1.09) p=0.002  1.05 (1.02, 1.08) p=0.002 
TFC >27 6.20 (2.23, 17.27) p<0.001  5.78 (2.18, 15.30) p<0.001  5.25 (2.01, 13.69) p=0.001 
TFC >26 (optimal threshold from AUC) 6.20 (2.23, 17.27) p<0.001  5.78 (2.18, 15.30) p<0.001  5.25 (2.01, 13.69) p=0.001 
TFC >18 (median) 3.68 (1.25, 10.85) p=0.018  1.05 (1.02, 1.09) p=0.002  3.89 (1.43, 10.55) p=0.008 
MPG £1 4.78 (1.74, 13.17) p=0.002  3.24 (1.28, 8.20) p=0.013  2.91 (1.17, 7.23) p=0.022 
 
Table 5.5 Unadjusted odds ratios and 95% CI, from logistic regression, showing associations of invasive parameters with clinical outcomes at 1-year 
post-STEMI (n=144). Different dichotomisations for IMR, CFR, RRR and TFC are shown, including according to median values and according to the 
optimal thresholds from AUCs.                                                                                                                                                                                              
*CFR £1.8 was the optimal threshold from AUC for predicting heart failure hospitalisation; CFR £1.3 was the optimal threshold from AUC for all-cause 
death and heart failure hospitalisation; CFR £1.3 was the optimal threshold from AUC for MACE.                                                                                             
†RRR £1.6 was the optimal threshold from AUC for predicting heart failure hospitalisation; RRR £1.6 was optimal threshold from AUC for predicting 




The findings presented in this chapter provide novel insights into the comparative clinical 
significance of invasive measures of microvascular function during primary PCI. Lower 
RRR was consistently associated with more MVO, even when different dichotomisations 
were used, and RRR ≤1.7 had incremental predictive utility compared to CFR ≤2.0 or IMR 
>40. When CFR or IMR were dichotomised by the optimal thresholds from the AUC (≤1.2 
and >40 respectively), then these parameters were associated with more MVO. However, 
other thresholds, or continuous CFR and IMR, were not associated with MVO extent. 
MPG ≤1 predicted larger MVO extent, whereas TFC was not associated with MVO.  
 
Lower RRR was consistently associated with more myocardial haemorrhage, even when 
different dichotomisations were used, and RRR ≤1.7 had incremental predictive utility 
compared to CFR ≤2.0 or IMR >40. A higher incidence of myocardial haemorrhage was 
associated with IMR >40 or MPG ≤1. Myocardial haemorrhage was not associated with 
CFR or TFC. 
 
Lower IMR and higher TFC were consistently associated with all 3 types of clinical 
outcomes, even when different dichotomisations were tested. MPG ≤1 was also associated 
with all 3 types of clinical outcomes. Lower RRR (dichotomised by the optimal thresholds 
from the AUC) was associated with all 3 types of clinical outcomes. Lower continuous 
RRR was associated with heart failure hospitalisation, but not all-cause death/ heart failure 
hospitalisations or MACE. There was no association between CFR ≤2.0 and clinical 
outcomes. Lower CFR (dichotomised by the optimal threshold from the AUC) was 
associated with heart failure hospitalisations, and all-cause death/ heart failure 
hospitalisations, but was not associated with MACE. Other CFR thresholds, or continuous 
CFR was not associated with clinical outcomes. 
 
Different aspects of microvascular function are reflected by IMR and RRR. Given that 
IMR does not reflect microvascular vasodilator capacity, it may not reflect the full 
potential for the microcirculation to recover following reperfusion. On the other hand, 
RRR reflects vasodilator capacity of the coronary microcirculation, i.e. it is a measure of 
the capacity of the coronary microcirculation to change from baseline to hyperaemia, 
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reflecting the ability to achieve maximal hyperaemia194 197. RRR may be superior to IMR 
in its ability to integrate a changing resistance from resting to hyperaemic conditions, as 
opposed to a fixed or absolute resistance assessed by IMR.  
 
Compared with CFR, RRR was a better predictor of MVO and myocardial haemorrhage. 
Compared with CFR, RRR may better reflect the potential for the microcirculation to 
recover following reperfusion. RRR may provide additional information than what is 
obtained from currently available measures of microvascular function (CFR and IMR).  
The findings suggest that RRR may have potential as a superior tool compared with CFR 
to guide patient selection for adjunctive therapy.   
 
Although RRR and CFR were correlated, discordance between high and low dichotomised 
CFR and RRR values occurred in 38 patients (26%), indicating that these parameters have 
overlapping and distinct behaviours. Furthermore, differences were observed in the 
associations of CFR and RRR, with MVO, myocardial haemorrhage and clinical outcomes, 
implying that CFR and RRR do not have equivalent clinical significance.  
 
In a prior study consisting of 45 STEMI patients, RRR ≤1.98 (median for the cohort) at the 
end of primary PCI was associated with MVO extent 2 days following PCI197.  The results 
presented in this chapter add to the findings from the previous study197, by validating the 
findings in a larger cohort and showing that RRR is associated with clinical outcomes.  
 
The reliable identification of patients with high probability of having microvascular 
damage has the potential to identify patients in the catheterisation laboratory for adjunctive 
therapies and inclusion in therapeutic trials. A test that has a binary cut-off, to identify 
normal and abnormal patients, is generally helpful for patient stratification in the clinic and 
in therapeutic trials. However, the optimal threshold may vary between different 
populations and different endpoints of interest. Therefore, IMR, RRR, CFR and TFC were 
dichotomised according to optimal thresholds from the AUC and median values, in 




Discordance was observed between dichotomised IMR >40 and MVO presence in just 
over one third of patients (42%), which is similar to prior literature155. Discordance 
between RRR ≤1.7 and MVO presence occurred in 51% of patients. Discordance between 
CFR ≤2.0 and MVO presence occurred in 58% of patients. There may be several 
explanations. First the extent of MVO varies in patients who have MVO present. The 
highest IMRs, lowest CFRs and lowest RRRs generally correspond to greater amounts of 
MVO, hence one expects discordance when binary thresholds are applied. Second, 
microvascular dysfunction is dynamic within minutes to the first few days following 
reperfusion. When microvascular function is measured immediately after primary PCI, 
reversible oedema and microvascular spasm may contribute more to microvascular 
dysfunction, than on CMR imaging 2 to 7 days later, where irreversible microvascular 
injury (including myocardial haemorrhage) may persist.  
 
Although TFC was associated with clinical outcomes, it was not associated with MVO or 
myocardial haemorrhage. Therefore, the findings do not support the use of TFC as a 
theragnostic biomarker to select patients for adjunctive therapies aimed at limiting 
microvascular damage, or to evaluate the response of the microvasculature to therapies. 
  
Although MPG ≤1 was multivariably associated with MVO, myocardial haemorrhage, and 
clinical outcomes, it has limitations for clinical translation as a theragnostic biomarker to 
select patients for adjunctive therapies in the catheterisation laboratory and to evaluate 
response to therapies. This is because MPG is non-quantitative and requires evaluation by 
an experienced observer for accurate interpretation116. 
5.6 Limitations 
This study has many strengths, including: (i) independent adjudication of clinical events, 
(ii) core laboratory analyses, (iii) multicentre enrolment, and (iv) blinding of coronary 
physiology measurements to minimise bias. However, a limitation is that the T-TIME 
population was selected for participation in a clinical trial, and there was a relatively low 
number of clinical events, which limited power to detect statistically significant 
associations. Furthermore, these were all emergent PCI cases, hence the patients would not 
have withheld from caffeine, which could have affected response to adenosine377. 
Therefore, maximal hyperaemia could not be guaranteed in all of the patients. However, 
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these limitations apply to the previously published coronary physiology studies in the 
context of acute STEMI140 148 155 156. 
5.7 Future work 
Further research is needed to determine whether the findings can be replicated in an 
independent population of acute STEMI patients. Another possibility for future research 
could be to investigate whether RRR may have utility in the assessment of the 
microcirculation in patients with ischaemia and no obstructive coronary disease.  
5.8 Conclusions 
In conclusion, in STEMI patients presenting within 6 hours of symptom onset, lower 
continuous RRR, IMR >40 and MPG ≤1 were associated with more MVO, myocardial 
haemorrhage presence and clinical outcomes, whereas CFR ≤2.0 was not. TFC >27 was 
associated with clinical outcomes, but not MVO or myocardial haemorrhage. Compared 




Chapter 6: Thermodilution-derived temperature recovery time 
(TRT) a novel predictor of microvascular reperfusion and prognosis 
after acute STEMI 
This work has been published (Maznyczka AM et al. Thermodilution-derived temperature 
recovery time, a novel predictor of microvascular reperfusion and prognosis after 
myocardial infarction. EuroIntervention. 2020. Epub ahead of print. Doi: 10.4244/EIJ-D-
19-00904 [available from: https://eurointervention.pcronline.com]378. The journal provided 
permission to reproduce Tables and Figures from this publication, for use in the thesis. 
6.1 Abstract 
Background: Novel parameters that detect failed microvascular reperfusion might better 
identify the patients who are most likely to benefit from adjunctive treatments during 
primary PCI. The aim of this chapter was to investigate whether a newly conceived 
parameter (thermodilution-derived temperature recovery time [TRT]) would be associated 
with MVO and clinical outcomes, following acute STEMI.  
Methods: TRT was derived retrospectively and validated prospectively in two distinct 
acute STEMI populations; from the MR-MI study and T-TIME trial, respectively. TRT 
was defined as the duration (in seconds) from the nadir of the hyperaemic thermodilution 
curve to 20% from return of the temperature to baseline. TRT was measured immediately 
post-PCI. The extent of MVO (% LV mass) was assessed by CMR, 2 to 7 days after 
emergency PCI. Participants were followed up for all-cause death/ heart failure 
hospitalisation, and MACE. 
Results: In the derivation cohort (n=271, mean age 60 ± 12 years, 72% male), higher TRT 
was associated with more MVO (coefficient: 4.09 [95% CI: 2.70, 5.48] p<0.001), 
independent of IMR >32, CFR ≤2.0, hyperaemic Tmn >0.4 (median value), thermodilution 
waveform (bimodal or wide unimodal vs. narrow unimodal), age and ischaemic time. At 5-
years, higher TRT was multivariably associated with all-cause death/ heart failure 
hospitalisation (OR: 4.41 [95% CI: 2.08, 8.25] p<0.001) and MACE (OR: 4.05 [95% CI: 
2.00, 8.21] p<0.001), independent of IMR >32, CFR ≤2.0, hyperaemic Tmn >0.4 (median 
value) and thermodilution waveform. In the validation population (n=144, mean age 59 ± 
11 years, 80% male) the findings were confirmed prospectively.  
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Conclusion: TRT is a novel invasive parameter for detecting MVO and predicting 
prognosis. TRT may represent a novel diagnostic advance, with potential to refine risk 

























MVO reflects failed microvascular reperfusion following STEMI. MVO affects about half 
of STEMI patients treated with standard primary PCI26, and is associated with a worse 
prognosis27 86, however there are no effective evidence-based therapies or interventions to 
treat MVO91 212 347. Novel parameters that accurately measure failed microvascular 
reperfusion, and provide prognostic information incremental to clinical indices, have 
potential to refine clinical trial design.  
 
Invasive coronary physiology parameters provide an immediate assessment of post-PCI 
microvascular function. Among these parameters, IMR has been validated in animals140 141 
and humans153 155 156 166. Higher IMR values indicate greater degrees of microvascular 
dysfunction156 164. An IMR ≥32, or >40 predicts all-cause death or heart failure 
hospitalisations164. An IMR ≥32 also predicts worse recovery of LV function following 
acute STEMI158. IMR >32 is being used to select patients for clinical trials (RESTORE-MI 
[ACTRN12618000778280]273). IMR >40 is also being used to select patients for clinical 
trials255, [NCT03581513]271. However, IMR has limitations for clinical translation. For 
example, manual saline injection can be a source of variability16, and when calculating 
IMR the clinician should verify that the software has correctly positioned the Pd marker at 
the lowest stable Pd/Pa in hyperaemia.  
 
CFR191 and bimodal thermodilution waveforms198 have been associated with MVO and 
clinical outcomes, following acute STEMI. However, due to variations in resting flow, 
CFR has inferior reproducibility, compared to IMR166. The potential of bimodal waveform 
for clinical translation is limited by requiring off-line processing for waveform 
classification. Furthermore, bimodal waveform is detected in only 9% to 17% of acute 
STEMI patients198 200 366, thus if used alone bimodal waveform may miss some high-risk 
patients16.  
 
Theoretically, the later part of the thermodilution curve might be less susceptible to 
variability in the speed of manual intracoronary saline injections. This chapter details the 
conception and evaluation of a novel parameter, termed TRT, which is the time taken (in 
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seconds) for temperature recorded at the distal wire sensor to recover from the nadir value 
to baseline body temperature, during maximal hyperaemia. 
 
The following hypotheses were evaluated: 
1) Higher TRT at the end of emergency PCI is associated with MVO on CMR 
imaging. 
 
2) Higher TRT at the end of emergency PCI is associated with increased rates of 
MACE, and the combination of all-cause death/ heart failure hospitalisation. 
6.3 Methods 
6.3.1 Summary of overall study design 
The summary of the study design for this chapter is depicted in Figure 6.1. TRT was 
derived from a retrospective cohort of 288 all-comer acute STEMI patients, from a single 
centre in Glasgow, in the British Heart Foundation funded MR-MI study 
(NCT02072850)149. The patients included in the MR-MI study were recruited near 
consecutively, and all underwent emergency PCI. The derivation cohort population is 
described in more detail in section 6.3.2.  
 
Validation of TRT was performed prospectively in patients from the physiology sub-study 
of the T-TIME trial366. The design, population, data acquisition and analysis for the T-






Figure 6.1 Study design for the retrospective derivation and prospective validation of TRT. Abbreviation: BHF, British Heart Foundation. Reproduced with permission 
from Maznyczka AM et al. Thermodilution-derived temperature recovery time, a novel predictor of microvascular reperfusion and prognosis after myocardial 
infarction. EuroIntervention. 2020 [Epub ahead of print]. Doi: 10.4244/EIJ-D-19-00904.
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6.3.2 Derivation cohort (MR-MI) setting and population 
Enrolment into the MR-MI cohort study was undertaken at the Golden Jubilee National 
Hospital in Glasgow, from 11th May 2011 to 22nd November 2012. Near consecutive 
patients were screened for inclusion in the study. Patients were included in the MR-MI 
study if they had acute STEMI within 12 hours of symptom onset, treated with primary 
PCI or emergency intravenous thrombolysis followed by PCI. Patients were excluded if 
they had contraindications to contrast enhanced CMR imaging. The MR-MI study was 
approved by the West of Scotland Research Ethics Service (10-S0703-28) (Appendix 10). 
Witnessed verbal assent to participate was obtained in the catheterisation laboratory and 
written informed consent was subsequently obtained on the ward. 
6.3.3 Derivation cohort (MR-MI) standard of care for primary PCI 
Patients in the MR-MI population received 300mg of aspirin, 600mg of clopidogrel and 
5000 units of intravenous unfractionated heparin. The PCI procedures were performed via 
the radial artery. The standard of care at the time of enrolment into the MR-MI study was 
to initiate glycoprotein IIbIIIa inhibitor therapy in most cases during the primary PCI 
procedure81 379, using initial bolus of tirofiban (25µg/kg) followed by intravenous infusion 
(0.15µg/kg/min), and to perform thrombus aspiration in the majority of patients. In line 
with clinical guidelines, multivessel PCI in the acute setting was not recommended81 379. 
6.3.4 Derivation cohort (MR-MI) physiology, angiogram, ECG and CMR acquisition 
and analyses 
Angiogram acquisition in the MR-MI study was undertaken in the same way as was 
described for the T-TIME trial (section 2.1.6). TIMI coronary flow grade (Figure 2.3) was 
evaluated at the start and at the end of the PCI procedure, according to core laboratory 
standards. TFC and MPG (Figure 2.4) were evaluated at the end of the PCI procedure, 
according to core laboratory standards. The ECG and coronary physiology acquisition and 
analysis for the MR-MI study was undertaken as described for the T-TIME trial (sections 
2.1.7 and 2.1.8). In the MR-MI study CMR imaging was obtained 2 to 7 days after PCI, 
and MVO was analysed in the same way as was described for the T-TIME trial (section 
2.1.8). 
6.3.5 Derivation cohort (MR-MI) clinical outcomes 
For the MR-MI study serious adverse events were independently assessed by a 
cardiologist, who was blinded to all other clinical data. MACE was defined as cardiac 
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death, or unplanned hospitalisation for MI or heart failure. Five-year follow-up was 
completed for all the participants in the MR-MI study, initially via telephone contact and 
clinic visits, and later from review of electronic medical records. 
6.3.6 TRT definition, acquisition and analysis 
TRT was measured at the end of the PCI procedure, using a pressure- and temperature- 
sensing guidewire (Abbott Vascular, California, U.S.A), using standard thermodilution 
methodology, as described in section 2.2.2. TRT was defined as the duration in seconds, 
from the nadir of the hyperaemic thermodilution curve, to 20% from baseline temperature 
on the recovery part of the thermodilution curve (Figure 6.2). 
 
Figure 6.2 Definition of TRT: duration (seconds) from the nadir of the hyperaemic 
thermodilution curve to 20% from return to baseline temperature. 
 
Time-temperature data was extracted into Excel files, from the distal thermistor, for the 
first 100 patients from the MR-MI cohort. The extracted time-temperature data showed the 
temperature recorded at the distal thermistor in the infarct-related coronary artery, in 0.01 
second intervals from the start of the recording. The distal thermistor was sensitive to small 
errors in the measurements for the recordings made close to when the temperature returned 
exactly to baseline. To identify the endpoint for measuring TRT, that was best at predicting 
MVO, and all-cause death/ heart failure hospitalisations, five percentage cut-offs (7.5%, 
10%, 20%, 30%, and 60%)  from the end of the recordings were compared, from the first 
100 consecutive patients in the derivation (MR-MI) cohort (Figure 6.3). The percentage 
cut-off that gave the highest AUC for predicting MVO, and all-cause heath/ heart failure 
hospitalisation on ROC analysis was used to define TRT (Figure 6.3). The 20% cut-off was 
found to have the best AUC for predicting MVO presence, and all-cause death/ heart 
failure hospitalisation (Figure 6.3). The mean value for TRT was obtained from triplicate 
measurements, and was calculated using an automated algorithm, using dedicated software 
(CoroventisTM, Uppsala, Sweden). Coroventis software did not have automated algorithms 
for calculating the duration of the thermodilution recovery curve from peak temperature 
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drop to 7.5%, 10%, 30%, or 60% from baseline temperature. There was excellent 
correlation between manually calculated TRT duration from peak temperature drop to 20% 
from baseline, using the data extracted into Excel files, and the TRT measurement 
calculated by Coroventis using the automated algorithm (rho: 0.98, 95% CI: 0.97, 0.99), 
p<0.001). 
 
In the derivation cohort, TRT was calculated retrospectively. In the validation cohort, TRT 
was calculated prospectively and was submitted to the clinical trial data coordination 
centre prior to database lock. 
6.3.7 Statistical analyses 
Between-group comparisons of continuous variables used the Student’s t-test (if normally 
distributed data), or Mann-Whitney test (if skewed data). Differences in proportions were 
assessed with a Chi-squared test. Associations with MVO extent were assessed with linear 
regression, and the regression coefficients represented mean change in MVO extent for a 
1-unit increase in TRT. Association with MVO presence, or clinical outcomes were 
evaluated using ORs, derived from logistic regression. A preponderance of heart failure 
episodes occurred during the index hospitalisation, therefore the assumption for the Cox 
proportional hazards regression model for constant effects over time was not met. The 
associations with MVO were adjusted for the following covariates: age, ischaemic time, 
CFR ≤2, IMR >32, hyperaemic Tmn >0.4 (median value) and thermodilution waveform 
(bimodal or wide unimodal vs. narrow unimodal). There was a priori concern that these 
covariates were clinically relevant confounders. Non-dichotomised continuous TRT, IMR, 
CFR, or hyperaemic Tmn were not included together in multivariable models due to 
collinearity. Stepwise regression was performed and the validity of regressions was 
verified by analysis of model residuals, and multicollinearity. The predictive value of TRT 
was evaluated using the McNemar test. ROC curve analysis was performed to detect the 
optimal thresholds for predicting MVO. In this, sensitivity and specificity were considered 
equally important, therefore the optimal cut-off was considered as the one giving the 
maximum Youden Index. ROC comparisons were made using the DeLong method376. All 
tests were 2-tailed and a p-value of <0.05 was considered statistically significant. There 
was no imputation for missing values. Statistical analyses were performed in SPSS 
(version 25.0, SPSS, IBM, Armonk, NY, USA), or MedCalc Statistical Software version 




Figure 6.3 Derivation of the optimal definition for TRT. Data are from the first 100 consecutive 
patients in the derivation (MR-MI) population. AUCs from ROC curve analyses, for predicting (A) 
MVO; (B) 30-day all-cause death/ heart failure hospitalisation, and; (C) 5-year all-cause death/ 
heart failure hospitalisation. Five different cut-offs from the end of the thermodilution curve (i.e. 
7.5%, 10%, 20%, 30% and 60%), were tested. The dots represent AUCs. The mean was calculated 
from 3 hyperaemic thermodilution curves for each percentage cut-off. Reproduced with permission 
from Maznyczka AM et al. Thermodilution-derived temperature recovery time, a novel predictor of 
microvascular reperfusion and prognosis after myocardial infarction. EuroIntervention. 2020 




6.4.1 Population characteristics 
Derivation (MR-MI) population 
Seventeen patients were excluded from the derivation (MR-MI) population, because 
coronary physiology recordings were not suitable for digital analysis. Among the 271 
included patients (mean age 60 ± 12 years, 72% male), the majority (92%) underwent 
primary PCI, whilst 7 had PCI after successful thrombolysis, and 14 had PCI after failed 
thrombolysis. The population and procedure characteristics for the derivation population 
are shown in Tables 6.1 and 6.2. 
Derivation Population Characteristics Overall (n=271) TRT £0.5 (n=143) TRT >0.5 (n=128) p-value 
Age, years 59.5 ± 1.5 57.2 ± 11.1 62.0 ± 11.4 0.001† 
Male 194 (72%) 98 (69%) 96 (75%) 0.239‡ 
Current smoker 170 (63%) 98 (69%) 72 (56%) 0.037‡ 
Body mass index, kg/m2 28.7 ± 4.8 29.2 ± 4.9 28.0 ± 4.5 0.040† 
Hypertension 85 (31%) 45 (32%) 40 (31%) 0.969‡ 
Diabetes mellitus 30 (11%) 15 (11%) 15 (12%) 0.747‡ 
Previous myocardial infarction 18 (7%) 9 (6%) 9 (7%) 0.808‡ 
Reperfusion strategy    0.344‡ 
        Primary PCI 250 (92%) 134 (94%) 116 (91%)  
        Thrombolysis followed by PCI 21 (8%) 9 (6%) 12 (9%)  
Presenting heart rate, beats per minute 78.1 ± 16.7 78.2 ± 16.9 78.0 ± 16.7 0.928† 
Presenting systolic blood pressure, mmHg 135.2 ± 25.1 134.5 ± 24.8 133.2 ± 25.4 0.217† 
Ischaemic time, hours, median (IQR) 2.92 (2.0 - 5.4) 2.8 (2.0 - 5.0) 3.4 (2.2 - 5.7) 0.101§ 
Baseline creatinine, µmol/L 76.9 ± 18.8 74.5 ± 19.1 79.7 ± 18.1 0.022‡ 
Procedural Characteristics     
Culprit artery:  LAD/ left main stem 100 (37%) 50 (35%) 50 (39%) 0.364‡ 
                         Cx  52 (19%) 32 (22%) 20 (16%)  
                         RCA 119 (44%)  61 (43%) 58 (45%)  
Number of main vessels diseased:  1 148 (55%) 78 (55%) 70 (55%) 0.650‡ 
                                                         2 84 (31%) 42 (29%) 42 (33%)  
                                                         3 39 (14%) 23 (16%) 16 (13%)  
Thrombus aspiration 195 (72%) 102 (71%) 93 (73%) 0.808‡ 
Glycoprotein IIbIIIa inhibitor 249 (92%) 132 (92%) 117 (91%) 0.786‡ 
Table 6.1 Population characteristics, grouped according to high and low TRT, from the 
derivation (MR-MI) cohort. Data are mean ± SD, or n (%) unless otherwise stated. 
†student’s t-test. ‡c2 test. §Mann-Whitney test. Missing data: ischaemic time, n=18; 
creatinine n=1.  
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Derivation Population Parameters Overall (n=271) TRT ≤0.5 (n=143) TRT >0.5 (n=128) p-value 
ECG      
ST-segment resolution: Complete, ³70% 








Angiogram     
Initial TIMI coronary flow grade:  0 
                                                        1 
                                                        2 















Final TIMI coronary flow grade:  1 
                                                      2 











TIMI frame count post-PCI, median (IQR) 14.0 (10.0 - 24.0) 12.0 (8.2 - 20.0) 17.8 (10.6 - 25.4) 0.004§ 
 
Myocardial perfusion grade post-PCI: ≤1 








Coronary Physiology Post-PCI     
Hyperaemic Pa, mmHg, median (IQR) 76.0 (68.0 - 87.0) 76.0 (68.0 - 89.0) 76.0 (67.0 - 86.5) 0.515§ 
Hyperaemic Pd, mmHg, median (IQR) 70.0 (60.0 - 80.0) 69.0 (60.0 - 79.8) 71.0 (60.0 - 81.5) 0.983§ 
IMR, median (IQR) 24.0 (15.0 - 43.0) 15.4 (11.0 - 21.1) 44.1 (27.0 - 63.0) <0.001§ 
IMR >32 100 (37%) 13 (9%) 87 (68%) <0.001‡ 
IMR >40 75 (28%) 4 (3%) 71 (56%) <0.001‡ 
CFR, median (IQR) 1.6 (1.1-2.1) 1.7 (1.3-2.4) 1.4 (1.0-1.8) <0.001§ 
CFR £2 196 (72%) 93 (66%) 103 (83%) 0.002‡ 
Hyperaemic Tmn, (s) median (IQR) 0.4 (0.2-0.6) 0.2 (0.2-0.3) 0.6 (0.4-0.9) <0.001§ 
Hyperaemic Tmn >median 132 (49%) 22 (15%) 110 (1%) <0.001‡ 
     
Waveform:  Bimodal 
                    Wide unimodal 











CMR 2 to 7days after PCI  
Time from PCI to CMR imaging (days) 2.1 ± 1.9 2.2 ± 1.9 1.9 ± 1.9 0.174† 
MVO extent (% LV mass) 0.2 (0.0 - 3.3) 0.0 (0.0 - 1.6) 2.0 (0.0 - 6.8) <0.001§ 
MVO present 137 (50.6) 52 (36.4) 85 (66.4) <0.001‡ 
 
Table 6.2 From the derivation (MR-MI) cohort, ECG, angiographic, and coronary 
physiology parameters on admission and CMR findings at 2 to 7 days post-STEMI, 
grouped according to high and low TRT. Data are mean ± SD, or n (%) unless otherwise 
stated. ‡c2 test. §Mann-Whitney test. †student t-test. Missing: CFR, n=6; Pa post-PCI, 
n=57; ST-segment resolution, n=1, MVO extent, n=1. 
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From the derivation population, TRT had a right-skewed distribution (Figure 6.4). The 
median TRT was 0.5 (range: 0.1 – 2.5). 
 
Figure 6.4 From the derivation (MR-MI) population, distribution of TRT (n=271). 
Reproduced with permission from Maznyczka AM et al. Thermodilution-derived 
temperature recovery time, a novel predictor of microvascular reperfusion and prognosis 
after myocardial infarction. EuroIntervention. 2020 [Epub ahead of print]. Doi: 
10.4244/EIJ-D-19-00904 
 
TRT was correlated with IMR (r=0.8, p<0.001), CFR (r= -0.3, p<0.001) and with 
hyperaemic Tmn (r=0.9, p<0.001). In the derivation (MR-MI) population, characteristics 
associated with higher TRT, in multivariable linear regression analysis, were as follows: 
IMR >32 (p<0.001), hyperaemic Tmn >0.4 (median value) (p<0.002), CFR ≤2.0 
(p<0.001), bimodal or wide unimodal thermodilution waveform (p=0.018), TIMI coronary 
flow grade post-PCI ≤2 (p<0.001), and higher creatinine (p=0.044). 
Validation (T-TIME) population 
The population and procedure characteristics for the validation population, i.e. the T-TIME 
cohort, have been described in section 4.4.2, and Tables 4.1 to 4.3. The median TRT in the 
validation population (n=144) was 0.5 (range: 0.2 – 2.4). Characteristics associated with 
higher TRT in the validation population, in multivariable linear regression were: bimodal 
or wide unimodal thermodilution waveform, higher TFC and hyperaemic Tmn >0.4 
(median value) (all p<0.001).  
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In the T-TIME population there was no overall significant treatment effect of intracoronary 
alteplase on TRT. The relative difference in TRT for 20mg alteplase (median: 0.6 [IQR: 
0.4 – 1.1]) vs. placebo (median: 0.6 [IQR: 0.4 -1.0]) was 1.19 (95% CI: 0.93, 1.51) 
p=0.164. The relative difference in TRT for 10mg alteplase (median: 0.5 [IQR: 0.3 – 0.7]) 
vs. placebo was 0.90 (95% CI: 0.69, 1.15) p=0.394. The relative difference in TRT for 
10mg and 20mg combined vs. placebo was 1.04 (95% CI: 0.84, 1.29) p=0.686. 
6.4.2 Associations of TRT with MVO 
Derivation (MR-MI) population 
In the derivation population, CMR imaging with MVO presence/ absence evaluable was 
available in 271 participants, at 2 to 7 days post-PCI, and MVO extent was evaluable in 
270 patients. MVO was present in 138 patients (51%). On ROC curve analysis there was 
no difference in the discriminatory ability of TRT compared to IMR for predicting MVO 
presence (Figure 6.5). The TRT threshold with the highest combination of sensitivity 
(61%) and specificity (68%) for predicting MVO was >0.5. 
 
Figure 6.6 shows discordance between IMR and TRT. TRT dichotomised by 0.5 correctly 
predicted MVO presence or absence, in 65% (n=175/ 271) of patients. IMR dichotomised 
by 32 correctly predicted MVO presence or absence in 62% (n=167/271) of patients. There 
was no difference in the predictive accuracy for detecting MVO presence or absence when 
TRT dichotomised by 0.5, and IMR dichotomised by 32 were compared, using the 
McNemar test (difference: 2.95% [95% CI: -2.39%, 8.29%] p=0.341).  
 
In the derivation population, higher continuous TRT was multivariably associated with 
larger MVO extent (coefficient: 4.24 [CI: 2.26, 6.22] p<0.001), independent of IMR >32, 
CFR ≤2.0, hyperaemic Tmn >0.4 (median value), thermodilution waveform, age and 
ischaemic time (Table 6.3). This means that MVO extent increased by 4.24 units for every 
1-unit increase in TRT. TRT was also a multivariable predictor of MVO presence (OR: 
3.01 [95% CI: 1.75, 5.16] p<0.001) (Table 6.3). The findings were similar when IMR >32 









Figure 6.5 ROC curves from the derivation (MR-MI) population, for association of TRT, 
IMR, CFR and hyperaemic Tmn with: (A) presence of MVO; (B & C) all-cause death/ 




Figure 6.6 From the derivation (MR-MI) population: (A) example of IMR – TRT discordance. The 
patient had high TRT and normal IMR at the end of primary PCI. CMR imaging revealed 
transmural antero-septal MI, complicated by MVO; (B) scatter graph showing IMR – TRT 
discordance, and IMR/ TRT – MVO discordance, and; (C) patients with MVO stratified by 
combinations of IMR ≤32, IMR >32, TRT ≤0.5, and TRT >0.5 (p-values from Chi-squared test). 
Reproduced with permission from Maznyczka AM et al. Thermodilution-derived temperature 
recovery time, a novel predictor of microvascular reperfusion and prognosis after myocardial 




 Univariable analysis Multivariable analysis 
 OR/ coefficient 
(95% CI) 




Associations with MVO extent (%LV mass) on CMR 2-7 days post-PCI* 
TRT continuous  4.38 (3.07, 5.68) <0.001 4.09 (2.70, 5.48) <0.001 
TRT >0.5  2.84 (1.71, 3.97) <0.001 2.69 (1.49, 3.89) <0.001 
TRT >0.5 (IMR >32, substituted by continuous 
IMR in model) 
  1.53 (-0.18, 3.23) 0.080 
*Other variables in multivariable model: age, ischaemic time, IMR >32, CFR ≤2, hyperaemic Tmn >median, 
thermodilution waveform  
 
Associations with MVO presence on CMR 2-7 days post-PCI† 
TRT continuous  5.52 (2.59, 11.77) <0.001 5.26 (2.52, 11.74) <0.001 
TRT >0.5  3.36(2.04, 5.53) <0.001 3.01 (1.75, 5.16) <0.001 
TRT >0.5 (IMR >32, substituted by continuous 
IMR in model) 
  1.72 (0.78, 3.77) 0.178 
† Other variables in multivariable model: age, ischaemic time, IMR >32, CFR ≤2, hyperaemic Tmn >median, 
thermodilution waveform 
 
Associations with 30-day death/ heart failure hospitalisation‡ 
TRT continuous  6.64 (2.90, 15.24) <0.001 7.37 (2.37, 22.94) 0.001 
TRT >0.5  8.14 (2.35, 28.20) 0.001 7.13 (1.78, 28.66) 0.006 
TRT >0.5 (IMR >32, substituted by continuous 
IMR in model) 
  4.48 (1.14, 17.63) 0.032 
‡Other variables in multivariable model: IMR >32 
 
Associations with death/ heart failure hospitalisation at median 5-years§ 
TRT continuous  3.85 (1.97, 7.51) <0.001 4.14 (2.08, 8.25) <0.001 
TRT >0.5  3.11 (1.63, 5.93) 0.001 6.44 (2.48, 16.71) <0.001 
TRT >0.5 (IMR >32, substituted by continuous 
IMR in model) 
  5.37 (2.00, 14.43) 0.001 
§Other variables in multivariable model: IMR >32, CFR ≤2, hyperaemic Tmn>median, thermodilution waveform  
 
Associations with 30-day MACE‡ 
TRT continuous 6.51 (2.89, 14.69) <0.001 7.38 (2.41, 22.55) <0.001 
TRT >0.5 9.16 (2.66, 31.51) <0.001 8.57 (2.18, 33.63) 0.002 
TRT >0.5 (IMR >32, substituted by continuous 
IMR in model) 
  5.18 (1.34, 19.99) 0.017 
‡Other variables in multivariable model: IMR >32 
 
Associations with MACE at median 5-years§ 
TRT continuous 3.55 (1.79, 7.03) <0.001 4.05 (2.00, 8.21) <0.001 
TRT >0.5 2.39 (1.21, 4.71) 0.012 2.65 (1.32, 5.30) 0.006 
TRT >0.5 (IMR >32, substituted by continuous 
IMR in model) 
  2.19 (0.76, 6.29) 0.145 
§Other variables in multivariable model: IMR >32, CFR ≤2, hyperaemic Tmn>median, thermodilution waveform  
 
Table 6.3 From the derivation (MR-MI) cohort, logistic and linear regression analyses, 
showing associations between TRT and MVO, or TRT and clinical outcomes (with IMR 
>32 in multivariable models). 
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 Univariable analysis Multivariable analysis 
 OR/ coefficient 
(95% CI) 




Associations with MVO extent (%LV mass) on CMR 2-7 days post-PCI* 
TRT continuous  4.38 (3.07, 5.68) <0.001 4.09 (2.70, 5.48) <0.001 
TRT >0.5  2.84 (1.71, 3.97) <0.001 1.70 (0.25, 3.15) 0.022 
TRT >0.5 (IMR >40, substituted by continuous 
IMR in model) 
  1.53 (-0.18, 3.23) 0.080 
*Other variables in multivariable model: age, ischaemic time, IMR >40, CFR ≤2, hyperaemic Tmn >median, 
thermodilution waveform  
 
Associations with MVO presence on CMR 2-7 days post-PCI† 
TRT continuous  5.52 (2.59, 11.77) <0.001 5.26 (2.36, 11.74) <0.001 
TRT >0.5  3.36 (2.04, 5.53) <0.001 3.01 (1.75, 5.16) <0.001 
TRT >0.5 (IMR >40, substituted by continuous 
IMR in model) 
  1.72 (0.78, 3.77) 0.178 
† Other variables in multivariable model: age, ischaemic time, IMR >40, CFR ≤2, hyperaemic Tmn >median, 
thermodilution waveform 
 
Associations with 30-day mortality or heart failure hospitalisation‡ 
TRT continuous  6.64 (2.90, 15.24) <0.001 6.27 (1.89, 20.78) 0.003 
TRT >0.5  8.14 (2.35, 28.20) 0.001 5.77 (1.44, 23.14) 0.013 
TRT >0.5 (IMR >40, substituted by continuous 
IMR in model) 
  4.48 (1.14, 17.63) 0.032 
‡Other variables in multivariable model: IMR >40 
 
Associations with mortality or heart failure hospitalisation at median 5-years§ 
TRT continuous  3.85 (1.97, 7.51) <0.001 4.14 (2.08, 8.25) <0.001 
TRT >0.5  3.11 (1.63, 5.93) 0.001 5.81 (2.16, 15.63) <0.001 
TRT >0.5 (IMR >40, substituted by continuous 
IMR in model) 
  5.37 (2.00, 14.43) 0.001 
§Other variables in multivariable model: IMR >40, CFR ≤2, hyperaemic Tmn>median, thermodilution waveform  
 
Associations with 30-day MACE‡ 
TRT continuous 6.51 (2.89, 14.69) <0.001 6.06 (1.88, 19.57) 0.003 
TRT >0.5 9.16 (2.66, 31.51) <0.001 6.81 (1.74, 26.62) 0.006 
TRT >0.5 (IMR >40, substituted by continuous 
IMR in model) 
  5.18 (1.34, 19.99) 0.017 
‡Other variables in multivariable model: IMR >40 
 
Associations with MACE at median 5-years§ 
TRT continuous 3.55 (1.79, 7.03) <0.001 4.05 (2.00, 8.21) <0.001 
TRT >0.5 2.39 (1.21, 4.71) 0.012 2.65 (1.32, 5.30) 0.006 
TRT >0.5 (IMR >40, substituted by continuous 
IMR in model) 
  2.19 (0.76, 6.29) 0.145 
§Other variables in multivariable model: IMR >40, CFR ≤2, hyperaemic Tmn>median, thermodilution waveform  
 
Table 6.4 From the derivation (MR-MI) cohort, summary of logistic and linear regression 
analyses, showing associations between TRT and MVO, or TRT and clinical outcomes 




Validation (T-TIME) population 
In the validation population, higher continuous TRT was multivariably associated with 
MVO extent (coefficient: 2.86 [95% CI: 1.26, 4.46] p=0.001). Case examples are shown in 
Figure 6.7. 
 
Figure 6.7 Case examples showing TRT measured in 2 patients with acute STEMI treated by 
primary PCI. Both patients had TIMI 3 flow in the infarct-related artery, post-PCI. A, Normal 
TRT: The infarct-related artery was an occluded RCA. IMR and TRT were normal, indicating 
successful myocardial reperfusion. ECGs showed complete resolution of inferior ST-segment 
elevation. CMR imaging performed 2-days post STEMI revealed a small subendocardial infarct 
without MVO. B, Increased TRT: The infarct-related artery was an occluded Cx. Invasively 
measured microvascular function was abnormal (IMR 49, TRT 1.1), indicating impaired 
myocardial reperfusion. ECGs showed only partial resolution of infero-lateral ST-segment 
elevation. CMR imaging, 2-days later, revealed MVO. Reproduced with permission from 
Maznyczka AM et al. Thermodilution-derived temperature recovery time, a novel predictor of 
microvascular reperfusion and prognosis after myocardial infarction. EuroIntervention. 2020 
[Epub ahead of print]. Doi: 10.4244/EIJ-D-19-00904 
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6.4.3 Associations of TRT with clinical outcomes 
Derivation (MR-MI) population  
In the first 30 days following acute STEMI, all-cause death/ heart failure hospitalisation 
occurred in 22 patients (8%), and MACE occurred in 24 patients (9%). ROC curve analysis 
revealed that TRT had superior discriminatory ability compare to CFR for predicting 30-
day clinical outcomes (Figure 6.5). In the derivation cohort, continuous TRT was a 
multivariable predictor of 30-day death/ heart failure hospitalisation (OR: 7.37 [95% CI: 
2.36, 22.94] p<0.001), and 30-day MACE (OR: 7.38 [95% CI: 2.41, 22.55) p<0.001), with 
IMR >32 in the model (Table 6.3). TRT >0.5 was also a multivariable predictor of 30-day 
death/ heart failure hospitalisation (OR: 4.48 [95% CI: 1.14, 17.63] p=0.032) and 30-day 
MACE (OR: 5.18 [95% CI: 1.34, 19.99] p=0.017), with continuous IMR in the model 
(Table 6.3). The findings were similar when IMR >32 was substituted for IMR >40 in 
multivariable models (Table 6.4). 
 
During a median follow-up of 5 years in the derivation cohort, 52 patients died or 
experienced heart failure hospitalisation, and 43 patients experienced MACE. ROC curve 
analysis showed that TRT had superior discriminatory ability compared to CFR for 
predicting 5-year MACE (Figure 6.5). Continuous TRT was a multivariable predictor of 5-
year death/ heart failure hospitalisation (OR: 4.14 [95% CI: 2.08, 8.25] p<0.001), and 5-
year MACE (OR: 4.05 [95% CI: 2.00, 8.21] p<0.001), with IMR >32 in the model (Table 
6.3). TRT >0.5 was also a multivariable predictor of 5-year death/ heart failure 
hospitalisation, and MACE, with IMR >32 in the model (Table 6.3). The findings were 
similar when IMR >32 was substituted for IMR >40 in multivariable models (Table 6.4).  
Validation (T-TIME) population 
During 1-year follow up in the validation population, all-cause death/ heart failure 
hospitalisation occurred in 22 patients (15%), and MACE occurred in 23 patients (16%). 
Higher continuous TRT was associated with all-cause death/ heart failure hospitalisation 
(OR: 6.10 [95% CI: 2.42, 15.42] p<0.001) and MACE (OR: 7.65 [95% CI: 1.87, 31.29] 
p=0.005), independent of IMR >32, CFR ≤2.0, hyperaemic Tmn >median and 
thermodilution waveform. The results were similar when IMR >32 was substituted for 
IMR >40 in the multivariable model (all-cause death/ heart failure hospitalisation: OR, 




6.4.4 Repeatability of TRT  
Paired TRT measurements, obtained 0.5 to 8 minutes apart, post-primary PCI by 4 
cardiologists in 13 patients were correlated (r=0.93, p<0.001), with a mean difference 
between duplicate TRT measurements of 0.02 ± 0.08 (p=0.489). The coefficient of 
variation from duplicate TRT measurements was 12.7%. The coefficient of variation from 
duplicate IMR measurements was 15.5%. The Bland-Altman plot is shown in Figure 6.8. 
 
Figure 6.8 Bland-Altman plot of differences plotted against the averages of paired TRT 
measurements. Horizontal lines are drawn at the mean difference and at the limits of 
agreement. 
 
6.4.5 Associations of TRT with systemic and coronary haemodynamics 
The relationships between TRT, IMR, CFR or hyperaemic Tmn, with Pa, Pd and heart rate 
were examined in the derivation (MR-MI) cohort, because predictive performance may be 
impaired if influenced by haemodynamic conditions. Pd did not correlate with TRT (r= -
0.04, p=0.543), or hyperaemic Tmn (r= -0.01, p=0.883). However, Pd and IMR were 
correlated (r=0.3, p<0.001), and Pd was correlated with CFR (r=0.2, p=0.014). Pa did not 
correlate with TRT (r= -0.1, p=0.311), or hyperaemic Tmn (r= -0.05, p=0.506). However, 
Pa was correlated with IMR (r=0.2, p=0.001) and CFR (r=0.2, p=0.011). TRT, IMR, or 
TRT were not correlated with heart rate (TRT [r= -0.1, p=0.399]; IMR [r=0.01, p=0.926]; 





In this chapter a novel parameter has been described and validated, for measuring the 
efficacy of microvascular reperfusion. Higher TRT was a multivariable predicted of more 
MVO and clinical outcomes, in two independent acute STEMI cohorts. 
 
Though TRT and IMR are correlated, discordance occurred between high and low IMR 
(dichotomised by 40) and TRT (dichotomised by 0.5) in 20% of patients (n=54) from the 
derivation cohort, indicating that TRT and IMR are not one and the same. When an IMR 
threshold of 40 was used, discordance between high and low dichotomised IMR and TRT 
occurred in 23% of patients (n=61) from the derivation cohort. TRT measures different 
aspects of the thermodilution curve than hyperaemic Tmn, which is used to calculate IMR. 
For calculating IMR, the Tmn starts at the steepest downslope of the temperature-time 
curve (measured by the wire’s shaft thermistor). The transit time measurement ends 
midway between the peak temperature drop (measured by the wire’s distal thermistor) and 
10% from return of the distal thermistor temperature to baseline. In contrast, the TRT 
measurement only incorporates the part of the temperature-time curve from peak 
temperature drop to 20% from return to baseline temperature. The independence of TRT, 
but not IMR, from coronary and systemic haemodynamics further distinguishes TRT from 
IMR.  
 
With regards to translation to clinical practice, measuring TRT could potentially be more 
straightforward for use by clinicians who are less experienced with thermodilution 
methodology. This is because TRT is calculated precisely using an automated algorithm 
using dedicated software (CoroventisTM, Uppsala, Sweden) in the catheterisation 
laboratory. On the other hand, for precise calculation of IMR the operator must verify that 
the position of the marker is at the lowest stable Pd/Pa during hyperaemia, which is not 
always positioned correctly by the automated software. The classification of bimodal 
waveforms is not automatically determined by the analysis software, and thus an 
experienced operator is required to interpret the thermodilution waveform. CFR, which 
reflects epicardial and microcirculatory vasodilator capacity, and residual epicardial 
stenosis, is calculated using an automated algorithm, however CFR does not improve the 




The clinical relevance of these findings is that they support the potential clinical utility of 
TRT for refining risk stratification and selection of acute STEMI patients for adjunctive 
treatments during primary PCI. The reliable identification of patients with a high 
probability of having MVO may potentially improve research study design, by improving 
selection of the highest risk patients in the catheterisation laboratory for inclusion in 
therapeutic trials. Furthermore, accurate identification of acute STEMI patients who will 
not develop MVO, could potentially reduce healthcare costs through stratification and 
triage for early hospital discharge165. Though MVO revealed by CMR imaging can 
accurately detect failed myocardial reperfusion, CMR is not feasible in the acute setting, 
and therefore does not have potential clinical utility for selecting patients for adjunctive 
treatments during primary PCI. 
6.6 Limitations 
The strengths of this study include the high follow up rates for CMR, the prospective 
validation of TRT in a distinct population independent from the derivation population, and 
independent adjudication of clinical events, however there are some limitations.  
 
The study presented in this chapter was not designed to comprehensively test the 
reproducibility of TRT. Paired TRT measurements were only available in 13 participants, 
which is insufficient to draw conclusions on the reproducibility of TRT compared to IMR.  
 
Limitations of the bolus-derived thermodilution technique should be considered. First, 
manual bolus-injections of saline may be a source of variability16. Previous published 
literature has shown that the speed of injection is a source of variability in calculating 
cardiac output using thermodilution380. It is theoretically plausible that when injection 
speed is slower, it would take longer for the initial part of the intracoronary thermodilution 
curve to reach the peak temperature drop, than when injection speed is faster. It is 
potentially plausible that the recovery part of the thermodilution curve (nadir to return to 
baseline body temperature) may be less sensitive to variability in manual injection speed. 
However, there is no data available that evaluates this theory, and therefore future research 
is needed. Thermodilution-based absolute flow and microvascular resistance 
measurements, using continuous infusion of saline to induce steady-state maximal 
hyperaemia, has potential to have superior reproducibility than manual bolus saline 
214 
 
injections185. However, thermodilution-based absolute flow requires a dedicated infusion 
catheter with side holes183, can be more technically challenging and although early studies 
have shown feasibility larger studies in STEMI are awaited184.  
 
A second limitation of the bolus-derived thermodilution technique is that higher intra-
observer variability of thermodilution-, compared to Doppler-derived CFR measurements 
has been demonstrated169. It is important to consider that reliable Doppler flow velocity 
tracings are required for measurement, and Doppler flow velocity signals may be 
inconsistent and are particularly influenced by the wire tip position135. This weakness of 
Doppler derived parameters is exemplified by a study that evaluated HMR as a predictor of 
MVO after acute STEMI, and found that 8% of invasive measurements had to be excluded 
due to poor Doppler flow signals or iatrogenic coronary dissection in one patient178. 
 
Although TRT was derived and validated in distinct populations, the limited number of 
composite outcome events constrained the statistical power of multivariable models. A 
more robust way to validate TRT could be a comparison with positron emission 
tomography, or an experimental model with perivascular flow probes or microspheres, 
enabling calculation of coronary flow and myocardial resistance.  
6.7 Future work 
Future research is warranted to further validate the novel findings reported in this chapter 
and to study the reproducibility of TRT compared to IMR in a larger number of patients. 
Moreover, future research is of interest to determine whether this new metric (TRT) may 
have utility in the assessment of the microcirculation in patients with ischaemia and no 
obstructive coronary artery disease.  
6.8 Conclusion 
In conclusion, higher TRT predicts more MVO and clinical outcomes following acute 
STEMI, independently of established predictors. TRT represents a novel parameter for 
detecting failure of microvascular perfusion and may have potential to refine risk 
stratification after primary PCI. Further research is needed to evaluate the potential clinical 
utility of TRT-guided selection of patients for adjunctive treatments during primary PCI.  
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Chapter 7: Concluding remarks and future directions 
The work presented in this thesis provides novel insights regarding the use of invasive 
quantitative parameters to measure impaired myocardial perfusion, and to predict 1-year 
clinical outcomes. The ideal test should be straightforward to perform during the primary 
PCI procedure, reliable, prognostically validated, and responsive to the effects of therapies 
on microvascular perfusion. A test that fulfils these criteria would potentially be a practice 
advance for the following areas of interest: (i) selection of the highest risk patients for 
adjunctive therapies designed to minimise microvascular injury; (ii) selection of the lowest 
risk patients for potential early discharge, and; (iii) serving as an immediate test of the 
efficacy of therapies. In current clinical practice, persistent microvascular injury typically 
passes undetected after primary PCI, and is a clinical problem of unmet therapeutic need. 
 
The findings from the comparison of established and novel invasive measures of coronary 
microvascular function, for predicting MVO, myocardial haemorrhage and prognosis in 
acute STEMI patients, adds novel understanding on the potential role of RRR as a measure 
of microvascular function and as a prognostic biomarker for risk stratification. The 
findings in Chapter 5 showed for the first time, that lower RRR in acute STEMI patients 
was associated with adverse clinical outcomes. IMR and RRR reflect different aspects of 
microvascular function, i.e. RRR is a measure of the vasodilatory capacity of the 
microcirculation, whereas IMR is a measure of the minimum achievable microvascular 
resistance at peak hyperaemia. RRR and IMR are complimentary, and the findings 
presented in chapter 5 support IMR in conjunction with RRR, instead of CFR, as a tool to 
select patients for adjunctive therapy during primary PCI. Future studies are anticipated to 
determine the wider external validity of these findings. 
 
Although IMR is a validated invasive coronary physiology test for evaluating the 
immediate efficacy of microcirculatory reperfusion, it has some limitations for clinical 
translation. In chapter 6, a newly conceived parameter, termed TRT, was described and 
validated for the first time, and was shown to be predictive of MVO and prognosis, 
independent of IMR >32, or IMR >40, and other established predictors. TRT is a novel 
diagnostic advance for detecting failed microcirculatory reperfusion, which may have 
potential to refine risk stratification and selection of patients for adjunctive treatments after 
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primary PCI. Further research is warranted to validate the findings in other cohorts and to 
examine the reproducibility of TRT, compared to IMR, in a larger number of patients.  
 
This thesis also provides novel insights into the mechanistic effects of intracoronary 
alteplase, administered during primary PCI, on the coronary microcirculation. The notable 
finding of associations between intracoronary alteplase and MVO, and myocardial 
haemorrhage presence, in patients with TIMI flow £2 immediately preceding study drug 
administration, suggests that low-dose intracoronary alteplase may be harmful when 
administered to STEMI patients who have impaired coronary flow (chapter 3). The 
potential explanations include increased local exposure to alteplase, due to impaired 
washout of alteplase from the microcirculation, which appears to enhance haemorrhagic 
transformation in the infarct core and seems to augment the undesired procoagulant effects 
of alteplase, thereby promoting microvascular thrombosis. These interpretations were 
supported by results from the analyses of coagulation parameters. Nonetheless, no 
adjustment for multiplicity was made in this sub-group analysis, which should be 
interpreted as exploratory and not definitive. Further research is needed to validate the 
findings. 
 
Although no overall differences in acute invasive measures of microvascular function 
(IMR, CFR, or RRR) were seen after intracoronary alteplase vs. placebo, the sub-group 
analyses in the T-TIME physiology sub-study provide further novel insights into the 
mechanistic effects of low-dose intracoronary alteplase (chapter 4). Notably, in the sub-
group of patients with ischaemic time <2 hours, there were significant improvements in 
CFR and RRR (but not IMR) with alteplase vs. placebo, whereas in the sub-group of 
patients with ischaemic time ³4 hours, MVO was worse with alteplase vs. placebo. These 
clinically relevant results, do not support administering intracoronary alteplase in patients with 
STEMI presenting with an ischemic time ≥4 hours. However, due to the potential for type 1 
statistical error, the findings from the sub-group analyses, should be interpreted as 
exploratory/ hypothesis generating, rather than definitive. 
 
In summary, the implications of the research presented in this thesis is that RRR and TRT 
may have clinical utility to risk stratify patients for adjunctive treatments, in the 
catheterisation laboratory. This targeted therapy approach has potential to reduce the 
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number of patients needed in clinical trials for STEMI research, to achieve adequate power 
to ascertain improvements in trial endpoints. Secondly, the finding of increased presence of 
MVO with alteplase vs. placebo in patients with TIMI flow <3 is clinically relevant, as a 
disincentive to interventional cardiologists when considering bail-out intracoronary 
alteplase for angiographic “no-reflow”. 
 
The weaknesses of the project should be considered. Importantly, the T-TIME population 
may be a relatively low risk population of STEMI patients, because the eligibility criteria 
excluded higher risk patients with ischaemic times >6 hours, or patients with cardiogenic 
shock. As a result, most of the patients (59%) included in the T-TIME physiology sub-
study did not have MVO present. This may affect the generalisability of the findings to 
other populations of STEMI patients, and may have affected the magnitude of the 
differences in MVO between treatment groups. For example, in the T-TIME angiographic 
study the absolute difference in the extent of MVO with 20mg of alteplase vs. placebo in 
patients with TIMI flow ≤2 immediately before drug delivery was only 2.8% (% LV mass). 
Although this difference was found to be statistically significant (p-value <0.05), it is 
uncertain whether this difference is clinically meaningful, since it did not translate to a 
difference in infarct size at 3-months between the 20mg alteplase group vs. placebo group. 
 
Another important consideration is whether the effect sizes that formed the foundation of 
the sample size calculation for the T-TIME physiology sub-study were realistic. This 
sample size calculation assumed a mean IMR of 33.9 and SD of 25.2. Whereas the actual 
mean and SD for IMR in the T-TIME physiology sub-study were 40.7 and 32.4 
respectively. Therefore, the actual SD was larger than what was expected, leading to a 
decreased power. However, given that the result of the main T-TIME trial found overall no 
difference in MVO between alteplase vs. placebo, it is unlikely that having more patients 
in the T-TIME physiology sub-study would have resulted in an overall difference in IMR 
between treatment groups. Furthermore, the sample size calculation assumed a mean 
difference in IMR of 10 units between alteplase 10mg and placebo, and a mean difference 
in IMR of 20 units between alteplase 20mg and placebo. Expecting to detect a between-
group difference in mean IMR of 20 units may be considered unrealistic, since the 
previous study by Sezer et al found a statistically significant difference in IMR of 13.6 




Another weakness of the project is that the trial was stopped early by the sponsor, for 
futility, following an interim analysis. When a clinical trial is stopped due to futility, this 
means that the interim data imply a very low likelihood of observing statistically 
significant superior efficacy if the trial continues to termination381. The potential 
disadvantage of stopping a clinical trial early, due to futility is that the premature 
termination of a trial could lead to equivocal results. However, exposing patients to 
potential side effects of a therapy in a clinical trial that has little chance of demonstrating 
efficacy may be unethical. As a result of T-TIME stopping early, the number of patients in 
each treatment arm for the sub-group analyses were relatively small, which may have 
resulted in type 2 statistical error, i.e false negative results. On the other hand, with 
multiple statistical testing in sub-group analyses there is also a risk of type 1 statistical 
error. Therefore, the findings from the sub-group analyses are exploratory, and should be 
interpreted with caution. 
 
Several uncertainties remain, including whether intracoronary tenecteplase administered at 
the end of primary PCI (post-stenting), after normal antegrade flow has been established, 
might have a beneficial effect on minimising microvascular injury in patients with short 
ischaemic time (<4 hours). Tenecteplase has higher fibrin specificity than alteplase382, and 
is also less procoagulant than alteplase318. One can therefore speculate, that intracoronary 
tenecteplase administered post-stenting, in acute STEMI patients with large thrombus 
burden and short ischaemic time might possibly have potential to be an effective treatment 
for microvascular thrombosis and distal embolization. Further research is needed, and the 
findings from the ongoing RESTORE-MI trial [ACTRN12618000778280]273, should help 
address uncertainties. 
 
Recent randomised controlled trials of therapeutic interventions designed to reduce 
microvascular injury have failed to provide evidence of benefit. Therefore, MVO is a 
common adverse complication of acute STEMI, for which there is no evidence-based 
therapy. At present, the most effective strategy to limit microvascular injury in STEMI 
appears to be restoring coronary flow as quick as possible, to shorten the ischaemic time. 
Further research is warranted. Given the conflicting results of the EARLY BAMI212, and 
METOCARD-CNIC trials239, intravenous metoprolol may merit further investigation in an 
adequately powered randomised clinical trial. Furthermore, the results of the ongoing 
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randomised studies to evaluate whether PICSO270 or intracoronary hypothermia253 might 
reduce infarct size, in patients undergoing primary PCI are eagerly anticipated. 
 
Regarding future work for risk stratification of patients in the catheterisation laboratory, 
during primary PCI, application of computational fluid dynamics to derive angiography-
based pressure wire free parameters are emerging. Recently, IMRangio defined as Pa 
(measured during hyperaemia) multiplied by quantitative flow ratio (Pd/Pa derived from 
the angiogram) and multiplied by TFC in the infarct-related artery correlated with pressure 
wire derived IMR and MVO in 45 acute STEMI patients383. In another study, quantitative 
flow ratio was derived from 130 acute STEMI patients using contrast induced-hyperaemia, 
and was correlated with MVO on CMR imaging384. A limitation of current techniques is 
that calculation of quantitative flow ratio requires a stenosis, so it is being measured pre-
stent implantation. A better time point to assess microvascular function in the infarct-
related artery would be post-stenting. A prospective trial is ongoing to investigate whether 
quantitative flow ratio computed post-stenting in the infarct-related artery, using a partially 
inflated balloon, is associated with CMR defined MVO (NCT03910400)385. Looking 
forwards, measuring microvascular function in the infarct-related artery post-stenting, from 










































































Appendix 2: T-TIME trial short patient information sheet and 
consent form (for use in the catheterisation laboratory for witnessed 
























Appendix 3: T-TIME trial patient information sheet and consent 











































Appendix 4: T-TIME trial standard operating procedures for 











































































































Appendix 5: T-TIME trial standard operating procedure for CMR 


































































































Appendix 6: T-TIME trial standard operating procedure for 
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